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THE ROLE OF REACTIVE OXYGEN SPECIES IN REGULATING
MACROPHAGE AND FIBROBLAST ACTIVATION WITHIN THE BREAST
CANCER TUMOR MICROENVIRONMENT
Brandon Joseph Griess, Ph.D.
University of Nebraska, 2019

Supervisor: Melissa Teoh-Fitzgerald, Ph.D.
The tumor microenvironment (TME) is a key determining factor in breast cancer,
especially the more aggressive subtype triple negative breast cancer (TNBC). The
activated fibroblasts and macrophages within the TME have many tumor promoting
functions. Therefore, targeting their activation presents a novel therapeutic approach in
TNBC. My work studied the role of reactive oxygen species (ROS) during fibroblast and
macrophage activation in breast cancer.
My studies showed that expression of the secreted antioxidant enzyme, EcSOD,
is silenced in breast cancer samples, in part, via increased promoter methylation. The
re-expression of EcSOD inhibited c-Met activation in the TNBC cell line, MDA-MB231.
HGF, the ligand for c-Met, is secreted by surrounding fibroblasts in breast cancer. Due to
its extracellular localization, EcSOD significantly inhibited the paracrine HGF/c-Met
signaling during co-culture of MDA-MB231 with HGF overexpressing mammary
fibroblast, RMF-HGF. EcSOD and a SOD mimetic, MnTE-2-PyP, inhibited the HGFmediated 3D growth and invasion of MDA-MB231 in co-culture with RMF-HGF. EcSOD
also inhibited RMF-HGF-stimulated orthotopic tumor growth of MDA-MB231.
Interestingly, long-term co-culture showed that EcSOD expression in MDA-MB231
inhibited the aggressive phenotype in RMF-HGF. Additionally, upregulation of the ROS
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generating enzyme, Nox4, increased the aggressiveness of RMF-HGF over control RMF
cells.
Tumor associated macrophages (TAM), which resemble the M2 type, enhance
the aggressiveness of breast cancer. M2 polarization was selectively inhibited by MnTE2-PyP. MnTE-2-PyP reduced M2 markers and inhibited the macrophage-mediated
cancer cell growth. Additionally, MnTE-2-PyP inhibited M2-mediated T cell suppression,
in part, via decreased PD-L2 levels. This study also determined that M2 macrophages
have lower levels of reactive oxygen species (ROS) and lower production of extracellular
hydrogen peroxide compared to the anti-tumor M1 macrophages, due to reduced levels
of pro-oxidants enzymes and higher levels of antioxidant enzymes. Despite lower ROS
levels, M2 macrophages require ROS for proper polarization as MnTE-2-PyP reduced
ROS levels. Additionally, inhibition of Nox-derived ROS with DPI inhibited M2 markers,
while adding hydrogen peroxide increased M2 markers. Mechanistically, MnTE-2-PyP
and DPI inhibited M2 polarization via decreased Stat3 activation.
Overall, my work shows ROS promotes an aggressive phenotype in
macrophages and fibroblasts, which can be significantly inhibited using the redox active
drug MnTE-2-PyP.
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CHAPTER 1:

Introduction

2

1. Introduction

1.1

Breast Cancer

Breast cancer is the most common type of cancer diagnosed in United States
women. It is the second leading cause of cancer-related deaths in women surpassed
only by lung cancer. This year alone, there are an estimated 268,600 newly diagnosed
cases of invasive breast cancer and 41,760 deaths [1]. The lifetime risk for women to
develop invasive breast cancer is 1 in 8 or 13%. There are several known risk factors for
breast cancer development; body mass index (BMI), age at menarche, age at first live
birth, number of births, hormone usage, alcohol usage, and smoking [2, 3]. The
incidence rate within the US has varied depending on those factors. For example, the
large drop in incidence rate between 1999 and 2004 was due in large part to a reduction
in hormone therapy [4]. Since 2004, the breast cancer incidence rate has remained
steady with a slight increase of about 0.3% [1]. The reduction in births are estimated to
be the major factor accounting for the current changes in incidence rate [2]. Despite the
increase in incidence, the mortality rate has dropped by 40% from 1975 to 2017 due to
increases in early detection and improvements in treatment [1, 5]. This has resulted in a
5-year survival rate of ~90%. However, these improvements have not benefitted all
breast cancer patient, as survival rates and treatment options are varied amongst the
different subtypes.
Breast cancer, like all cancers, is not one type of cancer. Initial research
indicated that breast cancer can be fractionated into 4 major subtypes based on the
presence or absence of certain markers. These markers are the oestrogen receptor
(ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2
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(Her2). There is the Luminal A subtype that is ER/PR positive, Her2 negative, most
common and least aggressive. The luminal B subtype is similar with ER/PR expression,
Her2 expression, and a faster proliferation rate. The Her2 subtype is ER/PR negative
and Her2 positive. The triple negative breast cancer (TNBC) subtype is negative for all
three markers. These markers help stratify breast cancer patients to help determine
severity of the disease and treatment options. The following data is taken directly from
the Surveillance, Epidemiology, and End Results (SEER) program from patients
between 2012 and 2016. Luminal A and luminal B made up 67% and 10% of patients
with a 5-year survival rate of 94% and 90% respectively. Her2 only made up 4% of
patients diagnosed with a survival rate of 83%. TNBC was more common making up
10% of patients with an even further reduced survival rate of 77%. The remaining 8% of
patients had an unknown status and resulting 77% survival rate.
Treatment for all localized breast cancer subtypes is surgical resection with
addition of either radiation or chemotherapy [6]. There are targeted systemic therapies
for BC presenting with ER/PR or Her2 expression. ER/PR positive cancers receive
endocrine therapy, typically tamoxifen, which is a selective estrogen receptor inhibitor.
While, Her2 positive cancers typically receive chemotherapy in combination with
trastuzumab, a monoclonal antibody targeting Her2. Inclusion of trastuzumab has
significantly increased survival in Her2 positive patients compared to chemotherapy
alone [7]. TNBC to date lacks any targeted therapy. Therefore, the treatment regimen for
TNBC is chemotherapy. However, newer clinical trials are being performed combining
chemotherapy with immunotherapies, such as atezolizumab that target programmed
death-ligand 1 (PD-L1). However, these combinatorial treatments are only currently in
metastatic TNBC [8].
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Due to the advances in DNA/RNA sequencing, there has been a further
classification of subtypes amongst breast cancer to help determine driving factors that
could be targeted. The immunohistochemistry (IHC) analysis of ER/PR/Her2, while
hugely beneficial, has not been able to accurately account for the complexity found using
gene signatures. The unbiased analysis of gene signature revealed 5 main clusters. It
caused a split in the TNBC subtype into two different subtypes, the basal-like breast
cancer and the normal-like breast cancer [9]. The basal-like tumors expression keratins
5/6 and 17 indicative of basal breast cells. The normal-like tumors are similarly express
high basal-like and low luminal gene expression in combination with higher adipose cell
and non-epithelial gene expression [10]. Other studies have developed different
methods of stratification to help determine potential drivers and targets using a larger
size of TNBC samples [11]. Interestingly, two of three large scale studies found distinct
subtypes of TNBC are dependent on the immune response to the tumor [12, 13]. The
study done by Jézéquel et al. is particularly interesting in the context of this dissertation.
They showed a subset of TNBC samples that have a low immune response and a high
M2-like macrophage signature had a higher grade and lower survival than other TNBC
clusters [12]. Additionally, this cluster was the purest basal-like cluster. The importance
of these findings will become more clear when the role of the tumor microenvironment
on breast cancer outcome is discussed later in this dissertation.
Interestingly, the risk factors associated with breast cancer incidence do not
affect all subtypes equally. The known risk factors stated earlier are largely indicative of
incidence in the luminal A subtype with breastfeeding, a higher premenopausal BMI, a
higher number of births, and use of oral contraceptives having a negative association
and alcohol use, younger age at menarche, older age at first birth, and older age at
menopause having a positive association [14]. Most of the risk factors had unknown
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effect on luminal B and Her2 subtypes [14]. While, TNBC was affected by the known risk
factors in a similar manner as luminal A [14]. The disparate risk factors between luminal
A and TNBC were an increased risk in TNBC with a higher number of births, a higher
premenopausal BMI, and a weak increase risk with the use of oral contraceptives [14].
This study serves to further highlight the distinct differences found throughout breast
cancer and how those differences affect both outcome and incidence rates.

1.2

Reactive Oxygen Species & Reactive Nitrogen Species

Reactive oxygen species, or ROS, and the closely related reactive nitrogen
species, or RNS, are aptly named chemicals that contain either oxygen or nitrogen
respectively and readily and easily react with surrounding chemicals and molecules.
While there are many different species included under the ROS/RNS banner, the main
species studied are superoxide, hydrogen peroxide, the hydroxyl radical, nitric oxide and
peroxynitrite, as they are the most common species produced by mammalian cells.
These species are also involved in a complex web of reactions that ultimately dictates
their effect within the cell. They affect mechanisms throughout the cell via their ability to
oxidize surrounding molecules, such as proteins, lipids, RNA, and DNA. This oxidation
can result in cellular damage, such as mutations of DNA, increased membrane
permeability, and modification of protein activity. However, ROS and RNS are integrally
engrained into signal propagation within eukaryotic physiology and have essential roles
in metabolism, innate immunity, differentiation and cell survival. As such, ROS signaling
has been linked to aging, cardiovascular pathologies, inflammation, neurodegeneration
and cancer [15-19]. Due to this dual-sided nature of ROS as an effector of cell signaling
and a damage inducing molecule, it has results in the idea of a Goldilocks zone of ROS
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within cells. Very low levels of ROS lead to cytostatic effects on cells, while high levels
can lead to tumorigenesis or cytotoxic ROS-mediated cell death as seen in figure 1.1.
Therefore, insights into ROS produced by regulated processes and the defenses
evolved to protect against these disruptions of homeostatic redox states have fueled
intense interest in the search for drug targets and clinical antioxidants. Additionally, ROS
is implicated as an important secondary messenger in most of the hallmarks of cancer
[20]. Thus, ROS remains an attractive target when developing cancer therapies.

1.2.1

Superoxide
In order to understand the complexities of ROS and its effect within the cell, the

web of reactions between ROS and RNS must be further explained. Within the cell, ROS
is commonly generated first as superoxide. Superoxide is a formed when molecular
oxygen gains an additional electron. This often occurs when electrons from the electron
transport chain leak out of the inner mitochondrial membrane on to oxygen creating
superoxide. However, superoxide is also produced by cellular enzymes, called NAPDH
oxidases, further indicating that ROS is required for normal cellular function [21].
However, it is difficult to directly measure due to a short half-life and is quickly converted
to other ROS, which makes studying the direct effects of superoxide difficult. However,
its unique position as the progenitor for most cellular ROS, as indicated in figure 1.2,
making it vitally important for cells to control its levels to regulate ROS levels as a whole.
Once generated, superoxide can head in three main directions. The first direction is to
either spontaneously or enzymatically dismutate as indicated in figure 1.2 [22]. This
requires two superoxide molecules to form water and hydrogen peroxide. This hydrogen
peroxide is another of the main ROS species, which will be discussed shortly. This
reaction can occur spontaneously. However, the enzyme family superoxide dismutases,
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Figure 1.1. The effect of cellular ROS levels on cell proliferation
The diagram indicates potential intracellular ROS levels in the red wedge and its effect
on cell proliferation. Proteins known to modify cellular ROS are listed below the ROS
wedge.
Figure from:
Schieber M. and Chandel N.S. ROS Function in Redox Signaling and Oxidative Stress.
Current Biology. 2014; 24 (10): R453-R462.
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Figure 1.2. Interconnections between ROS and RNS
The diagram represents the interconnected nature of ROS and RNS with a main focus
on superoxide (shown in red). It also highlights the main molecules shown to affect
cellular signaling.
Figure from:
Wang Y., Branicky R., Noë A., Hekimi S. Superoxide dismutases: Dual roles in
controlling ROS damage and regulating ROS signaling. Journal of Cell Biology. 2018;
217 (6): 1915-1928.
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or SODs, speed up this reaction to 2 x 109 M-1s-1, which is a diffusion-limited reaction that
is ~104 faster than spontaneous dismutation [22]. This family of enzymes is vital to my
research and will be discussed in more detail later in this dissertation. The second
direction for superoxide is the forming the hydroxyl radical, one of the most reactive
ROS, via the Haber-Weiss reaction (Figure 1.2). This reaction requires free transition
metal ions, such as iron or copper, to act as a catalyst. This reaction rate is very slow (3
M-1s-1) making it unlikely to occur in biological systems [23]. The third direction for
superoxide is to interact with nitric oxide to form peroxynitrite, which is a strong oxidant
that can modify proteins via nitration of specific amino, like tyrosine, tryptophan,
methionine, and cysteine [24]. This direction for superoxide is where the webs of ROS
and RNS meet and add complexity to the situation, since nitric oxide and peroxynitrite
are RNS. This reaction is also diffusion-limited with speeds at 6.7 x 109 M-1s-1 (Figure
1.2) [25]. The effect of these different directions for superoxide will become clear as
each species of ROS and RNS have different effects and different targets, which
unsurprisingly result in varying effects on cellular function.
Due to its negative charge, superoxide does not easily cross cellular membranes.
This combined with the short half-life has led to idea that superoxide acts where it is
produced. Thus, it is important to know any additional biological targets of superoxide.
First, it can promote iron release from Fe-S cluster enzymes via oxidation or from the
iron storing protein, ferritin, via reduction. This reaction occurs at a range of rates from
106 to 107 M-1s-1, depending on the exact Fe-S cluster enzyme [26]. The release of iron
from these enzymes can further contribute to oxidative stress induced by superoxide as
it is a required catalyst for the Haber-Weiss and Fenton reactions. Thus, unregulated
levels of superoxide can lead to a cascade of even more reactive species, such as the
hydroxyl radical. Secondly, superoxide can also directly oxidize thiols. However, the
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exact rate of this reaction is disputed. The rate has been measured as high as > 105 M1 -1

s and as low as 15 M-1s-1 [27]. PTP1B, a common cellular protein tyrosine

phosphatase, is oxidized by superoxide at a rate of 334 M-1s-1 for example [28].
However, this reaction speed is orders of magnitude slower that its reaction with nitric
oxide, SOD enzymes, or Fe-S clusters. Thus, thiols are unlikely to outcompete these
other superoxide sinks making thiol oxidation an unlikely reaction to occur inside cells.
Additionally, the steady state levels of superoxide are in the range of 10-11 – 10-12 mol l-1
[29]. Therefore, it is hypothesized that while vitally important to control the levels of
superoxide to regulate ROS levels, a different species may be the main culprit acting as
a secondary messenger during cell signaling.

1.2.2

Hydrogen Peroxide
The most oft cited species responsible for acting as that secondary messenger is

hydrogen peroxide. Hydrogen peroxide is one of the major products downstream of
superoxide production. Also, like superoxide, there are enzymes (26 of them) that
produce hydrogen peroxide [30]. However, hydrogen peroxide is usually produced as a
by-product of these reactions not the main product like is seen with superoxide.
Hydrogen peroxide is also 3 orders of magnitude more abundant than superoxide, as
levels are estimated to be 10-9 – 10-7 M [29]. Hydrogen peroxide is also uncharged and
can easily to diffuse across cellular membranes, especially through aquaporin channels
[31]. Additionally, the cytosolic lifespan of H2O2 has been determined to be one
millisecond, enabling diffusion from endogenous sources approximately 1 m from its
origin [32, 33]. In addition to its greater ability to diffuse across membranes, there is also
a hydrogen peroxide gradient across the cell membrane as extracellular levels within the
blood are ~ 1 – 5 μM [34]. Various studies have attempted to determine how step the
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gradient is actually. The studies range from 7 to 5000 times as much extracellular
hydrogen peroxide as intracellular [34]. Thus, removal of hydrogen peroxide from within
the cell is likely a greater determent of cellular hydrogen peroxide levels than
intracellular production. To further support this claim, cells in vitro treated with either a
bolus or steady dose of exogenous hydrogen peroxide returned to steady state levels
within 90 minutes of either treatment [35].
Within the cell, there are three main directions for hydrogen peroxide to go once
produced. The first direction is to react with iron and superoxide in the Haber-Weiss
reaction as mentioned above (Figure 1.2). The next direction is elimination of ROS by
the cellular antioxidant network. These include scavenging through three different types
of enzymes; glutathione peroxidases (Gpx), peroxiredoxin (Prx), and catalase (Figure
1.2). These reactions are quite quick with reaction rates ranging from 3 x 105 up to 6 x
107 M-1s-1 [36]. These enzymes will be examined more closely later in this dissertation.
The other direction is reacting with low pKa thiols, typically found on reactive site
cysteines within certain proteins. This occurs most commonly on protein tyrosine
phosphatases, such as PTP1B and PTEN, which require an active site cysteine with a
low pKa for their activity [37-40]. However, much like superoxide, the oxidation rate of
PTPs (101 – 103 M-1 s-1) is orders of magnitude slower than scavenging by enzymes [39,
40]. Therefore, PTPs are unlikely to outcompete hydrogen peroxide scavengers. Thus,
it is currently unclear the exact mechanism that superoxide or hydrogen peroxide oxidize
proteins within the cell. The effect of both hydrogen peroxide and superoxide on cellular
signaling will be explained in section 1.2.4.
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1.2.3

Reactive Nitrogen Species
Nitric oxide, NO•, generated by nitric oxide synthases (NOSs) plays an important

role as neurotransmitter, in regulating vessel relaxation in endothelial cells, and in
mediating neutrophil and macrophage functions. Since superoxide reacts at a diffusionlimit rate with NO•, oxidation of this NO• into ONOO- can result in alterations of cellular
function as well [41]. The actions of NO• are mainly mediated through increasing cGMPmediated signaling. The non-cGMP-dependent actions of NO• are carried out mainly in
three ways: (i) interaction with proteins containing transition metal, (ii) interaction with
proteins, and (iii) modulation of cell signaling by forming S-nitrosothiol- (SNO)
modification on proteins. NO• has been shown to either facilitate cancer-promoting
effects or act as an anti-cancer agent. Pro-tumor effects of NO• were linked to the
expression of NO•-producing enzymes in tumor progression [42]. While, anti-tumor
effects were mediated by utilizing the immune defense mechanisms in animal models of
various human cancers [43]. Recent evidence indicates that most of the cytotoxicity
attributed to NO• is rather due to ONOO-, produced from the diffusion-controlled reaction
between NO• and superoxide anion. Peroxynitrite interacts with lipids, DNA, and
proteins. These reactions result in cellular responses that vary from modulations of cell
signaling to nitrosylative stress that triggers necrotic or apoptotic cell death [24]. In vivo,
ONOO- generation has been implicated in many conditions such as stroke, chronic heart
failure, diabetes, chronic inflammatory diseases, cancer, and neurodegenerative
disorders [24]. Hence, novel pharmacological strategies aimed at removing ONOOmight represent powerful therapeutic tools in the future. EcSOD, in preserving
bioavailability of NO•, is expected to have an indirect consequential effect in cancer
through alterations of these NO•/ONOO- signaling. The seemingly paradoxical role of
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NO• in cancer has been quite extensively covered in other reviews [44] and is not
discussed in detail here.

1.2.4

Role of Superoxide versus H2O2 Signaling in Oncogenesis
Deregulation of redox homeostasis has long been implicated in a variety of

diseases and the role of ROS in oncogenesis remains an area of major interest.
Nevertheless, ROS should not be considered as one single biochemical entity that has a
single global effect in cancer. Rather, ROS function as cellular secondary messengers,
with each reactive species orchestrating unique signaling events, in a temporal and
spatial manner. Although H2O2 has been the main focus as the ROS-mediated signaling
molecule, partly due to the conception that it is more stable and longer lived than
superoxide, the insight starts to emerge that O2•- may also be an important mediator of
cellular effects. This is further supported by the fact that most cells possess enzymatic
systems that are capable of producing O2•-, whereas to date no cellular system is known
that exclusively generates H2O2 and not as a by-product of other reactions mentioned
earlier [45].
Superoxide is believed to function as a signaling molecule in a distinct manner
from those mediated by H2O2, •OH, and ONOO-, although the mechanism is not fully
understood. The name, superoxide is misleading in a sense that it is not a super-oxidant
but a relatively moderate reductant. However, superoxide, being both a radical and an
anion, can react with organic molecules by nucleophilic mechanism. Owing to this
nucleophilic property, superoxide is able to rapidly deprotonize alcohols, phenols, and
thiols, and hydrolyze esters as proposed [46]. By deprotonation of protein serine or
threonine residues, superoxide is able to mediate phosphorylation of numerous proteins
by protein kinases, thereby accelerating the rates of nucleophilic reaction between
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kinases and phosphorylating proteins. For examples, superoxide has been shown to
mediate the activation of many protein kinases including PKC, PKD (protein kinase D),
PKB (Akt) (protein kinase B), and mitogen-activated (MAPK) kinases, p42/44, p38, and
ERK [47-50]. Another important stimulus of enzymatic phosphorylation by superoxide
signaling is via phosphatidylinositol 3-kinase activation, which subsequently activates
PKB and MAPK [48, 51].
Furthermore, O2•- can promote protein phosphorylation by inhibiting
dephosphorylation catalyzed by protein phosphatases. Superoxide affects both
serine/threonine protein phosphatases (PPs) and protein tyrosine phosphatases (PTPs),
by oxidizing the metal ion center of the former class of phosphatases and via
nucleophilic attack of the cysteine residue in the later class [52, 53]. While H2O2 has also
been demonstrated to inactivate PTPs, the rate of superoxide signaling is about 10-100
times higher than that of hydrogen peroxide signaling [54, 55]. In addition to being
kinetically more efficient, O2•- is chemically more specific than H2O2 in this process as the
catalytic site of PTP-1B is surrounded by positively charged residues [28]. Moreover,
O2•--inactivated PTP-1B is more reversible than that of H2O2 since significantly more
methionine residues are oxidized by H2O2. This provides an efficient fine-tuning ability of
O2•- in regulating PTP-1B in signal transduction. This emphasizes an importance of O2•signaling in many oncogenic signaling processes and the potential application of the
specific superoxide inhibitors for their regulation.
It has long been recognized that low levels of O2•- and H2O2 are involved in
proliferative signaling, partly via alterations in the activities of protein kinases and
oxidative inactivation of phosphatases, as discussed earlier. Although these two major
ROS are considered oncogenic ROS, there is strong evidence to support that these two
ROS diverge in their roles in cellular survival/death pathways. Indeed, it is the ratio of
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intracellular superoxide to H2O2 that could dictate the fate of cells as discussed in detail
by Pervaiz and Clement [56]. A prominent increase in superoxide in the absence of
cytotoxic levels of H2O2 supports cell survival and promotes oncogenesis by inhibiting
activation of the pro-apoptotic pathway [57, 58]. In contrast, a rise in H2O2 levels with an
accompanying decrease in superoxide facilitates apoptotic execution by activating
caspase proteases [59, 60]. Superoxide, due to its specific anti-apoptotic effect in
creating an environment conducive for cellular survival and proliferation in favor of
oncogenesis, has been termed “Onco-ROS” [56]. However, competition between
superoxide and hydrogen peroxide in cells might be more complicated.

1.3

Extracellular Superoxide Dismutase

1.3.1

Distribution and Function of the Three Sods in Mammalian Cells
One of the essential enzymatic components of the antioxidant defense system

are the metal ion-dependent superoxide dismutases (SODs). There are three members
of the SOD family present in mammalian physiology, with tightly regulated localization
patterns. Of these, there are two copper/zinc containing members, CuZnSOD (SOD1)
within the cytosol, mitochondrial inter membrane space, and nucleus, and EcSOD
(SOD3) is the predominant antioxidant enzyme secreted into the extracellular space [61,
62]. The manganese-containing MnSOD (SOD2), localizes to the mitochondrial matrix, is
the most divergent and displays minimal similarity to the other SODs, which share 60%
homology around the catalytic and metal-binding domains [63]. All SOD family members
require metal cofactors for catalyzing one-electron oxidation followed by one-electron
reduction of two O2•- anions to affect disproportionation. Due to their distinct localizations,
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and membrane impermeability of O2•-, each member of the SOD family is expected to
have specific compartmentalized roles, such as regulation of redox sensitive
transcription factors [64], mitochondrial oxygen level sensing [65], or protection of
surrounding tissue from oxidative inflammation during infection [66]. This implies SOD
functions are non-redundant, despite having similar rate constants. Tumor suppressive
effects of Cu/ZnSOD and MnSOD have been well described [67-69]. In this review, we
will focus on EcSOD, its features and potential role in oncogenesis.

1.3.2

EcSOD Tissue-Specific Expression and Localization
While the other SODs are ubiquitously expressed, EcSOD is more restricted in a

cell type and tissue dependent manner. EcSOD demonstrates high levels of protein
expression within the cardiovascular endothelium, lungs, and placenta, displays
moderately within kidney, pancreas and uterus, cartilage, skeletal muscle, adipose
tissue, brain, and eye [62]. Abundantly secreted into the extracellular compartment,
presence of EcSOD is detectable in milk, plasma, synovium, and lymph [61, 70]. Once
secreted, EcSOD is bound to cell surface proteoglycans through its positively charged
heparin-binding domain (HBD). A portion of secreted EcSOD is subjected to intracellular
proteolytic cleavage removing the HBD, which precludes tethering to the cell surface,
and facilitates distribution in the extracellular milieu and circulation [71, 72]. The secreted
full length enzyme has been observed to be taken up by cells via endocytosis, facilitated
by surface binding to proteoglycans and internalized through clathrin-coated pits [73]. In
addition, EcSOD has been detected in nuclei associated with chromatin [74, 75], and
trafficking through the endo-lysosome system has been suggested [73-75]. Thus,
although EcSOD, as the name implies, mainly resides in the extracellular space this
enzyme has other intracellular localizations.
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1.3.3

Molecular Characteristics: EcSOD
The monomeric subunit of human EcSOD is synthesized as a 32 kDa monomeric

protein that exhibits higher order dimers, tetramers and octamers cross-linked through
disulfide bridges between cysteine residues in the C-terminal region [76-79]. A 240
amino acid propeptide contains a signal peptide on the N-terminal required for secretion
and is cleaved to generate a 222 amino acid protein making up the mature form [80]
(Figure 1.3). Mature EcSOD can be separated into 3 regions, the amino-terminal
features an asparagine at position 89 revealed by mass spectrometry to be a singular
glycosylated residue greatly enhancing protein solubility and has been demonstrated as
required for secretion but not activity [81-83]. The second domain bears 60% homology
to CuZnSOD and contains the conserved active site and ion binding folds for the
singular copper and zinc ions required for catalysis [84, 85]. EcSOD is remarkably stable
and resistant to extreme temperature, pH, urea and guanidinium chloride concentrations
[84].

1.3.3.1 Heparin Binding Domain
The third domain is unique to EcSOD and tethers it to the surface glycocalyx with
high affinity, via a cleavable C-terminal heparin-binding domain (HBD). The HBD
comprises a cluster of positively-charged arginine and lysine residues (SERKKRRR)
which associates electrostatically with proteoglycans, notably heparin but also collagen
type I and fibulin-5, on endothelial surfaces and tissue matrix, where it protects against
oxidative fragmentation [80, 86-88]. Intracellular proteolytic cleavage by a furin-like
protease followed by carboxypeptidase activity within the HBD is expected to account for
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Figure 1.3. Schematic illustration of human EcSOD protein structure
The 240 amino acid pro-peptide features an N-terminal signal peptide (green) cleaved to
generate the 222 amino acid matured protein. Asparagine 89 is depicted as the singular
glycosylated residue. The C-terminal heparin binding domain is depicted (blue).
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release of EcSOD into plasma and fluids [71, 89, 90]. Secreted distribution of heterooligomers possess a range of binding affinities and enzymatic activity. Tetramers
separate into three fractions entirely with or without the HBD, or as a mixture of intact
and truncated monomers [71, 72, 82, 91]. Secretion of both full length and truncated
forms of EcSOD with varying degrees of heparin affinity allows for differential tissue
distribution in regulating specific protection from ROS [91]. Endothelial cells prominently
feature EcSOD bound to the surface, do not synthesize the protein on their own, and
acquire secreted EcSOD from vascular smooth muscle cells [92]. The positively charged
HBD resembles a nuclear localization signal. Heparin binding not only enables O2• scavenging on cell surfaces and where EcSOD is tethered, but also mediates
endocytosis [75]. Internalized EcSOD has been observed to be associated with
lysosomes, suggesting a possible degradation pathway. This HBD-mediated
endocytosis has also been linked to localization of EcSOD to the nucleus [74, 75]. The
EcSOD crystal structure has been solved at a resolution of 1.7 angstroms. The overall
tetramer is held together by disulfide bonds positioned towards the N-terminal, and
uniquely features two grooves (‘major’ and ‘minor’) at polar ends, a result of dimeric
organization [93]. Molecular modeling indicates the major groove accommodates
binding of the heparin molecule some distance from the active site, consistent with
previous reports that enzymatic activity is not inhibited while retained at the cell surface
[86]. While missing from the overall structure, the C-terminal HBD is expected to be
located along the top of this major groove to facilitate heparin binding, a conformational
change ‘locking’ heparin into place protects EcSOD from proteolysis [94]. The minor
groove on the reverse face is proposed to interact with collagen and involves
electrostatic interaction with the C-terminus.
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A naturally occurring polymorphism at arginine 213 (R213G) located in the HBD
impairs heparin binding, increasing the concentration of EcSOD released into plasma.
This results in no overt clinical phenotype, and does not appear to affect its intracellular
distribution [95, 96]. Interestingly, this renders EcSOD resistant to trypsin-like proteases
[97]. The R213G polymorphism also confers resistance to furin protease activity,
promoting secretion of an active, full-length molecule unable to bind heparin [90]. Full
length EcSOD has a significantly longer tissue half-life than the truncated and released
form (85 versus 7 hours respectively), while the HBD-null form shows less clearance by
the liver due to its reduced ability to be endocytosed [98].
In diabetic patients, elevated blood glucose promotes non-enzymatic glycation
products of EcSOD disrupting heparin binding but not catalytic activity [99, 100]. While
the R213G polymorphism has not been directly linked to diabetic susceptibility, diabetic
patients on hemodialysis exhibit increased risk of ischemic complications of the
cardiovascular system due to diminished EcSOD protection when absent from the
surface endothelium [101, 102]. Presence of R213G correlates with decline in lung
function and susceptibility to chronic obstructive pulmonary disease [103].
Controversially, other studies have suggested a protective role, the polymorphism being
more common among smokers resistant to COPD development [104].
Development of therapeutic intervention strategies for ameliorating the negative
effects of oxidative stress have produced both pharmacological and gene therapy based
approaches for preventing tissue injury in disease models [105, 106]. SODs have shown
promise as treatment in the laboratory, yet clinical efforts are stymied by source
purification, clearance rate, and distribution [107-109]. To circumvent these challenges,
a chimeric fusion of MnSOD with the EcSOD HBD, designed to promote its cellular
internalization, successfully prevented vascular edema in two models of inflammation
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[109]. The highly basic residues of the HBD domain of EcSOD that form a predominantly
helical structure is similar to the features described for cell penetrating peptides (CPPs),
such as the HIV transactivator protein (TAT) and other experimental CPPs [110, 111].
This unique domain of EcSOD has been demonstrated to possess efficacy as a CPP,
where synthetic peptide corresponding to this region translocates into the cytoplasm and
nucleus when added exogenously [111]. When this peptide is linked with apoptin
(chicken anemia virus-derived protein), the recombinant apoptin-HBD fusion protein
exhibited a significant and specific anti-tumor effect versus the apoptin protein alone, in
the Lewis Lung carcinoma model in mice [111]. Although the uptake mechanism and
intracellular fate of this highly basic EcSOD HBD peptide is not clear at this point,
EcSOD HBD exhibits potential clinical application as a delivery tool to translocate cargo
molecules into cells.

1.3.3.2 Catalytic Domain and Reaction Mechanism
EcSOD scavenges O2•- through the catalyzed dismutation of two molecules of
O2•- to bimolecular oxygen and H2O2, which is subsequently reduced to water by
catalase, peroxiredoxins and other enzymes [112]. EcSOD requires a redox-active
Cu1+/2+ ion at its active site. Three histidine residues anchor the catalytic copper in place.
One of these, the “bridging histidine”, also ligates the zinc ion, which itself requires an
aspartic acid and additional electrostatic contributions from three separate histidines.
The zinc ion is not required for catalytic activity, but facilitates protonation between the
bridging histidine and confers thermal stability [113]. Electrostatic guidance of O2•- into
the positively-charged catalytic active site requires Lys134 and Glu131 for approach
from longer-range, and Arg141 for a more local orienting effect [114].
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Superoxide disproportionation occurs by a ping-pong mechanism which proceeds
in two steps. Step one begins as the O2•- substrate binds to copper2+. Superoxide anion
donates an electron to become molecular oxygen, in the process reducing copper2+ to
copper1+. The bond between copper and its anchoring histidine is broken, and histidine
becomes protonated. In step two, this proton is donated along with the electron from
copper1+ to a second O2•- anion, forming H2O2, and copper2+ reforms its histidine bond
[115]. A transfer of one electron from O2•- to copper reduces the oxidized copper ion. The
reduced copper is oxidized, donating an electron to a second O2•- anion at rates close to
diffusion limits [116]. The overall stoichiometry results in formation of molecular oxygen
and H2O2 from two O2•- molecules. The remarkable structure of SODs have pioneered
mechanistic studies of ‘electrostatic guidance’, described in intricate detail within an
excellent review [117].
1.

Cu2+ZnSOD + O2•- → Cu+ZnSOD + O2

2.

Cu+ ZnSOD + O2•- + 2H+ → Cu2+ZnSOD + H2O2

Despite abundant documentation on SODs as anti-oxidants, a theme suggesting
a pro-oxidant role is also coming into focus, with generation of H2O2 suggested to
account for deleterious effects seen in some SOD overexpression systems [118]. In
consideration, dismutation, spontaneous or catalyzed, yields identical amounts of H2O2,
though with significantly different kinetics. In single-celled E.coli, endogenous SOD
expression levels conferred 95% protection from O2•- induced damage to sensitive
targets, this suggests the effects of SOD overexpression on H2O2 production should be
negligible as O2•- concentrations would already be limited [118, 119]. This however does
not account for the rapidity of H2O2 formation or subcellularly localized bursts of
increased H2O2 concentration. Such phenomena arguably would result from the
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presence of NADPH oxidase (NOX) enzymes not found in prokaryotic organisms, having
made their first appearance later in evolution and function as compartmentalized
producers of O2•- [120]. Whether SODs have pro-oxidant effects is likely to remain a
conflicting issue. It is critical to know the answer to this antioxidant conundrum as there
is accumulating evidence to support divergent effects on cell proliferation and death
signaling for the two major intracellular ROS, O2•- and H2O2, as discussed in a later
section. In addition to scavenging O2•-, SODs exhibit less efficient, non-specific
peroxidase activity [121-124]. Here, the Cu/Zn-containing enzymes require CO2,
ultimately generating a diffusible carbonate radical. This in turn disables the enzyme and
thus the peroxidase action of both CuZnSOD and EcSOD functions as a ‘suicide
reaction’ [121-124]. Determination of the precise mechanism has been notably
contentious, and it remains to be seen whether SOD peroxidase activity is significant
within living organisms, or can occur at physiological concentrations of H2O2 [118, 125].

1.3.4

EcSOD as a Primary Defense Against Other ROS and RNS
The primary function of EcSOD is a superoxide scavenger, as the name implies.

However, its redox modulation effect is not limited to controlling the levels of this radical.
Superoxide is a precursor of many ROS and RNS as described [126]. By suppressing
the accumulation of superoxide, EcSOD also prevents spontaneous dismutation of
superoxide into H2O2. Generation of •OH via Fenton reaction and Harber Weiss reaction,
can also be inhibited by EcSOD. Furthermore, by preventing the superoxide-mediated
oxidation of NO•, EcSOD also controls the formation of ONOO-, which as discussed
earlier plays a significant role in the pathogenesis of diseases, such as stroke,
myocardial infarction, chronic heart failure, diabetes, circulatory shock, chronic
inflammatory diseases, cancer, and neurodegenerative disorders.
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1.3.5

Gene Regulation and Transcription
Human SOD3 is located on chromosome 4p with approximately 5.9 kilobase

pairs, and contains two exons and one intron [127]. The entirety of the 722 bp coding
region is within exon 2. The promoter contains two CAAT-box elements but is without a
TATA promoter sequence [127]. Features in common with the other two SOD family
members include antioxidant response elements (ARE), AP-1 and AP-2 binding sites,
and NF-B motifs. A more recent study of EcSOD transcriptional regulation that looked
at tissue-specific expression in the mouse revealed a repressor role for myeloid zinc
finger 1 and Krüppel-like transcription factors, whereas Ets family members, Elf-1 and
GA-binding protein α and β, were transcriptional activators [128]. The farnesoid x
receptor was found to bind an inverted repeat, IR-1 element promoting transcription
[129].
Various growth factors, cytokines and ions likely play a role in transcriptional
control of EcSOD mRNA expression. EcSOD was reportedly induced in response to
interferon-γ and IL-4, but downregulated by TNF-α [130]. Rat brain astrocytes were
protected from H2O2 by purinergic receptor agonists, which increased expression of both
MnSOD and EcSOD, an effect likely dependent on intracellular calcium ion, cyclic AMP
and PKA activity [131]. Leukemia inhibitor factor increases EcSOD expression and
activity in brain tissue, protecting neurons from ischemic damage [132]. Exendin-4, a
glucagon-like peptide-1 receptor agonist, induced the expression of EcSOD through
epigenetic regulation at its proximal promoter by influencing the acetylation of histone H3
[133]. Lastly, the presence of metal ions bear influence on modulating EcSOD
expression. Dietary copper/zinc levels [134, 135] influence EcSOD levels, and the
intrinsic transcriptional activity of copper chaperone Atox1, can be stimulated to
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translocate to the nucleus and bind a response element in the EcSOD promoter [136].
Unexpectedly, the application of various oxidizing conditions reduced EcSOD expression
levels, although these results may be confounded by general toxicity [137].

1.3.6

SOD3 KO Models
Whole body EcSOD null mice are born at Mendelian ratios, are fertile, appear to

develop normally, and adult mice are healthy to 14 months of age [138]. Other
antioxidant genes (catalase, glutathione peroxidase, glutathione reductase, glucose-6phosphate dehydrogenase), were also reported as unchanged. Common hematological
markers reported as normal. Significantly, SOD3-/- mice were more susceptible to
oxidative stress resulting from hyperoxic exposure, with considerably diminished survival
rates to wild type counterparts. When exposed to hyperoxic conditions whole body KO
mice developed severe and sudden, inflammatory pulmonary edema, with enhanced
neutrophil recruitment, signs of intra-alveolar hemorrhage, vascular congestion and
thickening of alveolar septa. The expression levels of the other two SOD family
members were examined, but no compensatory changes were observed. Moreover, a
double knockout model for both SOD1 and SOD3 reported mild phenotypes, suggesting
limited or no functional redundancy exists between these two family members [139].
Whole body KO mice do not have increased tumor incidence. Possibly, these
conditions are not ideal to study the role of EcSOD in tumorigenesis. In dramatic
contrast to the whole body knockout, an inducible deletion of EcSOD in adult mice
exhibited an 85% mortality rate in ambient air conditions, 3-7 days after tamoxifen
injection, and demonstrated severe respiratory distress, highlighting the critical role of
EcSOD at the oxygen interface in the lungs [140]. This suggests that animals with an
embryonic deletion of EcSOD have compensated/adapted, and will not demonstrate
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accurate phenotypic identities as reflected upon deletion in adult mice. While the whole
body KO model suggests loss of EcSOD expression alone is not an initiating factor in
inducing tumorigenesis, reduced function of this antioxidant will likely contribute to
oncogenesis as demonstrated by numerous studies further discussed in the following.

1.3.7

Expression Levels and Effects of EcSOD in Cancers
Oncomine analysis of neoplastic versus normal tissues showed that EcSOD (or

SOD3) expression levels were significantly down-regulated across a majority of cancers
including breast cancer, head and neck cancer, lung cancer, and sarcoma (Figure 1.4),
suggesting that loss of EcSOD could contributes to oncogenesis. Amongst the
Oncomine datasets, the breast cancer category shows the highest number of analyses
that met the threshold, where 18 out of 53 analyses in 5 out of 14 breast cancer datasets
met the thresholds for P-value < 0.01 and changes in EcSOD expression is scored in the
top 10% of gene rank for most significantly under-expressed genes. Specific studies
examining the expression level and function of EcSOD in various cancers are further
discussed in the following.

1.3.7.1 Breast Cancer
In breast cancer cells, overexpression of EcSOD inhibited in vitro proliferation,
clonogenic survival, and invasion of a triple negative breast cancer cell line partly via
suppressing heparanase-mediated fragmentation of cell surface proteoglycans and by
reducing VEGF bioavailability [141]. Overexpression of EcSOD also significantly
inhibited tumor metastasis in both an experimental lung and a spontaneous metastasis
mouse model [142], further suggesting a role for this extracellular enzyme as in
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Figure 1.4. Oncomine gene analysis of SOD1-3 in solid cancers versus normal
counterparts.
Oncomine gene summary view comparing the number of datasets that had significant
changes in mRNA expression for EcSOD (SOD3), CuZnSOD (SOD2), and MnSOD
(SOD2) in cancer versus normal tissues. Thresholds were set for P<0.01 and top 10%
score in gene rank for most significantly changed genes. Blue boxes indicate
downregulation and red represents upregulation. Number in each box shows the number
of analyses that met the thresholds.
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suppressing tumor progression. Concurrently, in a normal mammary epithelial cell line,
siRNA-mediated knockdown of EcSOD promoted clonogenic capacity, tumorsphere
formation, and wound healing in MCF10A cells [143]. In addition to the Oncomine
analysis showing a prominent down-regulation of EcSOD expression in breast
carcinomas, an inverse correlation between the mRNA expression levels of EcSOD and
breast cancer stage has been reported [142, 144]. Immunohistochemistry data also
show a significant decrease in EcSOD protein expression in both ductal carcinoma in
situ and invasive breast carcinoma compared to normal tissue [142], further suggesting
that loss of EcSOD provides a selective advantage in cancer cells. In contrast to the
tumor suppressive role, EcSOD may be an important mediator in VEGF-C-promoted
oncogenesis. Expression levels of EcSOD were found to be down-regulated when
VEGF-C is knocked down in claudin-low breast cancers, and EcSOD was partly required
for VEGF-C-mediated cell survival in response to oxidative stress and for VEGF-Cmediated metastasis [145]. This apparent discrepancy in the role of EcSOD in breast
cancer hints at the complexity of redox-mediated cellular processes. It should be
emphasized that these experiments were performed in a single murine mammary
carcinoma cell line that constitutively expressed EcSOD. Since EcSOD expression is
downregulated or absent in the majority of human breast cancer cases, the relevance of
these studies with respect to the role of EcSOD in human breast cancer progression
remain unclear.
Interesting, long-term estradiol stimulation resulted in significantly downregulated
EcSOD in normal mammary epithelial cells, and in tumors derived from the ACI rat
model of breast cancer [143, 146, 147]. The exact mechanism involved in the estrogenmediated loss of EcSOD is not clear. The induction of neoplastic transformation by
estrogen can be mediated through non-receptor alpha regulated mechanisms, via a
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direct genotoxic effect. Russo et al [148] found that loss of chromosome 4 is associated
with a tumorigenic phenotype by using an in vitro transformation model of normal
mammary epithelial cells treated with 17-beta estradiol to elucidate a sequence of
chromosomal changes correlating with specific stages of neoplastic progression. The
authors implicated Slit2 as a candidate tumor suppressor located at 4p15.2 that was
silenced in the estrogen-induced tumors. However, considering the fact that the EcSOD
gene or SOD3 is also located in the chromosome 4p15.2 region, it is tempting to
speculate that re-expression of EcSOD in their C5 cells (tumorigenic cell line derived
from estrogen treated MCF10A cells) would inhibit tumorigenicity. Chromosome 4p15.115.3 is one of the most commonly deleted region (57%) reported in breast cancer [149],
which would deplete expression of EcSOD in these cancers.
Loss of EcSOD expression, in addition to having a tumor promoting effect, also
contributes to tumor recurrence and poor patient outcome. Local relapse remains a
significant issue for breast cancer patients who have undergone breast conserving
surgery [150]. In a murine 4T1 cytoreductive surgery model study aimed at identifying
mechanisms driving local recurrence, EcSOD was found to be one of the top 40 genes
underexpressed in the recurrent tumors versus primary tumors (fold change = 4.8)
[151]. The recurrent tumors grew at a significantly accelerated rate compared to
controls, suggesting that down-regulation of EcSOD is one of the contributing factors
leading to tumor aggressiveness. More significantly, low expression levels of EcSOD are
associated with reduced relapse-free survival in multiple subtypes of breast cancer. An
integrative microarray data analysis using the Kaplan Meier Plotter [152] shows that low
EcSOD expression is associated with significantly reduced relapse free survival in all
breast cancers, as well as in Luminal A (ER+ and/or PR+, Her2−), Luminal B (ER+
and/or PR+, Her2+), Her2+, or basal-like (ER−, PR−, Her2−, CK 5/6+, and/or EGFR+)
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breast cancers (Figure 1.5). More profound changes in the hazard ratio (HR) for the
association are seen when restriction was set to exclude untreated patients (systemic
therapies) in the analysis (right panel). Taken together, all of the evidence discussed
here underscores the importance of EcSOD as a potential tumor suppressor gene,
inhibiting the progression of malignant phenotype in human breast cancer.

1.3.7.2 Lung Cancer
Despite the protective role of EcSOD in normal lung function, relatively little
information describes its role in lung cancer. EcSOD expression is significantly downregulated in primary human lung cancer compared to normal lung tissue, with further
reduction occurring between stages I and IV [153-155]. Overexpression of this
extracellular enzyme in lung cancer cells reduced clonogenic survival and invasion via
inhibition of NF-κB activation [153, 156], suggesting a tumor suppressive role of EcSOD
in lung cancer. EcSOD may also play a role in gemcitabine resistance, as it is was
identified amongst the gene set that was found to be upregulated in resistant non-small
cell lung cancer cell lines [157]. However, it is not known if EcSOD directly confers
resistance of cells against gemcitabine or upregulation of this gene is merely an indirect
response to the cytotoxic effects of gemcitabine. In summation, EcSOD likely functions
as a tumor suppressor and further investigation of its direct involvement in mediating
sensitivity to gemcitabine would help to shed light on its role in drug resistance in lung
cancer.

1.3.7.3 Prostate Cancer
Confirming Oncomine analysis, IHC studies of prostate tissue revealed a
significant reduction of EcSOD expression in cancer tissue compared to the normal
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Figure 1.5. Analysis of breast cancer data by Kaplan-Meier Plotter stratifying patient
outcomes based on EcSOD expression in breast cancer subtypes
Kaplan-Meier plots (http://kmplot.com) show that low EcSOD expression is significantly
associated with poor outcome (relapse free survival, RFS) in all types of breast cancer
examined. Left panel shows analyses performed on all patients regardless of treatments
while systemically untreated patients were excluded in analyses shown on the right. In
red, patients with expression above the median and in black, patients with expressions
below the median. The numbers of samples in each group are indicated in parentheses,
and the hazard ratios (HR) and log rank p values are shown. Gene expression data and
survival information are downloaded from GEO (Affymetrix HGU133A and HGU133+2
microarrays), EGA and TCGA.
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counterparts [158]. Additionally, EcSOD levels and activity significantly decreased
between high and intermediate grade prostate carcinomas, as well as in prostate cancer
cell lines compared to normal prostate epithelial cells [159]. Migration and cell growth
was also inhibited in a dose-dependent manner by overexpression of EcSOD or addition
of recombinant human EcSOD [158]. The authors further showed that the inhibitory
effects of EcSOD are due to reduced MMP2/MMP9 expression and activity, as well as
increased H2O2 production. Other groups have since further correlated EcSOD
expression with reduction of MMP2 activity and invasion in prostate cancer [159, 160].
These studies highlight the role of this secreted antioxidant in regulating key extracellular
enzymatic activities that promote invasion and metastasis.

1.3.7.4 Pancreatic Cancer
EcSOD mRNA expression and IHC analysis reveal significantly decreased
levels of EcSOD in tumor tissue compared to normal pancreatic ductal epithelium in
paired and unpaired samples [161]. EcSOD loss is associated with a reduction in mean
survival from 11.0 to 6.5 months in patients with pancreatic adenocarcinoma [161].
EcSOD over-expression inhibits in vitro cell proliferation, invasion, and clonogenic
capacity of pancreatic cancer cells in a dose-dependent manner [161-163]. Furthermore,
both transient and stable over-expression of EcSOD inhibited primary tumor growth and
increased survival in tumor xenograft models [161-163]. EcSOD was also found to
decrease levels of VEGF and HIF-1α protein levels in pancreatic cancer cell lines [162,
163]. Since HIF-1α and VEGF promote angiogenesis, EcSOD is likely inhibitory,
restricting blood flow to the tumor. However, EcSOD may also promote survival of
quiescent pancreatic cancer cells as revealed by Deng et al [164] where they showed
that Mirk/Dyrk1B kinase maintains the viability of quiescent pancreatic cancer cells by
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upregulation of both CuZnSOD and EcSOD thereby lowering ROS levels in quiescent
SU86.86 and Panc1 cells.

1.3.7.5 Thyroid Cancer
Expression levels of EcSOD have been shown to be slightly increased in a
benign thyroid tumor goiter model but gradually downregulated in cell lines that model
advanced papillary and anaplastic thyroid cancers correlating with the level of Ras
oncogene activation [165, 166]. Although growth promoting effects of EcSOD at lower
levels have been shown in a thyroid cancer cell line, PCCL3 [167, 168], inhibitory effects
of this antioxidant in cells harboring p53 mutations resulted in reductions in cell growth,
invasion, and soft agar colony formation [169, 170]. Thus, EcSOD may have biphasic
effects on tumor progression switching from a tumor promoter during tumorigenesis to a
tumor suppresser shortly after transformation. The authors further implied that disparate
effects seen with EcSOD overexpression are due to the dose-dependent responses.
Interestingly, high levels of EcSOD, although inhibited cellular proliferation were found to
promote phosphorylation of various receptor tyrosine and non-receptor tyrosine kinases
such as EGFR, ERBB2, and FLT-3 [166, 169]. Propagation of cellular signaling was
halted due to inhibition of small GTPases, (Ras, Rac, Rho, and CDC42), thereby
decreasing activation of downstream effectors MEK and Erk [166, 169]. Thus, EcSOD
overexpression can promote cell cycle arrest and apoptosis via activation of p53 and
reduce cell growth via promoting inactivation of GTPases. Intriguingly, secretion of
EcSOD in the tumor stroma by mesenchymal stem cells (MSCs) increased the growth of
thyroid cancer cells in co-culture models despite having an inhibitory effect on their
migration (106). Further studies are needed to assess the extent and role of stromalderived EcSOD versus cancer cell-expressed EcSOD in thyroid cancer.
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1.3.7.6 Melanoma
Overexpression of EcSOD showed a prominent inhibitory effect in melanomas.
Inhibition of cell proliferation by IFN was mediated through increased expression of
EcSOD [171]. Moreover, muscle cell-mediated EcSOD secretion inhibited the growth of
B16 melanoma in mice via a decrease in VEGF expression [172]. Similarly, EcSOD
overexpressing transgenic mice demonstrated reduced growth of metastatic cancer cells
despite no effect on infiltration to the lungs after tail vein injection [171]. In a DMPA/TPAinduced skin carcinogenic model, skin-specific EcSOD transgenic mice showed half the
number of tumors compared with the nontransgenic mice by reducing DNA damage
associated with the carcinogens [173]. A metabolomics and transcriptomics analysis
however, revealed EcSOD as one of the upregulated genes in tumors recovering from
chemotherapy treatment [174]. This is likely due to the severe oxidative stress in both
localized chemotherapy-treated and bystander tumors as suggested by the authors.
Overall, EcSOD has a clear anti-proliferative and anti-tumor role in melanoma.

1.3.7.7 Additional Cancers
In addition to the cancer models described above, EcSOD expression is also
decreased in colorectal cancer compared to paired normal controls [175]. In a liver
cancer study, expression of EcSOD was increased by Farnesoid X receptor activity,
which by inhibiting JNK activation, inhibited liver carcinogenesis, providing indirect
evidence of the tumor suppressive role of EcSOD [129]. In renal cell carcinoma tissues,
higher EcSOD expression correlated significantly with higher levels of apoptosis, as
indicated by TUNEL staining [176]. Although down-regulation of EcSOD is reported in a
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majority of cancers, serum levels of EcSOD were observed to be increased in patients
with gastric adenocarcinoma and prolactinoma, a benign pituitary gland tumor,
compared to healthy controls [177, 178]. However, the cause or role of increased serum
EcSOD in either case remains unclear.
Other studies further indicate a potential role of EcSOD in therapy response and
tumorigenesis. EcSOD expression can promote inhibition of radiation induced lung
damage, such as myofibroblast expansion, oxidative stress, and fibrosis, via injection of
mesenchymal stromal cells [179]. Additionally, EcSOD may play a role in obesity
induced tumorigenesis, as EcSOD gene transfer in mice inhibited high fat diet-induced
obesity and fatty liver [180]. It also reduced pro-inflammatory crowns, which are formed
by the recruitment of macrophages to hypertrophic and necrotic adipose cells [180]. Both
obesity and crown-like structures are associated with increased risk of breast cancer
[181, 182]. These studies highlight the potential role of EcSOD in protecting healthy
tissue from chronic inflammation and reducing the risk of cancer.

1.3.8

Plasma EcSOD in Cancer
Since EcSOD is a secreted protein, whether there is any correlations between

the plasma levels of this antioxidant with cancer progression are of a high interest.
Numerous studies have assessed the activity of serum/plasma SOD in cancer patients
versus the normal patients but the results are controversial and largely inconclusive. For
example, in breast cancer studies, plasma SOD activity has been found to be lower in
patients with malignancy in comparison with the control group [183-185], while a reverse
observation was reported showing higher SOD activities in patients with breast cancer
versus the control patients [186-188]. Similar opposing results were also reported for
prostate cancer [189, 190]. Importantly, these studies relied on commercially available
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SOD activity kit assays which do not discern the 3 distinct forms of SODs. Specific
activity of EcSOD can be further differentiated from the total SOD activities by including
a Concanavalin A–based purification step. However, since Concanavalin A only binds to
the full length ECSOD, this will exclude the detection of the truncated form of EcSOD,
and therefore may not be a reliable method to account for the total EcSOD activity
levels. Nevertheless, since circulating levels of EcSOD could be contributed by other
tissues and organs, assessing plasma levels of this antioxidant is likely not an accurate
measurement of the specific expression levels of EcSOD in localized tumor tissues.
Furthermore, EcSOD exists in both tissue-bound and freely circulating form due to its
unique HBD. A significant portion of the full length EcSOD, despite having a strong
affinity for negatively charged ECM molecules, is also released into the circulation.
Various factors such as heparin, a commonly used blood-thinning agent, also influence
this dynamic redistribution of EcSOD. Therefore, a snap-shot measurement of this
extracellular antioxidant in the blood is likely not a true reflection of the total levels of
EcSOD secreted by cancer cells. Perhaps determining the released form of EcSOD
locally i.e. in nipple aspiration fluid (NAF) may provide a better assessment in the breast
cancer model. The levels of SOD1 protein expression in NAF has been reported to be
similar between normal patients and breast cancer patients [191]. Although one would
speculate an alteration in the extracellular levels of EcSOD due to its secretory nature,
levels of EcSOD in NAF of breast cancer patients remain to be evaluated.

1.3.9

Deregulation of EcSOD in Cancers
The degree of difference in EcSOD expression in cancer versus normal

cells/tissues is more pronounced and prevalent than for other SODs as shown in
Oncomine analysis (Figure 1.5). Down-regulation of EcSOD expression in cancer has
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been associated with epigenetic silencing, upregulation of oncomir microRNA-21, Ras
oncogene-mediated gene silencing, chronic estrogen-induced gene suppression, single
nucleotide polymorphisms, DNA copy number variation, and loss of heterozygosity. All of
these observations imply that deregulation of EcSOD expression, distribution, or function
has a clinical significance. In view of predominantly down-regulated EcSOD expression
in a majority of cancers and a tumor suppressive role as supported by a large number of
in vitro and in vivo models, understanding the mechanisms involved in deregulation of its
expression could provide a tool towards therapeutic interventions. The mechanisms
known to regulate EcSOD expression in cancers is discussed in the following sections.

1.3.9.1 Epigenetic
One of the most well studied mechanisms regulating EcSOD silencing is DNA
methylation. EcSOD lacks a standard CpG island but contains a cluster of 18 CpG sites
surrounding the transcriptional start site (-550 bp upstream to 100 bp downstream) with
known transcription factor binding sites, such as Sp1/Sp3. SOD3 CpG sites have been
reported to be hypermethylated in tumor tissue from gallbladder, liver, prostate, lung,
and breast cancer samples [142, 153, 192-194]. Furthermore, SOD3 promoter
hypermethylation correlated with decreased mRNA expression indicating epigenetic
silencing via promoter DNA methylation [192]. SOD3 is also hypermethylated and
downregulated in other diseases, such as coronary artery disease [195]. Highlighting the
functional role of epigenetic silencing of EcSOD, treatment with 5-aza-2'-deoxycytidine
(5-aza-dC), an inhibitor of DNA methylation increased EcSOD expression in both
normal and cancer cells [142, 153, 159, 196-198]. This methyltransferase inhibitor
increased DNA accessibility via nucleosome remodeling thereby increasing RNA
polymerase II and Sp3 binding to the SOD3 promoter [198]. In Ras-driven thyroid
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cancers, loss of EcSOD expression has also been shown to be affected with 5-aza-dC
treatment, where mutant H-RasV12-mediated suppression of EcSOD was reverted
[166].
Interestingly, methylation status of the EcSOD promoter can be influenced by the
presence of extracellular matrix (ECM) or Matrigel in culture. While significant
expression of EcSOD is detected in mammary epithelial cells in normal tissues, once the
human mammary epithelial cells (HMECs) were isolated and plated as monolayer cells,
there was a progressive loss of EcSOD mRNA expression as the cells were passaged
without the ECM stimuli [142]. This was due to hypermethylated promoter of EcSOD
when cells lose their polarity and acinari architecture. On the other hand, restoring the
three dimensional (3D) acinar morphogenesis by culturing the HMEC cells in Matrigel
induces re-expression of EcSOD and its promoter region became largely unmethylated
[142]. Similarly, the expression pattern of another mammary-tissue specific gene, milk
casein has also been shown to be regulated in this manner, where cell culture content
and context can dictate gene expression via epigenetic mechanisms [199, 200].
Interestingly, the change to 3D culture did not restore EcSOD expression in the breast
cancer cells, presumably due to inability to form normal acini but instead displayed an
disorganized stellate growth in 3D culture [142]. These studies reveal a novel process by
which ECM integrates structure and function in mammary epithelial cells through
alterations of chromatin structure and epigenetic codes.
Additionally, SOD3 methylation patterns may be impaired via a reduced ability to
remove DNA methylation. DNA methylation removal is initiated by the ten-eleven
translocation (Tet) family members, which are dioxygenases of 5-methylcytosine (5-mC).
EcSOD expression is positively correlated with Tet1 expression in several tumor cell
types, where Tet1 expression increases EcSOD expression via de-methylation of its
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CpG sites [201]. Interestingly, Tet1 is often downregulated in several types of solid
cancer, such as breast, lung, colorectal, and gastric cancer [202], suggesting a potential
mechanism of EcSOD silencing in cancer via downregulation of Tet1 [201].
Alterations to the glutamate carboxypeptidase II (GCPII) also modify methylation
patterns resulting in changes in EcSOD expression. GCPII promotes folate uptake,
which promotes DNA methylation by regenerating the methyl donor S-adenosyl
methionine. In prostate cancer, EcSOD expression correlates with mutations in GCPII
[193]. The GCPII D191V mutation promotes SOD3 hypermethylation and is associated
with an increased risk of breast cancer [193, 203]. Additionally, the GCPII H475Y variant
is associated with decreased SOD3 methylation and decreased risk of breast and
prostate cancer [193, 204]. These studies imply an interplay between EcSOD and GCPII
variants associated with cancer risk via changes in the folate cycle and DNA methylation
status of EcSOD.
Histone modifications and histone variants can also play a pivotal role in
epigenetic regulation. Histone acetylation typically promotes gene expression by relaxing
the condensed nucleosome complex allowing for easier access to genes. Inhibitors
against histone acetyltransferases (HATs), such as GCN5, p300, and PCAF, prevented
EcSOD increases in a stimulated monocytic leukemia cell line, THP-1 [196]. Additionally,
several studies have demonstrated increased EcSOD expression with histone
deacetylase (HDAC) inhibitors [142, 196, 197, 205, 206]. Specifically, inhibition or
knockdown of HDAC3 led to increased EcSOD expression in pulmonary artery smooth
muscle cells [205]. HDAC3 is upregulated in many solid cancers, such as lung, breast,
pancreatic, liver, and colon, indicating another potential mechanism of EcSOD silencing
in cancer [207-211]. Although, HDAC inhibition may also indirectly increase EcSOD
expression via loss of thyroid stimulating hormone autocrine signaling [166, 168], these
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studies indicate that decreased histone acetylation can contribute to silencing of EcSOD
in cancer.
Not only are histone modifications able to modify EcSOD expression, but
changes in histone variants have recently been shown to play a role in expression of this
antioxidant. Histone variants mediate a variety of functions, such as modifying
expression, controlling chromatin condensation, sensing DNA damage, and controlling
the cellular response toward DNA damage repair or apoptosis [212]. MacroH2A isoforms
are unique H2A histone variants due to the presence of a 30-kDa non-histone domain
(macro domain) at their C-termini. MacroH2A variants are generally considered
transcriptionally repressive in nature due to their association with forms of condensed
chromatin such as the inactive X chromosome (Xi) and inactive genes [213, 214].
MacroH2A1, a variant in the H2A family, has dramatic effects on cancer progression
dependent on its splice variant expression. The splice variant, macroH2A1.1, inhibits
proliferation, invasion, migration, and is associated with better prognosis, while
macroH2A1.2 is associated with cancer progression [212]. Interestingly, altered RNA
splicing via increases in RNA helicase, Ddx5 and Ddx17 promoted macroH2A1.2 which
resulted in suppression of EcSOD expression in a mouse mammary tumor cell line, 4T1
[215]. These macroH2A1 splice variants had opposing effects on SOD3 expression.
MacroH2A1.1 increased SOD3 expression in 4T1 cells, while macroH2A1.2 decreased
its expression [215]. Ddx5 and/or Ddx17 is overexpressed in a variety of solid cancers,
such as breast, colon, prostate, non-small cell lung, head and neck, glioma, and
leukemia [216-222]. Therefore, increases in Ddx5 and Ddx17 leading to higher
macroH2A1.2 levels are an additional mechanism of EcSOD down-regulation in cancer.
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1.3.9.2 Single Nucleotide Polymorphisms
Alterations of EcSOD expression, tissue distribution, and/or function can also
occur via single nucleotide polymorphisms (SNPs). Here, we will highlight the research
into EcSOD SNPs and their effect on cancer risk and progression. These SNPs include
rs1799895, rs2536512, rs2284659, and rs699473 as shown in Table 1.1.
The most extensively studied SNP is rs1799895, which occurs in the protein
coding region and results in an arginine to glycine mutation at position 213 (R213G).
This missense mutation occurs within the heparin binding domain of EcSOD drastically
reducing the binding of EcSOD to heparin, as a result increasing circulating EcSOD [95].
The R213G mutation also inhibits the ability of EcSOD to bind lipoprotein receptorrelated protein (LRP), which promotes its uptake by LRP-mediated endocytosis and
eventual clearance by the liver [98]. As a result, patients with R213G have a ~10-fold
increase in plasma EcSOD activity levels [95]. It is also associated with decreased
development of chronic obstructive pulmonary disease (COPD) in smokers [223]. Metaanalysis of many studies indicate smokers with COPD are associated with an increased
risk of lung cancer [224]. These studies indicate it may provide protection to smokers
from lung cancer development. Indeed, the R213G SNP in lung cancer is associated
with a protective phenotype as it was enriched in healthy control smokers compared to
lung cancer patients [225]. It is also associated with the number of lesions in metastatic
gastric cancer [226]. Although, in a large study assessing the role of R213G SNP within
the Danish population, the mutation was found to have no effect on the overall risk of
cancer [227]. Despite the dramatic change in localization of SOD3 caused by the R213G
mutation, these studies suggest that it likely has no effect on cancer risk, except for a
potential protective role in lung cancer.
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Table 1.1. Summary of EcSOD SNPs with associated cancer risk.
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SNP

Location

Mutation Effect on Cancer

rs1799895

Coding region

C→G;

Decreased risk of lung cancer

R213G

[224]

(Ex3-631C>G)

Increased number of lesions in
metastatic gastric cancer [226]
rs2536512

Coding region

A→G;

Increased risk of hepatocellular

A58T

carcinoma [228]
Increased risk of glioma [229]
Associated with
estrogen/progesterone receptor
expression in breast cancer [144]

rs2284659

Promoter

G→T

In a 4 SNP set that results in
increased risk of breast cancer
[230]

rs699473
(IVS1+186C>T)

Promoter; AhR-

C→T

Enriched in high-grade prostate

XRE binding site,

cancer [231]

CpG Island

Decreased progression free
survival in breast cancer [144]
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The SNP, rs2536512, similarly occurs within the coding region of SOD3 and
results in a missense mutation of alanine to threonine at residue 58 (A58T). This
mutation occurs within the oligomerization domain of EcSOD and is hypothesized to play
a role in protein tetramerization. There are conflicting results about its effect on plasma
EcSOD activity [232, 233]. However, to date there is little known about the effect of the
A58T mutation on EcSOD activity, localization, or oligomerization. In cancer, it is
associated with increased risk of hepatocellular carcinoma and glioma [228, 229].
Similarly, it is correlated with estrogen and progesterone receptor expression in breast
cancer patients [144]. The A58T mutation also increases risk of other diseases, such a
cerebral infarction in women, type 2 diabetes mellitus, and diminished lung function in
children [234-236]. The functional effect of this mutation remains unclear and requires
further study to fully understand its role in cancer.
The SNP rs2284659 occurs within the SOD3 promoter. Due to its location in the
promoter, it may modify expression of EcSOD. However, the effect of this SNP on
EcSOD expression is unclear as it does not occur within any known transcription factor
binding domains. In cancer, the SNP rs2284659 is associated with an increase in breast
cancer incidence [230]. It is also associated with higher plasma levels of EcSOD in
diabetic patients [237]. However, the mechanism behind the increase in patients with the
SNP rs2284659 remains unclear.
Another EcSOD SNP shown to affect cancer risk is rs699473. This SNP occurs
within the aryl hydrocarbon receptor-xenobiotic response element (AhR-XRE) binding
motif of the EcSOD promoter. The mutation causes reduced binding capacity of nuclear
proteins and alteration of a CpG site potentially perturbing DNA methylation at this
location [153, 234]. The resulting effect on EcSOD expression remains unclear. In
cancer, the SNP rs699473 is associated with increased risk of high-grade prostate
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cancer [231]. Interestingly, this SNP was also found to protect patients from increased
risk of high grade prostate cancer after selenium supplementation in the Selenium and
Vitamin E Cancer Prevention Trial (SELECT) [238]. In breast cancer, SNP rs699473 is
associated with a significant reduction in the progression-free survival in breast cancer
compared to patients with wild type EcSOD [144]. This SNP has also been linked to an
increased risk of adult brain cancer, specifically meningioma and possibly glioma [239].

1.3.9.3 Loss of Heterozygosity
SNPs are not the only genetic abnormality regulating EcSOD in cancer. Loss of
heterozygosity (LOH), also known as allelic deletion, is the process by which a cell
deletes one of the two copies of a gene. Allelic deletion in cancer cells results in
hemizygotes containing only one parental copy of that gene. As EcSOD has several
SNPs, it is likely that parentally inherited SNPs of EcSOD exist in a heterozygous state.
Therefore, LOH may help expose functional roles of SNPs in EcSOD previously masked
by the deleted allele. In addition to unmasking SNP phenotypes, allelic deletion often
results in reduced gene expression. Several reports indicate the SOD3 gene, located on
chromosome 4p15.3-4p15.1, is a hotspot for LOH in cancer. The deletion of
chromosome 4p15.1-15.3 has been observed in many types of solid cancers, such as
cervical, breast, head and neck, liver, colorectal, lung, and bladder [149, 153, 240-248].
These loses range from 30% in bladder cancer up to 60% in lung cancer [245, 248].
LOH of this region increases dramatically between cervical intraepithelial neoplasia and
grade I cervical cancer suggesting that allelic deletion occurs early in tumorigenesis
[240]. LOH plays a role in EcSOD suppression in the lung cancer cell line, A549
indicating both LOH and DNA methylation mediate EcSOD silencing in these cells [153].
Moreover, 17β-estradiol induced transformation of the normal breast epithelial cell line,
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MCF10F, resulted in loss of chromosome 4p [249]. Thus, indicating a potential role of
estrogen in EcSOD deletion in breast cancer.

1.3.9.4 MicroRNA
Expression of EcSOD can also be regulated by microRNA, which are a class of
small (~22 nucleotides) non-coding RNAs that negatively regulate gene expression posttranscriptionally [250]. Currently, miR-21 is the only known microRNA to directly target
EcSOD, as it binds a 3’ UTR site in EcSOD mRNA [251]. MiR-21 is considered an
oncomir and is upregulated in both leukemias and solid cancers of the lung, breast,
prostate, pancreas, stomach, colon, ovaries, cervix, and thyroid [252-256]. MiR-21 has
diagnostic and prognostic value, as its expression typically increases with tumor grade
[256]. Other targets of miR-21 are tropomyosin 1 (TPM-1), programmed cell death
protein 4 (PCDCD4), reversion-inducing cysteine-rich protein with kazal (RECK),
maspin, NFIB, Sporouty2, and PTEN [256]. Overexpression of miR-21 in nontransformed immortalized human bronchial epithelial cells (NL20) reduced EcSOD levels
and increased transformation as shown via colony formation in soft agar [251].
Transformation was blunted by re-expression of EcSOD, supporting a tumor suppressive
role for EcSOD [251]. Additionally, miR-21 levels were significantly increased after >10
fold increases in Ras activity via expression of mutant H-RasV12 leading to decreased
EcSOD expression [166]. Therefore, cancer cells can also silence EcSOD expression
via upregulation of the oncomir miR-21.
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1.4

Redox-Active Drugs in Breast Cancer Treatment

As highlighted above, ROS is implicated in every hallmark of cancer. Therefore,
researchers have set out to find a way to target ROS effectively in the context of cancer
prevention and treatment. The first and most obvious choices for treatment were the
dietary antioxidants, beta-carotene, vitamin A, C, and E, to reduce cancer risk. There
have been many studies done to assess if low consumption of these antioxidants would
increase the risk of cancer. A meta-analysis of 11 different studies indicated that dietary
intake of β carotene, vitamin A, C, or E had no effect on breast cancer risk [257]. While
further analysis of serum levels of these same antioxidants also showed an
inconsistently mild effect or no effect at all on breast cancer risk [257]. Furthermore,
there have been several high-profile randomized clinical trials set up to test the idea of
antioxidant and/or multivitamin supplementation to reduce cancer risk. These trials
include the SELECT, SU.VI.MAX, CARET, and ATBC trials. These trials found no
evidence of reduction in cancer risk in women [258]. However, when using a
multivitamin, men had a slight reduction in cancer incidence in the SU.VI.MAX and
Physicians’ Health Study II trials [259, 260]. Therefore, while ROS may play a role during
tumor initiation, the use of dietary antioxidants is ultimately ineffective at preventing
cancer formation.
Despite the contention over the role ROS plays during cancer formation, it plays
an undeniable role during cancer treatment. Due to the inherent high levels of ROS in
cancer cells, there are two options for modifying ROS levels in cancer; increase ROS
levels to promote cell death or decrease ROS levels to inhibit cancer cell growth as
indicated in figure 1.1. This concept is oft referred to as the “double-edged” sword of
ROS in cancer treatment. The most common examples of ROS inducing cancer
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therapies are radiation and chemotherapy, which both rely on ROS to induce apoptosis.
Ionizing radiation generates ROS/RNS directly as it is absorbed by water or organic
molecules, which leads to toxic levels of ROS in cancer cells [261]. Chemotherapies are
a broad category of drugs that target cell growth. These chemotherapy drugs can result
in both a direct and an indirect increase of ROS levels ultimately leading to cytotoxic
effects [262]. This phenomenon is evident by analysis of chemoresistant breast cells.
These resistant cells have significantly increased genes required to produce glutathione
[263]. Furthermore, addition of antioxidants decreases cell death induced by doxorubicin
[264]. However, these therapies also have off-target effects due to damage induced to
normal cells. Due to the severity of these negative effects, the idea of combining
chemotherapy/radiation with antioxidants to reduce off-target effects has been tested.
The use of dietary antioxidants has been found to slightly reduce the severity of offtarget effects with little to no effect on tumor response [265].
Furthermore, the current therapeutic approach in cancer treatment is
combination of multiple drugs to enhance efficacy. In the context of redox-active drugs,
there are several drugs in clinical trials built on the idea of modifying ROS levels;
increasing ROS to enhance efficacy and reducing ROS to decrease off-target toxicity.
Targeting the antioxidant thioredoxin (TRX) system has been a promising approach. The
TRX system is upregulated in many cancers and is associated with higher proliferation,
metastasis, and chemoresistance, as well as decreased apoptosis [266, 267]. Thus,
TRX inhibitors, aurofin and arsenic trioxide, are both currently in multiple phase I/II
clinical trials for solo and combination therapy as cancer treatment [268]. Additionally,
sulindac, a non-steroidal anti-inflammatory drug, inhibited mammary carcinogenesis and
cancer cell growth, as well as induced apoptosis in breast cancer cell lines [269]. Later
studies determined that sulindac-derived ROS induced apoptosis via activation of p38
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mitogen-activated protein kinase and p53 [270]. A phase II clinical trial was launched to
determine if combination of docetaxel and sulindac would improve efficacy in advanced
breast cancer patients (NCT00039520).
Despite their lack of efficacy in cancer prevention, dietary antioxidants are
currently being tested for their efficacy as a treatment in cancer. Fenretinide is a
synthetic retinoid that induces apoptosis in a ROS-dependent mechanism [271]. A phase
III clinical trial in breast cancer patients showed that it decreased breast cancer
recurrence, especially in younger pre-menopausal patients [272]. Additionally, it is
currently being tested in a clinical trial in recurrent ovarian cancer patients
(NCT01535157). Vitamin C has also made a reappearance in cancer treatment. It was
found that high-dose vitamin C, which requires intravenous injection, generates ROS in
cancer cells. Due to the uniquely high intracellular free iron found in cancer cells, vitamin
C redox cycles with iron to generate H2O2, which ultimately creates toxic levels of ROS,
resulting in cancer cell death [273, 274]. The high-dose vitamin C, or pharmacological
ascorbate, therapy is currently in many phase II clinical trials for lymphoma
(NCT03418038), acute myeloid leukemia (NCT03397173), hepatocellular carcinoma
(NCT04033107), gastric cancer (NCT04033107), glioblastoma (NCT02344355), colon
cancer (NCT04035096, NCT03146962, NCT04033107), lung cancer (NCT02905591,
NCT02420314, NCT03146962) and pancreatic cancer (NCT03410030, NCT03146962,
NCT04033107, NCT02905578), as well as a phase III trial in gastric cancer
(NCT03015675). These trials highlight the optimism around this therapy, as well as
demonstrate the potential duplicity of redox-active drugs.
Current use of drugs to lower ROS levels are largely focused on reducing offtarget cytotoxic effects. Vitamin E has been used to reduce oral mucositis, an off-target
effect of radiation in head and neck cancers [275]. Additionally, N-acetyl cysteine
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(NAC), a well-known antioxidant and GSH precursor, is also being tested in a phase II
clinical trial to reduce oral mucositis in head and neck cancer patients undergoing
radiation therapy (NCT02123511). NAC was also used a phase IV clinical trial to reduce
cisplatin-induced toxicities in head and neck cancer patients (NCT02241876).
Furthermore, SOD mimetics are also being used to reduce the negative effects of high
ROS levels induced by chemotherapy and radiation. GC4419, a SOD mimetic,
completed a phase IIb clinical trial and has started a phase III trial to reduce severe oral
mucositis in head and neck patients that receive radiotherapy and cisplatin treatment
[276]. The rationale for this study was piloted by the work done with a different class of
SOD mimetics, the manganese porphyrin drugs. Due to the heavy use of the
manganese porphyrin in my work, the following is a more in-depth overview on this class
of redox-active drugs.

1.4.1

Manganese Porphyrin
Manganese (III) porphyrin (MnPs) are a family of redox-active drugs. They were

initially designed as a SOD mimetic. The manganese core of MnPs can accept and
donate electrons, which is a required a characteristic of SOD enzymes as mentioned
above. The structure of the porphyrin ring pulls electrons away from the Mn core
preventing stabilization of Mn(III) and allowing it to accept electrons from O2•− and other
ROS species. Thus, MnPs undergo a redox couple with MnIII/MnII, whereby MnPs react
two O2•− molecules to create O2 and H2O2 and regenerate Mn(III)P [277]. Several
analogs have been made over the years based off the initial MnTR-2-PyP5+ design,
where R indicates different substitutions. The main analog used in these studies is
MnTE-2-PyP5+ (MnTE) shown in figure 1.6. MnTE is well tolerated in pre-clinical trials
and is currently in clinical trials for acne vulgaris (NCT03752242), rosacea
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Figure 1.6. MnTE-2-PyP5+ chemical structure
The diagram represents the chemical structure of MnTE-2-PyP5+.
Figure from:
Tovmasyan A.G., Rajic Z., Spasojevic I., Reboucas J.S., Chen X., Salvemini D., Sheng
H., Warner D.S., Benov L., Batinic-Haberle I. Methoxy-derivation of alkyl chains
increases the in vivo efficacy of cationic Mn porphyrins. Synthesis, characterization,
SOD-like activity, and SOD-deficient E. coli study of meta Mn(III) N –
methoxyalkylpyridylporphyrins. Dalton Transactions. 2011; 40 (16): 4111-4121.
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(NCT03756389), atopic dermatitis and plaque psoriasis (NCT03381625) [278]. Another
analog of MnPs, MnTnBuOE-2-PyP5+, is also in clinical trials for anal cancer
(NCT03386500), glioma (NCT02655601), head and neck cancer (NCT02990468), and
patients with multiple brain metastases (NCT03608020) as a radioprotectant.
Interestingly, over the years, researchers have discovered that MnPs have much
a wider range of potential reactions than just mimicking SOD activity. The SOD enzymes
have the bulky tertiary protein structure that provides selectivity toward O2•−. However,
the MnPs lack this bulkiness allowing for a wider range of reactions to occur. MnPs have
been shown to react with ONOO−, H2O2, GSH, and ascorbate to name a few [279, 280].
Similarly, MnPs can act as both an oxidizing and reducing agent resulting in the
production of hydrogen peroxide [277]. These effects usually occur with combination of
MnPs and ascorbate and/or radiation [279, 281, 282]. MnPs may also redox couple via
MnIV/MnIII adding further complexity to range of MnP activity [277]. Due to the large
complex array of MnP reactions, the overall function of MnPs within the cell is highly
dependent on ROS levels, MnP concentration, and the associated rate constants of the
reaction. Thus, one can no longer generalize MnPs as a SOD mimetic requiring more
intense research on the exact effect of MnPs in each cellular context.
Studies have also found that MnPs affect not only ROS levels but also modify
signaling pathways and transcription factors. NF-κB, Nrf2, and Hif-1α are the
transcription factors that have their activity modified by MnPs. NF-κB is inactivated by
MnPs through glutathionylation of p65 [283]. Additionally, MnPs can increase protein
glutathionylation of mitochondrial proteins, Complex I and Complex III, inhibiting their
activity [284]. AP-1 activity, as assessed via an electrophoretic mobility shift assay
(EMSA), was inhibited via MnPs in the skin carcinogenesis mouse model induced via
12-O-tetradecanoylphorbol-13-acetate (TPA) treatment [285]. While the mechanism for
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this inhibition was never assessed, it is believed the mechanism is through MnPmediated ROS reduction, since ROS is a known activator of AP-1. Hif-1α protein levels
are decreased by MnPs during hypoxia in breast cancer cell line, MCF-7 [286]. MnPs
also decrease Hif-1α activity via disruption of the DNA binding of the CREB/HIF-1α
complex as seen in prostate cancer cell line, PC3 [281]. MnPs inhibited ROS-dependent
6-hydroxydopamine activation of ERK in neuronal B65 cells [287]. Additionally,
epigenetics is also regulated via MnPs. The histone acetyltransferase, p300, is inhibited
by MnPs in prostate cancer cells reducing HIF-1a [281]. Interestingly, MnPs can regulate
histone deacetylases as well. Recent studies have shown MnPs can modify the activity
of sirtuins via changes in the levels of their essential co-factor, NAD+, within the cell. The
NAD+ levels were increased via Nrf2-upregulation of Nqo1, a NAD(P)H dehydrogenase
that reduces quinones using NADPH or NADH in the process [288].
The effect of the MnPs on immune cells within the tumor is of particular interest
to my studies. In alveolar macrophages, MnPs reduces TGF-β and VEGF production
[289]. Also, macrophage infiltration in the 4T1 mouse model of stage IV breast cancer
was reduced by MnPs, along with reduced levels of angiogenesis and metastasis, which
are both induced by macrophages [290]. In other tumor mouse models, MnTnBuOE-2PyP5+ reduced monocyte infiltration and macrophage polarization [291]. Furthermore,
other immune cells, such as T cells, are affected by MnP treatment. CD4+ T cells
polarization is affected by MnP treatment with a skew toward TH1 [292-294].
Furthermore, splenic levels of T cells, B cells, and NK cells are increased after MnP
treatment [294].
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1.5

Breast Cancer Microenvironment

No man is an island. This is a common sayings used throughout academia to
highlight the collaborative work required to generate data while the spotlight is one
individual. These same sayings apply to cancer. Tumors are more than just the cancer
cells themselves. For many years, analyzing cancer cells growing in two dimensions on
plastic in hyperoxic conditions was the norm. Little energy was put into understanding
the three-dimensional nature of tumors could affect cancer cell aggressiveness.
Additionally, little research was done to understand the effect stromal cells within the
tumor on patient outcomes. However, in the last decade there has been an influx of
research into how the three-dimensional structure and the non-transformed surrounding
cells contribute to disease outcomes. These traits are all loosely grouped under the
umbrella term, the tumor microenvironment. The tumor microenvironment is an acidic,
oxidized, and hypoxic region made up of cancer cells, fibroblasts, endothelial cells,
lymphocytes, and myeloid cells held together by aberrant extracellular matrices.
Furthermore, a larger tumor stroma is a strong prognostic factor indicative poor survival
independent of breast cancer subtype [295, 296]. Many studies were launched to
determine if any of these characteristics within the tumor microenvironment play a role in
cancer growth, metastasis, recurrence, and patient survival to find new therapeutic
targets. I will focus on the role of fibroblasts and macrophages within the tumor
microenvironment, as well as the role of the oxidized nature of tumor, in this dissertation.
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1.5.1

Cancer Associated Fibroblasts
Cancer associated fibroblasts, or CAFs, are one of the most abundant cells in the

breast TME. These cells are commonly believed to originate from tissue resident
fibroblast. There are additional theories which suggest transdifferentiation of cancer cells
and other cell types, such as mesenchymal stem cells or pericytes, as an additional
source of CAFs [297]. Normal fibroblast activation into CAFs follows similar pathways as
myofibroblast activation. This activation is largely driven by transforming growth factor
beta (TGF-β) [298]. However, recent studies have determined that cancer cells secrete a
variety of additional factors that promote CAF activation, such as Wnt7a, osteopontin,
and breast cancer cell-derived exosomes [299-302]. Additionally, CAFs release TGF-β
and SDF-1 inducing signaling pathways in surrounding normal fibroblasts promoting
their activation [303]. These activated CAFs have higher levels of α-smooth muscle actin
(SMA), fibroblast activating protein (FAP), fibroblast stimulating protein (FSP), and
platelet-derived growth factor receptors alpha and beta (PDGFRα/β) [297]. CAFs are
also characterized by increased secretion of many cytokines, such as HGF, SDF-1, IL-6,
IL-10, and VEGF, and chemokines, such as CCL2, CCL5, and CCL20, which act to
directly promote tumor aggressiveness, metastasis, angiogenesis, and suppression of
the immune system [297, 304-306].
Additionally, CAFs cause dramatic changes to the extracellular matrix (ECM).
Interestingly, in breast cancer, there are specific ECM signatures that correlates with
breast cancer subtype and outcome [307]. The ECM components correlated with poor
survival in breast cancer are fibronectin, collagen, and tenascin-C, while laminins,
hyaluronic acid, and heparins are associated with a better outcome [308]. CAFs in
breast cancer produce high levels of fibronectin, collagen, and tenascin-C compared to
normal mammary fibroblasts, which promotes cancer cell migration [309-311]. CAFs
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also participate heavily in degrading the surrounding normal ECM with matrix
metallopetidases, MMPs. MMP-1, MMP-7, MMP-9, MMP-11, MMP-12, and MMP-14 are
all associated with a poor prognosis in breast cancer [297, 312]. Many of these MMPs
are upregulated during CAF activation [313, 314]. The combination of increased ECM
degradation with MMPs and increased ECM deposition results in a dramatic remodeling
of the ECM. This ECM remodeling promotes invasion of surrounding tissue by orienting
collagen perpendicular to the tumor boundary to allow for easier cancer cell migration
along these collagen highways [315]. Furthermore, increase ECM secretion enhances
the stiffness of the tumor and increases metastasis and tumor progression, as well as
promotes fibroblast growth and migration [316-319].
A newer study has also examined the stroma of breast cancer tumors to
determine what TME is indicative of a more aggressive disease. They found that stroma
with high levels of collagen or fibroblasts were indicative of a poor prognosis [320].
Additionally, many studies have begun using known CAF markers, α-SMA, FSP1, and
tenascin C, to determine if the number of activated fibroblasts within the tumor resulted
in a poorer prognosis [321-323]. These studies have repeatedly found that high level of
activated fibroblasts, or CAFs, are indicative of faster tumor growth, more metastasis,
and reduced survival independent of breast cancer subtype. Therefore, CAFs have a
vital role in determining the aggressiveness, especially in the most aggressive forms of
breast cancer, TNBC.
Interestingly, many studies are also beginning to highlight the heterogeneity that
exists within CAFs. Not only are there differences between normal fibroblasts and CAFs
as noted above, there are differences based on cancer cell that stimulates the transition
from normal fibroblast to CAF. The molecular subtype of breast cancer can result in
CAFs that have distinct gene and protein expression compared to the other subtypes
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[324, 325]. The data suggests that CAFs from Her2+ breast cancer were more divergent
than CAFs from either TNBC or ER+ breast cancer. These CAFs also had different
levels of aggressiveness as CAFs from TNBC and Her2+ breast cancer promoted
migration of breast cancer cells more than normal fibroblasts or CAFs from ER+ breast
cancer.
Newer studies have begun to use of single cell RNA-seq highlighting that there is
even CAF heterogeneity within tumors. Two new studies used this single cell
sequencing data to reveal that there are distinct populations of CAFs present within the
tumor. Busch et al. suggests that the distinct populations occur due to fibroblast
differentiation [326]. This model suggests stem-like fibroblasts progress through the
differentiation to activated CAFs that are predominantly either ECM-regulating
myofibrolasts or secretory myofibroblasts. However, Bartoschek et al. performing a
similar experiment on CAFs in the MMTV-PyMT mouse model found the cell of origin to
be the distinguishing factor between the different CAF populations. They found three
distinct CAFs populations originated from either resident fibroblasts, the perivascular
niche (potentially pericytes), or from malignant cells that had undergone epithelialmesenchymal transition [327]. The gene signature of the different CAF populations were
correlated with different levels of metastatic risk in patients from the TCGA database
indicative of different functions within the tumor.
In addition to the high-powered RNA-seq studies, loss of Cav1 has begun to be
recognized as a marker of a lethal TME in breast cancer, as it is linked to drug
resistance, metastasis, recurrence, and reduced survival [328, 329]. For example, low
stromal Cav1 TNBC had a ≤ 5 year survival rate, while high stromal Cav1 TNBC had a
12 year survival rate [330]. Unsurprisingly, Cav1 knockout fibroblasts have higher
myofibroblasts markers and collagen expression. However, these fibroblasts also have
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increased glycolytic markers, such as PKM2 and LDHA, suggesting these Cav1 loss
promotes increased glycolysis. Further research confirmed that Cav1 loss increased
aerobic glycolysis and lactate secretion through HIF-1α dependent mechanism [331].
Interestingly, the lactate was secreted by CAFs via increased levels of MCT4, a lactate
exporter, and taken up by nearby breast cancer cells expressing the lactate importer,
MCT1, suggesting CAFs may also modify the metabolism of the cancer cells within the
tumor [332]. Of particular interest to my research is the role ROS plays during activation.
Addition of hydrogen peroxide alone increased CAF markers and reduced Cav-1 levels
suggesting ROS plays a role during fibroblast activation toward CAFs [333].

1.5.2

Tumor Associated Macrophages
Macrophages are a key immune cell within the innate immune system. These

white blood cells are the first line of defense against most threats, including cancer.
These cells eat and degrade bacteria or defective/dying human cells via a process called
phagocytosis [334]. They also eat lipid particles and other non-cell particles. Thus,
during a typical wound response, macrophages play a key role during both the initial proinflammatory disinfect phase and the secondary wound closure phase. To provide both
functions’ macrophages undergo a process called polarization. Broadly, macrophages
can polarize toward two main extremes. This includes the pro-inflammatory M1 state and
immunosuppressive M2 state [335]. Macrophages polarize toward either of these states
depending on the external stimuli given to each individual cell. In practice, macrophage
polarization is much more complicated than either M1 or M2 states. Previously, IL-4, IL10, and conditioned media from cancer cells were thought to all produce M2
macrophages. However, recent studies using expression profiling and novel function
assays have determined these macrophages behave quite differently. Thus, some
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researchers have begun to subclassify M2 macrophages into M2a, M2b, and M2c class
depending on the stimulating agent [336]. Furthermore, recent studies have found novel
polarization states in macrophages, such as Mox and M4 in in atherosclerosis [337,
338]. While these systems provide a more nuanced view of macrophage polarization
and function, the initial M1/M2 model is still widely used and useful shorthand during
surface level discussions of macrophages in disease states.
To further stratify macrophage classifications, macrophages that invade into the
tumor stroma are called tumor associated macrophages (TAMs). TAMs are one of the
most abundant immune cells within breast cancer. TAMs typically have a M2-like
phenotype [339]. Functionally, TAMs play a key role in promoting an aggressive
phenotype in breast cancer via stimulating angiogenesis, metastasis, tumor growth, and
suppression of the immune system [340]. Co-culture experiments with macrophages and
a variety of breast cancer cell lines determined that TNBC cell lines polarized
macrophages more dramatically than other subtypes of breast cancer [341-343].
Analysis of cytokines secreted by these different cancer cell lines generated several
potential candidates responsible for polarizing macrophages, such as M-CSF, and GMCSF [342, 343]. Due to the high plasticity and ease at which macrophages adapt to their
surroundings, it is likely that it is a combination of signals that result in TAM formation.
Furthermore, cancer cells may not be the only cells within the tumor that affect
macrophage polarization. Recent evidence correlates macrophage infiltration and
fibroblast activation. M2 macrophages were positively correlated with CAF levels in
TNBC tumors before therapy as analyzed by IHC of CD163 as an M2 marker and αSMA and FAP as a CAF marker [344]. This correlation was suggested after analysis of
CAF secretome revealed secretion of cytokines and chemokines, such as IL-6, MCP-1,
and SDF-1, which are known to recruit the macrophage precursor, monocytes [304].
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Mechanistic studies using neutralizing antibodies revealed that CAFs secrete large
amounts of SDF-1 and MCP-1, which promoted monocyte recruitment [305, 345]. This
study also indicated that monocyte recruitment was similar in both CAFs and cancer
cells. Thus, CAFs, as well as cancer cells, play a key role in the enhanced macrophage
infiltration of breast tumors. Furthermore, CAFs also play a role in stimulating
macrophage polarization. Conditioned media from CAFs increased levels of M2 surface
markers, CD163 and CD206, as well as enhanced macrophage-mediated
immunosuppression compared to conditioned media from normal fibroblasts [305, 346].
Conditioned media from these CAF-conditioned macrophages also stimulated cancer
cell invasion further suggesting these macrophages are behaving as TAM. Interestingly,
conditioned media from M2 macrophages increased the CAF marker, SMA, in normal
fibroblasts suggesting a reciprocal interaction between CAFs and TAM [346]. These data
provide evidence that TAM recruitment and polarization is not a phenomenon solely
instituted by cancer cells but by multiple cells within the tumor.
Regardless of polarization state, the data is clear that macrophages overall
promote an aggressive phenotype in breast cancer. Several studies correlate increased
macrophage infiltration with increased metastasis and tumor size, as well as decreased
disease-free survival. More recent studies have begun testing if M2 markers provide a
better correlation than generic macrophage markers. These show similar trends from
generic macrophage markers, CD68, and M2 specific markers, CD163 [347-351]. Thus,
both macrophages generically and M2 specifically are associated with an aggressive
cancer. To test if there is a casual relationship, cancer mouse models were treated with
clodronate liposomes to remove macrophages [352]. The macrophage deficient mice
had decreased tumor growth and metastasis compared to control mice suggesting
macrophages play a casual role in the aggressiveness of breast cancer. Additionally,
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reprogramming of macrophages to M1 reduced 4T1 tumor growth [353]. These studies
provided the initial rationale for targeting macrophages moving forward.
The field is currently developing therapies to target macrophages through three
main methods: inhibiting macrophage recruitment, reprogramming TAM to the anti-tumor
M1 type, and depleting TAM by promoting cell death. The most well studied pathway
involved in macrophage recruitment in cancer is the CCL2/CCR2 pathways. CCL2
(MCP-1), a chemokine expressed by cancer cells and stromal cells, like adipocytes,
fibroblasts, endothelial cells, and macrophages, increases macrophage infiltration [354356]. Silencing of CCL2, reduced M2 macrophage recruitment and inhibited TNBC
progression in a humanized mouse model [357]. Similar to CCL2 inhibition, inhibition of
CSF1R reduces macrophage levels in tumors. However, CSF1R depletes macrophages
through removal a major survival pathway in macrophages [358, 359]. This results in
reduced metastasis in preclinical mouse models. Reprogramming of TAM is the most
diverse of the macrophage targeting strategies. These strategies range from targeting
histone deacetylases, CD47, MARCO, or PI3Kγ to activation of TLR7 or CD40 [360366]. All of these techniques have showed promise in mouse models and many of them
are currently in clinical trials highlighting the role of TAM during cancer progression.
Few studies have investigated the role of ROS in TAM polarization and function.
Modifying glutathione levels can alter macrophage secretion of IL-10 and IL-12
suggesting the redox status of macrophages could affect polarization [367].
Furthermore, the ROS inhibitor butylated hydroxyanisole (BHA), which prevents fatty
acid oxidation, inhibits M-CSF mediated M2 polarization [368]. However, BHA also has
off-target effects, which could also disrupt macrophage polarization [369]. Additionally,
loss of Nox-derived ROS inhibits M2 polarization in a mouse model for diabetes [370].
Whereas, increasing ROS induced M2 polarization in mouse macrophages [371].
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Despite these recent advances, the effect of ROS on polarization and function of TAM
and human macrophage polarization remains unclear.

1.5.3

Oxidized Tumor Microenvironment
It is well known that tumors have high levels of oxidation. Breast tumors have

increased levels of ROS markers, such as oxidized lipids, protein carbonyls, protein
nitrosylation, and others, compared to normal breast tissue [372-377]. Since breast
cancer cells have higher levels of ROS than normal breast epithelial cells, these data
were unsurprising [378]. Despite all the research done on how the increased intracellular
ROS levels affect breast cancer cells, very little data has been collected addressing the
role of extracellular ROS on tumor development and growth. However, there are some
studies that examined the role of exogenous ROS on cellular functions. Addition of H2O2
to fibroblasts promotes loss of Cav1, which as stated above promotes an aggressive
CAF phenotype in those fibroblasts [333]. The activated CAFs have increased hydrogen
peroxide secretion compared to normal fibroblasts, which inhibits PTEN activity in
normal epithelial cells ahead of the tumor, as well as promote tumor growth [379].
Furthermore, exogenous ROS can have immunosuppressive functions by promoting
Treg formation and by inhibiting the binding of the major histocompatibility complexes
(MHC) with the T cell receptor (TCR) in CD4 and CD8 T cells by nitrosylating the TCR
[380, 381].
Additionally, stromal cells within the TME are not the only thing affected by
increased ROS levels. The ECM is also modified by the oxTME. ECM proteins are
readily oxidized in vitro after addition of exogenous ROS. This oxidation causes
conformational changes that often result in fragmentation and degradation. ECM
fragments are known to have chemotactic activity for neutrophils and monocytes [382].
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They also induce pro-inflammatory gene expression and cytokine release in monocytes,
macrophages, and neutrophils. However, not all ECM fragments are created equal.
Different ECM fragments will have different effects on different target cells. Hyaluronan
fragments stimulates receptor CD44 and activates NF-κB activation and chemokine
expression in macrophages [383-385]. In breast cancer, hyaluronan fragments are
associated with poor outcome, disease recurrence, metastasis, and promote breast
cancer cell survival and migration [386, 387]. Heparan sulfate is also known to be
oxidized and fragmented via ROS. Oxidized heparan sulfate fragments activate the
TLR4 receptor and induce neutrophil chemotaxis [388]. Collagen, on the other hand,
undergoes proline oxidation causing backbone fragmentation into 2 pyrrolidone [389].
Oxidized type I collagen decreased cell survival in primary rat hepatocytes compared to
normal type I collagen. It also increased transcription factor activity in AP-1, Egr-1,
CREB, and NF-κB in these cells [390]. However, this effect may be cell-type specific as
oxidized collagen stimulated cell growth in vascular smooth muscle cells [391]. The
oxidized collagen may also affect the strength of attachment by smooth muscle cells as
they were detached via trypsin much easier than those grown on non-oxidized collagen.
In skeletal muscle cells, oxidized fibronectin increases focal adhesion kinase (FAK)
activation and promotes adhesion to the myotendinous junction [392]. Furthermore,
current studies are beginning to find that oxidation of polyunsaturated fats leads to 2-(ωcarboxyethyl) pyrrole (CEP) adducts that can bind to ECM proteins, such as fibrinogen.
These CEP-adducts are recognized by integrins αMβ2 and αDβ2 [393]. Macrophages that
express these integrins bind the CEP-adducts and increases their migration and
retention at the target site [394]. Interestingly, even amongst macrophages expression of
integrins αMβ2 and αDβ2 is varied depending on the polarization state. M1 macrophages
have higher levels of αDβ2 compared to M2, while both M1 and M2 macrophages have
moderate levels of αMβ2 compared to resident macrophages [395]. However, integrin
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expression has a biphasic effect on migration, where both high and low expression
reduce migration. Therefore, CEP-adducts caused by the oxTME likely increase
migration of M2 macrophages preferentially over M1 macrophages. Thus, the role of
oxidized ECM is highly dependent on both the cell-type interacting with the ECM and on
which member of the ECM is oxidized.
Due to its unique extracellular localization and ability to scavenge superoxide,
EcSOD is a key regulator in the oxTME. Unsurprisingly, EcSOD is a key enzyme to
prevent oxidative damage to ECM proteins. The first hints were found in the EcSOD
knockout mouse model. After bleomycin-induced pulmonary damage, the knockout mice
had enhanced 2-pyrrolidone levels, which is a marker of oxidized proline residues and
indicates fragmentation of collagen [396]. Future studies confirmed that EcSOD
expression reduced ROS-mediated fragmentation of type I collagen, hyaluronan, and
heparan sulfate [87, 388, 397]. Therefore, it is unsurprising that overexpression of
EcSOD reduced immune cell infiltration in mouse model of ischemia, inflammatory skin
disease, and radiation-induced lung damage [398-401].
Furthermore, the oxidative tumor microenvironment can play a role in the tumor
immune response, as EcSOD can regulate both innate and adaptive immune cell
infiltration and function. Macrophage infiltration, which is correlated with poor prognosis
in cancer [402], is reduced with EcSOD overexpression in acute inflammation mouse
models [401]. In addition to its role in the innate immune system, EcSOD selectively
inhibited Th2 and Th17 differentiation with no effect on Th1 [403], which are implicated in
tumor progression [404]. Additionally, macrophage-derived superoxide induces Treg
formation [381], indicating EcSOD may serve a potential inhibitory role for Tregs in
cancer. Therefore, EcSOD likely plays a key role controlling the activation of stromal
cells through its ability to regulate the oxTME.
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1.6

Dissertation Hypothesis
It is becoming increasingly clear that the TME can act as an active participant

during tumorigenesis rather than as a passive bystander. It can actively promote many
negative aspects of cancers, such as enhanced tumor growth, chemoresistance, and
metastasis. Therefore, therapeutic strategies targeting the TME and its interactions with
cancer cells opens a novel avenue of intervention. However, the TME is an extremely
complex network of many different cell types communicating back and forth with each
other and cancer cells within a tumor that is highly oxidatively stressed. Despite the
knowledge of the oxidative state within the tumor, it remains an understudied area of
research with the TME field. Therefore, in the broadest terms possible, the main goal of
this dissertation was to determine the role of ROS in promoting an aggressive phenotype
in the breast cancer TME and to use this knowledge to discover novel therapeutic
targets.
This work is predicated on previous findings of the loss of EcSOD in breast
cancer, as well as many other solid cancers. Previously, our laboratory found that reexpression of EcSOD in TNBC cell lines reduces proliferation, clonogenic survival, and
invasion. Low expression of EcSOD is also associated with a poorer relapse free
survival in all subtype of BC. Taken together these data suggests EcSOD acts a tumor
suppressor. However, it remained unclear exactly how EcSOD was having these effects.
Therefore, we sought to elucidate potential mechanisms behind the tumor suppressive
function of EcSOD, with a particular interest in TNBC. EcSOD is uniquely localized
extracellularly and attached via its heparin binding domain on the cell surface. Therefore,
we hypothesize that EcSOD plays a unique role in regulating signaling by controlling
ROS levels, since ROS is a well-established secondary messenger. To test this
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hypothesis, we re-expressed EcSOD in a TNBC cell line and analyzed activation of
receptor tyrosine kinases, which are located on the cell surface and ROS-sensitive. The
results of this screen returned c-Met, a receptor that is overexpressed in 20-30% of
breast cancer patients and is a prognostic indicator of poor survival. Due to the relatively
poor expression of the c-Met ligand, hepatocyte growth factor (HGF), in cancer cells, we
hypothesized that CAFs secreted HGF to activate c-Met on cancer cells. Furthermore,
we hypothesized that the oxTME created by loss of EcSOD promotes a HGF/c-Met
paracrine signaling axis between cancer cells and CAFs. Due to the high level of
oxidative stress within the TME, we hypothesized that ROS may play a role in activation
of fibroblasts.
Additionally, due to the effect of EcSOD on paracrine signaling between CAFs
and BC cells, we sought to expand the role of the oxTME plays on additional cell types
within the TME. The next most common cell type found within breast tumors is
macrophages. Previous studies into macrophages focused almost entirely on the
classically activated anti-tumor M1 macrophages, which are known to produce high
levels of ROS to kill microbes. However, there was very little information on the
alternatively activated pro-tumor M2 macrophages and how ROS affects them.
Additionally, previous studies found that modification of the reduced and oxidized levels
of glutathione, a key cellular antioxidant. Therefore, we hypothesized that there are
inherent differences in how M1 and M2 macrophages produce and control ROS, which
thereby modify their sensitivities to ROS manipulation allowing for targeting of the protumor M2 macrophages. Furthermore, much like ROS contributing to activation of CAFs,
we hypothesized that increased exogenous ROS levels would result in increased
polarization to the pro-tumor M2 macrophage. To test this hypothesis, we utilized
polarized human macrophages derived from primary human monocytes of healthy
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donors to analyze any inherent differences between M1 and M2 macrophages.
Furthermore, we utilized MnTE-2-PyP5+, a MnP class redox-active drug currently in
clinical trials, to assess its ability to modify macrophage polarization based on the
assumption that it would be equivalent to re-expression of EcSOD in breast cancer cells.
This study was done to provide initial data to further examine the role of the oxTME,
caused in part by reduction in EcSOD levels, in controlling signaling between cancer
cells and the surrounding stromal cells.
Finally, we sought to determine potential mechanisms of EcSOD loss in breast
cancer patients. Based on previous data collected in our laboratory, we knew EcSOD
was regulated in part by DNA methylation of its promoter in cancer cell lines compared
normal breast epithelial cell lines and in a limited number of patient samples. We sought
to expand upon this work by analyzing DNA methylation patterns of the EcSOD
promoter compared to mRNA expression levels in a larger cohort of breast cancer
patients. Due to differences in genome stability and methylation rate of breast cancer
subtypes, we hypothesized that different subtypes of BC, specifically luminal B, would
have higher levels of DNA methylation mediated suppression of EcSOD expression. We
also hypothesized that EcSOD genomic deletion would be highest in TNBC, the subtype
with the highest genomic instability. To test this hypothesis, we used patient samples
from the Northern Great Plains Personalized Breast Cancer Program, which were
initially collected for whole exome sequencing to identify specific genetic driver
mutations, to examine the methylation status of key CpG sites within the EcSOD
promoter. Furthermore, we used microarray expression data to examine any correlation
between expression levels and promoter methylation.
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CHAPTER 2:

Materials and Methods
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2.1

Cells Lines and Culture Conditions

2.1.1

Cell Lines
Breast cancer cell lines, MDA-MB231 and MDA-MB468, were purchased from

the American Type Cell Culture Collection (Manassas, VA, USA). A firefly luciferase
expressing stable cell line, MDA-MB231.luc, was previously generated as described
[405]. Stable EcSOD overexpressing MDA-MB231 cell line, Ec.20 were generated as
previously described [142]. Reduction mammoplasty fibroblasts expressing human HGF
(RMF-HGF) and their parental normal fibroblasts (RMF) were generated by Dr. Charlotte
Kuperwasser (Tufts University, Boston, MA, USA) [406]. Primary human monocytes and
Peripheral blood leukocytes (PBLs) were purchased from the UNMC Elutriation core
after isolation and separation from human donor whole blood. Cells were tested routinely
for mycoplasma contamination using the MycoAlert Mycoplasma Detection Kit (LT07118, Lonza). Diphenyleneiodonium chloride (DPI) (Sigma #D2926), recombinant human
Hepatocyte Growth Factor (EMD Millipore #GF116), MnTE-2-PyP (a kind gift from Dr.
James Crapo), and N-acetyl cysteine (NAC, MP Bio #02100098) were all added to cells
as indicated in their respective figures.

2.1.2

2D Culture Conditions
Human monocytes, PBLs, and MDA-MB231 were maintained in RPMI1640

containing 10% FBS and 1X Pen/Strep. MDA-MB468, RMF, RMF-HGF, and MDAMB231 during co-culture with fibroblasts were grown in DMEM + 10% fetal bovine serum
media and 1X Pen/Strep. All cells are maintained at 37ºC, 5% O2.
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2.1.3

2D Co-culture
For prolonged 2D co-culture between fibroblasts and cancer cells, 6 well

transwell plates (3450, Corning) were used to allow for easier separation of each cell
type. Fibroblasts (1 x 105) were grown in the bottom of a 6-well plate and 1 x 105 MDAMB231 cells were seeded on the 0.4 uM polyester membrane of a transwell insert to
prevent invasion of cancer cells through the membrane. Cells were co-cultured in DMEM
+ 10% fetal bovine serum media and 1X Pen/Strep. After 48h of co-culture, these two
cell types were trypsinized, counted and seeded in subsequent co-cultures for a total of
4 passages.

2.1.4

3D Monoculture
Mammary epithelial cell were propagated in 3D culture using the ‘on-top assay’

as described [407]. Briefly, 4-chamber slides were coated with 150 uL of Matrigel (BD
Biosciences, San Jose, CA, USA). While the matrigel was solidifying in the incubator,
cells were trypsinized and counted. Single cells were then overlaid on the Matrigel at 2 x
104 cells per chamber in 350 µL of 3D culture media. The 3D culture media is
DMEM/F12 with the following additives: 250 ng/mL insulin (I-6634, Sigma), 10 µg/mL
transferrin (T-2252, Sigma), 2.6 ng/mL sodium selenite (40201, Sigma), 1010 M estradiol
(E-2758, Sigma), 1.4 x 10-6 M hydrocortisone (H-0888, Sigma), and 5 µg/mL prolactin
(559006, BioLegend) [142]. Cells were allowed to attach to the matrigel for 30 minutes.
After attachment, an additional 350 µL of 3D culture media with 4% matrigel was added
to the top of the cells gently to provide coating “on-top” of the cells for a final 2% matrigel
concentration. The media was replaced every 3 days with 3D media containing 2%
matrigel. Any solution containing matrigel was kept on ice until added to the plate to
ensure that it would not prematurely solidify.
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This protocol was also adapted to the µ-Slide angiogenesis with ibiTreat
(#81506, iBidi USA, Fitchburg, Wisconsin, USA) using 10uL of matrigel coating the well
and 2.5 x 103 cells per well overlayed in 40 µL of 3D media. After attachment, 10 µL of
10% matrigel solution in the 3D media to provide the 2% matrigel coating.
Breast cancers were also grown in 3D conditions using conditioned media from
fibroblasts. The following are the adjustments to the protocol to collect and use the
conditioned media. To generate the conditioned media, 5 x 104 fibroblasts were plated
per well on a 24 well plate in complete media. On the following day, the media was
changed to 1 mL of DMEM/F12 in 1% fetal bovine serum. After 48 hours, the media was
collected and filtered through a 0.22 µm filter. The 3D media was prepared at 10x
solution and diluted to 1x with the collected conditioned media. The new solution is
called the 3D conditioned media. Breast cancer cells were seeded and grown in the 3D
conditioned media.

2.1.5

3D Co-culture
The 3D co-culture method follows the 3D monoculture method with the following

exceptions. The bottom of the chamber was coated with 100 µL of matrigel to prevent
direct interaction with plate. The matrigel was allowed to solidify in the incubator for 30
minutes, while the fibroblasts were trypsinized and counted. To embed the fibroblasts
into the matrigel, 3 x 104 fibroblasts were resuspended slowly in 100 µL matrigel per
chamber of the 4-chamber slide. The matrigel and cell mixture was allowed to solidify for
another 30 minutes in the incubator. Once solidified, 2 x 104 breast cancer cells were
seeded on top of the matrix in 350 µL 3D media. After the cells are allowed to attach for
30 minutes, 350 µL of 4% matrigel in 3D media was added to the plate. The media was
replaced every 3 days with 3D media containing 2% matrigel.
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2.1.6

Generation of Catalytically Inactive Mutant EcSOD MDA-MB231 Cell Line
First, the catalytically inactive mutant EcSOD (N180A, R186A) was generated

using primers designed by Dr. Briana Ormsbee Golden to create the N180A and R186A
mutations. The SOD3 was amplified into separate DNA segments using these two sets
of primers: the first set (forward primer 5’TCTTATACTTGGATCCATGCTGGCGCTACTGTGTTCC-3’ and reverse primer 5’GCCCGGCCCGCGTTCCCGGCCTCCACGCTGGC-3’) and the second set (forward
primer 5’-GCCGGGAACGCGGGCCGGGCGCTGGCCTGC-3’ and reverse primer 5’GCCGGGGCGGCCGCTCAGGCGGCCTTGCACTCG-3’). The vector pLVX-TRE3GIRES (Takara Bio USA) was digested in the multiple cloning site 1 using the restriction
digest enzymes BamHI (FD0054, ThermoFisher) and NotI (FD0594, ThermoFisher). The
cut vector and two SOD3 gene segments were joined using InFusion cloning system
(Takara Bio USA).
The doxycycline-inducible catalytically inactive mutant EcSOD expressing MDAMB231 (iMutEcSOD) were generated using the Lenti-X Tet-On 3G Inducible Expression
System (Takara Bio USA). Briefly, this is a two-vector system. One vector expresses a
doxycycline-sensing transactivator protein, while the other vector expresses the gene-ofinterest in a dox-inducible manner. Lentiviral particles were generated by transfection of
the Lenti-X HTX packaging mix and either the transactivator vector (pLVX-EF1α-Tet3G,
Takara Bio USA) or the generated mutant EcSOD vector into LentiX-293T (Takara Bio
USA). The virus-containing media was collected after 72 hours and filtered through a
0.45 µm filter to avoid cellular debris. MDA-MB231 were seeded on a 6 well plate at 3 x
105 in complete media. The virus-containing media (150 µL for the Tet3G virus and 150
µL for the mutantSOD3 virus) was diluted with 700 µL of complete media with the
addition of 10 µg/mL polybrene. The media on the MDA-MB231 cells was replaced with
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this new mixture. The cells were transduced for 24 hours before replacement with
complete media with puromycin (0.6 µg/mL) and G418 (1.2 mg/mL). Selection was
maintained for two weeks before reduction to half concentration for maintenance. A nontransduced control well of MDA-MB231 was also treated with puromycin and G418 to
ensure cells without the required virus were selected against and died. Mutant EcSOD
expression was confirmed by addition of doxycycline (100 ng/mL) for 3 days in complete
media. The media was collected and the cells were lysed with non-reducing lysis buffer.
An in-gel SOD activity was performed on the media and lysate to confirm that there was
no EcSOD expression. A Western blot was performed to confirm that EcSOD expression
was induced with addition of doxycycline.

2.1.7

Macrophage Differentiation and Polarization
Polarization of macrophages was induced as described [408] with the following

modifications. Primary human monocytes were purchased from the University of
Nebraska Medical Center Elutriation core facility. The monocytes were seeded on tissue
culture treated plates/dishes at 1000 cells/mm2 growth area in complete RPMI (RPMI
1640 +10% FBS +1x Pen/Strep). Monocytes were differentiated and polarized to M1
macrophages with GM-CSF (100ng/mL, BioLegend #572904) for seven days to promote
monocyte differentiation and growth. The media was replaced one to two times during
those seven days. Before the media was replaced, the plates were washed twice with
phosphate buffer solution (PBS) to remove any undifferentiated monocytes or
contaminating PBLs. Then, the GM-CSF stimulated macrophages were polarized to M1
by addition of IFN-γ (20ng/mL, BioLegend #570204) and LPS (20ng/mL, Sigma # L6529)
for 24 hours. Monocytes were differentiated and polarized to M2 macrophages with MCSF (100ng/mL, BioLegend #574806) for 7 days to promote monocyte differentiation
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and growth. Like M1 macrophages, the media was replaced, and the cells were washed
one to two times during differentiation. Then, the M-CSF stimulated macrophages were
polarized to M2 by addition of IL-4 (20ng/mL, BioLegend #574002) for 24 hours. After 24
hours of polarization both M1 and M2 macrophages were ready for down-stream
applications.

2.1.8

Macrophage Trypsinization
Macrophages were removed from the cell culture surface via Accutase (Corning

#25-058-Cl). Macrophages were washed with cold PBS. Then, macrophages were
incubated at room temperature with Accutase for 30 minutes. Macrophages were gentle
pipetted up and down to help remove cell from the cell culture plate.

2.2

Genetic Manipulation

2.2.1

Adenovirus Transduction
Cells were transduced with adenovirus using the following protocol. Cells were

seeded to be ~90% confluent 24 hours. For example, 2.5 x 105 MDA-MB231 cells were
seeded into one well of a 6-well plate. To ensure an accurate multiplicity of infection
(MOI), an extra well of cells was seeded to count just before addition of virus. After 24
hours of seeding, cells were washed with serum free media twice. The extra well of cells
were counted. The appropriate amount of virus was added to 600 µL of serum free
media. The multiplicity of infection (MOI) of 50 was used. Cells were transduced for 24
hours. After transduction, the media was replaced with complete media. The cells were
harvested after an additional 24 hours for downstream applications. Overexpression of
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EcSOD and Nox4 was achieved by this protocol. AdEcSOD, AdNox4, and
Ad5CMVempty (AdEmpty) were purchased from University of Iowa Vector Core Facility.

2.2.2

Silencing RNA Transfection
Transfection with siRNA was performed using Lipofectamine RNAiMAX reagent

(ThermoFisher Scientific #13778030) following the manufacturer’s protocol. Cells were
seeded to 75% confluency the night before transfection. For example, 2 x 105 RMF-HGF
cells were seeded in a 6-well plate. In a microcentrifuge, 9 µL of the Lipofectamine
RNAiMAX reagent was diluted into 150 µL of Opti-MEM medium (ThermoFisher
Scientific #31985088) and mixed gently. In a separate microcentrifuge tube, 10 nM of
siRNA was diluted into another 150 µL of Opti-MEM and mixed gently. The diluted
siRNA was then added to the diluted Lipofectamine RNAiMAX reagent mixture. The
combined solution was mixed gently and incubated at room temperature for 5-10
minutes. The media was changed on the RMF-HGF cells from DMEM to 700 µL OptiMEM. The 300 µL combined solution was then added to the cells dropwise to bring the
total volume up to 1 mL. Cell was transfected overnight before the media was changed
to fresh DMEM. The siRNA used were siNC#1 (Thermo Fisher Scientific #4390843) and
the siNox4 (Thermo Fisher Scientific #4392420; ID#s224159).

2.3

Cell Lysis
Protein lysate was isolated from cells using two different buffers, the denaturing

RIPA buffer and the non-denaturing lysis buffer. Cells were lysed in either buffer
depending on the downstream applications. In general, the RIPA buffer was used for
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Western blotting, while the non-denaturing lysis buffer was used for either Western
blotting or activity assays.
The RIPA buffer was made using the following recipe; 10 mM trisaminomethane
chloride (pH 8.0), 1 mM ethylenediaminetetraacetic acid, 0.5 mM egtazic acid, 1% Triton
X-100, 0.1% sodium deoxycholate, 0.1% sodium dodecyl sulfate, and 140 mM sodium
chloride. Before use of the RIPA buffer, 1 mM phenylmethane sulfonyl fluoride and 1x
HaltTM Protease and Phosphatase Inhibitor Cocktail (ThermoFisher Scientific #78440)
was added before use to inhibit proteases and phosphatases. Before addition of the
RIPA lysis buffer, cells were washed with cold PBS twice. RIPA buffer was then added
(~100 µL per well for a 6-well plate). While keeping the plate on ice, cells were scrapped
using a plastic cell scrapper to one edge of the well and collected in a clean
microcentrifuge tube. The lysate was kept on ice for an additional 30 minutes with
vortexing every 10 minutes. Cell debris was pelleted by centrifuge at max speed for 15
minutes at 4 °C. The supernant was transferred to a clean microcentrifuge and kept at 20 °C for later use.
The non-denaturing lysis buffer was purchased from Cell Signaling (Cell
Signaling #9803S) and diluted from 10x to 1x. Like the RIPA buffer, PMSF and Halt TM
was added before use. The protocol for this buffer was largely similar to the RIPA buffer
protocol with the one exception. Instead of vortexing the samples, the samples were
sonicated for 10 seconds with a 30 second incubation on ice three times to ensure
throughout lysis of both the cell and nuclear membranes.
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2.4

Electrophoresis and Western Blotting

2.4.1

Western Blotting
Protein lysates were diluted with water, 4x NuPAGETM LDS Sample Buffer

(ThermoFisher Scientific #NP0007), and 10x NuPAGETM Sample Reducing Agent
(ThermoFisher Scientific #NP0004). The samples were boiled at 80 °C for 10 minutes.
Samples were cooled on ice and spun down to collect precipitated droplets. The wells of
NovexTM 4-20% Tris-Glycine mini-gels (ThermoFisher #XP04200BOX) were washed.
After washing, 10 µg of reduced protein lysate were run at 150V in tris-glycine buffer
until the dye front has run out of the gel. The gel was removed from the plastic mold and
rinsed in deionized water. Once rinsed, the proteins were transferred to a PVDF
membrane using an iBlot Dry Blotting transfer system for 6 minutes and 30 seconds on
program P3. Proteins were also transferred using wet transfer using the Mini Gel Tank
and Blot Module (ThermoFisher Scientific #NW2000) for one hour at 23 V at room
temperature. The transfer buffer was tris-glycine in 20% methanol. Membranes were
blocked by rocking in 5% dry milk in TBST for one hour at room temperature.
Membranes were then probed overnight in the primary antibody that was diluted in 3%
BSA TBST solution. After probing with primary antibodies, membranes were washed
with TBST four times for 10 minutes each. After washing, membranes were probed with
secondary antibodies conjugated to HRP for 1-2 hours in 5% milk or 3% BSA at room
temperature. The secondary antibody was washed off the membrane with TBST for 10
minutes for four times. Protein quantity was measured using Classic Autoradiography
Film (MidSci #BX57) exposed to membranes incubated in either SuperSignalTM West
Pico (ThermoFisher Scientific #34577) or West Femto (ThermoFisher Scientific #34094)
depending on protein quantity. The intensity of the protein bands were quantified using
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ImageJ software (NIH). The list of primary and secondary antibodies is included in Table
2.1.

2.4.2

Electrophoresis for In-Gel Activity Assays
In-gel activity assays were performed to determine SOD or GPX activity of

specific members of each protein family. The GPX and SOD activity assays were
performed as previously described [409, 410]. Briefly, both assays rely on native
polyacrylamide gel electrophoresis with different staining protocols. The native gel
protocol is as follows. Native polyacrylamide gels were poured with 10% acrylamide for
SOD assays and 8% acrylamide for GPX assays. The electrophoresis buffer (50 mM
Tris pH 8.3, 5 mM EDTA pH 8.0, 0.34 M glycine) was pre-chilled to 4 °C. Samples were
loaded on the gel (~40 µg of lysate for SOD assays and 100 µg of lysate for GPX
assays) with an empty lane between the samples and the reduced kaleidoscope
prestained protein standards (BioRad #1610375). Cu/ZnSOD migrates near the green
band. MnSOD migrates near the pink band. EcSOD runs above the pink band. None of
the GPX family members have been matched up to this ladder. Therefore, running an
extra gel alongside to transfer and probe with antibodies is advised. Additionally, 0.5
units of bovine Cu/ZnSOD or 0.5 µg of bovine GPX (Sigma #G-6137) can be used as
positive controls. An empty lane between the positive controls and samples is also
advised. Lysates were mixed with a 10x sample loading buffer (50 mM Tris pH 6.8, 5
mM EDTA, 9.5 mL 100% glycerol, and small amount of bromophenol blue) and added to
the wells. Gels were run at 80 mA for 3-4 hours at 4 °C to prevent protein degradation
due to heat.
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TABLE 2.1. Antibody list
The table includes all antibodies used throughout the dissertation. The source,
concentration, and vendor of each antibody are also included in the list
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Antibody
β-Actin
p-c-Met [D26]

Company

Part Number

Concentration Source

Sigma

A2066

1:5,000

rabbit

Cell Signaling

3077

1:1,000

rabbit

Cell Signaling

4560S

1:1,000

rabbit

Cell Signaling

9101

1:1,000

rabbit

Cell Signaling

9102

1:1,000

rabbit

Cell Signaling

2118

1:5,000

rabbit

ThermoFisher

LF-MA0206

1:1,000

mouse

Abcam

ab125066

1:10,000

rabbit

Abcam

ab129068

1:5,000

rabbit

Abcam

Ab133303

1:1,000

rabbit

Cell Signaling

4312

1:1,000

rabbit

Santa Cruz

sc-360

1:5,000

rabbit

[411]

1:5,000

rabbit

[411]

1:5,000

rabbit

1:5,000

rabbit

(Tyr1234/Tyr1235)
c-Met
p-Erk1/2
(Thr202/Tyr204)
Erk1/2
GAPDH [14C10]
Gpx1 [13B2AF]
Gpx4
[EPNCIR144]
Nox2 [EPR6991]
Nox4
[UOTR1B493]
p47phox
RhoGDI
SOD1
SOD2

A kind gift

National Jewish

from Dr.

Medical and

p-Stat3 (Tyr705)

Cell Signaling
James Crapo

9145
Research Center,

1:1,000

rabbit

[D3A7]
Stat3 [79D7]

Cell Signaling

4904
Denver CO

1:2,000

rabbit

EMD Millipore

AP187P

1:20,000

goat

Proteintech

SA00001-1

1:5,000

goat

SOD3

Anti-rabbit HRP
Anti-mouse HRP
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SOD activity assays were incubated in solution A (2.5 mM nitro blue tetrazolium
chloride) for 20 minutes rocking at room temperature in the dark. After incubation in
solution A, the gel was incubated in solution B (28 mM TEMED, 28 µM riboflavin-5’monophosphate diluted in a 36 mM phosphate buffer pH 7.8). The gels were incubated
on a light box while shaking to avoid precipitate settling on the gel. After five minutes,
gels were incubated for an additional five minutes in fresh solution B. Once the gel
begins to turn purple and the clear SOD bands became clear, solution B was replaced
with deionized water. Gels were left on the light box in deionized water to enhance the
signal to noise ratio. All stains were done in a glass container not a plastic one to reduce
background.
For GPX activity assays, the gel was incubated in 1 mM reduced glutathione
(Sigma #G-4251) in deionized water for 10 minutes 3 times. The gel was rocked during
incubation to ensure even distribution of GSH. The gel was incubated deionized water
contained 0.008% cumene hydroperoxide (Sigma #247502) for 10 minutes. The gel was
rinsed with deionized water twice. The gel was stained simultaneously with two separate
solutions; 2% ferric chloride and 2% potassium ferricyanide. The gel was mixed with
freshly mixed dyes for a few minutes until clear bands appeared and the gel was stained
dark green. All stains were done in a glass container not a plastic one to reduce
background.

2.4.3

Receptor Tyrosine Kinase Array
Cell lysates were quantified by Bradford assay (Protein Assay, Bio-Rad, USA)

and incubated with the PathScan RTK signaling kit array chip (#7949, Cell Signaling
Technology, USA) according to the protocol provided by the manufacturer. Briefly, after
incubation of the samples, biotin-labeled anti-pan-phospho-tyrosine antibodies and
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specific anti-phospho-residue antibodies were used to detect phosphorylated proteins
captured on each spot on the nitrocellulose membrane. After incubation with DyLight
680-linked streptavidin, the chip was washed, fully dried and imaged using a Li-COR
Odyssey imager. The pixel density of the background was subtracted from the pixel
density of each spot, and the average of duplicate spots was determined. Next, Signal
intensity was calculated by the normalization of mean pixel density in each spot against
the pixel density of the positive control.

2.5

Flow Cytometry

2.5.1

ROS Measurements
ROS was measured using dihydroethidium (DHE) (ThermoFisher Scientific

#D1168), 2’,7’-dichlorodihydrofluorescein diacetate (DCFH) (ThermoFisher Scientific
#C400), and CellRox Deep Red reagent (ThermoFisher Scientific #C10422). Cells in
single cell suspension were incubated in the dark with either DHE (10 µM), DCFH (10
µM), or CellRox (3 µM) for 40 minutes at 37°C in Hank’s Balanced Salt Solution (HBSS).
Cells were then diluted and washed with HBSS and strained to ensure single cell
suspension. Fluorescence was measured via flow cytometry on a BD LSRII. For DHE,
superoxide-enriched fluorescence was measured using the 405nm laser, while
fluorescence induced by superoxide and non-specific ROS was measured using the
488nm laser. For DCFH and CellROX, the excitation was the 405nm laser and 633nm
laser, respectively.
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2.5.2

Surface Marker Expression
Cells in single cell suspension were counted and primary fluorescently tagged

antibodies were added at a concentration of 5 µL antibody per 1x106 cells in FACS
buffer (1% BSA in HBSS without Ca2+/Mg2+). Cells were incubated in antibody mix for 30
minutes at room temperature in the dark. After diluting and washing in FACS buffer, cells
were strained to remove cell clumps. Stained cells were measured using a LSRII flow
cytometer. The antibodies used were FITC-CD80 (BioLegend #305205), PE/DazzleCD86 (BioLegend #305433), AlexaFluor647-CD163 (BioLegend #333619),
BrillantViolet421-CD206 (BioLegend #321125), and Pe/Cy7-CD273 (BioLegend
#345511). When used in combination with additional antibodies, single stain controls
were used to compensate for bleed over between the fluorophores.

2.5.3

CFSE Cell Growth Measurements
Single cells were labeled with 7.5 µM carboxyfluorescein succinimidyl ester

(CFSE) (BD Biosciences #565082) for 15 minutes in a 37 °C water bath in the dark.
Cells were vortexed immediately after addition of CFSE to prevent uneven staining.
Cells were diluted and washed with PBS. Cells were stimulated and grown for multiple
days. The cells were then collected, washed, strained, and resuspended in FACS buffer.
CFSE was measured using a LSRII flow cytometer using a 488nm laser.

2.6

Reverse Transcriptase and Quantitative PCR

2.6.1

Reverse Transcriptase
Total RNA was isolated using Quick RNA Miniprep (Zymo Research #R1054).

Cells in a 6-well plate were lysed using 300 µL of RNA lysis buffer included in the kit.
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The lysate was scrapped using an RNase-free cell scrapper and collected in an RNasefree microcentrifuge tube. RNA lysate was either frozen at -80 °C for later RNA isolation
or RNA was immediately isolated. The Zymo-SpinTM columns were used to isolate RNA
from the cell debris. Genomic DNA was digested by DNase treatment and rinsed away.
RNA was eluted off the columns using RNase-Free water. RNA concentration and purity
were measured using 2 µL of RNA on a NanoQuant PlateTM in the Tecan Infinite M200
PRO plate reader. After quantification, RNA was converted to cDNA using a HighCapacity cDNA Reverse Transcription Kit (ThermoFisher Scientific #4368813). The RNA
was added to master mix of random primers, dNTPs, reverse transcriptase enzyme, and
buffer. The final concentration of RNA was made to be multiples of 20 ng/µL up to 80
ng/µL to make it easier for use in quantitative real-time PCR (qRT-PCR).

2.6.2

Real-Time Quantitative PCR
Quantitative real-time PCR (qRT-PCR) was performed using Maxima SYBR

Green (Thermo Fisher Scientific #K0221). RNA (40 ng) and primer pairs (µM) were
diluted with water and SYBR Green master mix. Each primer pair and RNA sample were
done in triplicate. The qRT-PCR was done on an ABI 7000 Fast machine. The fold
change was calculated using the 2^(-ddCt) method using 18S as the reference gene.
The primer pair sequences are found in Table 2.2.

2.7

Plate Reader Assays

2.7.1

Amplex Red Assay
Extracellular H2O2 production was measured using the Amplex Red Hydrogen

Peroxide Assay kit (ThermoFisher Scientific #A22188). RMF and RMF-HGF fibroblasts
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TABLE 2.2. Primer list for qRT-PCR
The list is of the primer sequences used during qRT-PCR throughout the dissertation.
Both the forward and reverse primers for each gene are included in the 5’ → 3’
orientation.
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Forward Primer 5’ → 3’

Reverse Primer 5’ → 3’

18S

CCTTGGATGTGGTAGCCGTTT

AACTTTCGATGGTAGTCGCCG

Catalase

TCCACTGTTGCTGGAGAATC

CGAGATCCCAGTTACCATCTTC

CCL18

AGCCAGGTGTCATCCTAA

CAGCTTCAGGTCGCTGATGTA

CD163

AGCATGGAAGCGGTCTCTGTGATT

AGCTGACTCATTCCCACGACAAGA

AGGATGAAGAGAGGCATGTTG

ATGGTCTCCTGAGAGTGAGAT

CYBA
(SOD1)

CGTCCTGCATCTCCTGCT

GTAGATGCCGCTCGCAAT

DuoxA1
(p22phox)

CACATTGACCACAGGACTGC

CCAGCATGGGGTCTTCATCC

Duox1

ATGCTGCGGGACCACAATAG

CACTCTGGGAGAGGGACAGAT

FAP

TGTTTCGGTCCTGTCTATATGTG

CCCATCCAGTTCTGCTTTCT

Gene

Cu/ZnSOD

Fibronectin1 GCTCCTGCACATGCTTTGG

TCTCTGTCAGCCTGTACATC

Gpx1
(FN1)

GGGCAAGGTACTTATCGAG

CTCGTTCATCTGGGTGTAGTC

Gpx4

AGATCAAAGAGTTCGCCGC

CTTGATGGCATTTCCCAGGAT

HGF

ATGTCAGCGTTGGGATTCTC

TCGGATGTTTGGATCAGTGG

IL-10

AGGCTGAGGCTACGGCGCT

TAGATGCCTTTCTCTTGGAG

IL-12b

ATTGAGGTCATGGTGGATG

TGATGTCCCTGAAGAAGC

MnSOD

GGCCTACGTGAACAACCTGAA

CTGTAACATCTCCCTTGGCCA

Nox1
(SOD2)

GTTATGCACCCATCCAAAG

CTGGAGCAGAGGTCAAAGTAAA

Nox2

GGCTTCCTCAGCTACAACATCT

GTGCACAGCAAAGTGATTGG

Nox4

AACACCTCTGCCTGTTCATC

GATACTCTGGCCCTTGGTTATAC

Nox5

CACCCCTTCACCATCAGCAGT

AGTATCTCAGAGCCCTTGGACG

PDGFRα

TGCCTGACATTGACCCTGT

CCGTCTCAATGGCACTCTCT

SDF-1

GACCCAACGTCAAGCATCTC

CGGGTCAATGCACACTTGTC

SMA

GCGTGGCTATTCCTTCGTTA

TCAGGCAACTCGTAACTCTTCTC

TNFa

AGCCCATGTAGCAAACC

TATCTCTCAGCTCCACGCCA
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(1.8x10^5 cells) were plated in a 12 well format for 48 hours. After washing with PBS,
cells were incubated in 1mL of the Amplex Red reaction mixture consisting of 50µM
Amplex Red reagent and 0.1 U/mL HRP in HBSS +Ca2+/Mg2+. For every measurement,
300µL (3 x 100µL) of the reaction mixture was removed from each sample and put into a
96-well black plate. The fluorescence product indicative of the amount of H2O2 produced
was measured using a Tecan Infinite M200 PRO plate reader at excitation of 560nm and
emission of 590nm. This assay was also done for macrophages and modified to a 24
well plate format.

2.7.2

GSH/GSSG Assay
Total (GSH) and oxidized glutathione (GSSG) levels were measured using the

GSH/GSSG-Glo kit (Promega #V6611) following the manufacturer’s protocol. In brief,
this assay produces luminescence by coupling glutathione S-transferase with luciferase
to produce light in a GSH-dependent manner. Cells were plated and lysed in 96-well
white plate to measure total GSH levels (10,000 cells/well) or oxidized glutathione
(20,000 cells/well). The cells were lysed using either the total glutathione lysis reagent or
the oxidized glutathione lysis reagent that contains N-ethylmaleimide to block the
reduced GSH from measurement. The cells are incubated at room temperature while
shaking. After five minutes, luciferin generation reagent was added. The plate was
shaken briefly and incubated for 30 minutes. After incubation, the luciferin detection
reagent was added. The plate was shaken and incubated for 15 additional minutes.
Finally, luminescence was measured using the Tecan Infinite M200 PRO plate reader.
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2.8

Electron Paramagnetic Resonance Spectroscopy (EPR)
Superoxide levels were measured using 1-hydroxy-3-methoxycarbonyl-2,2,5,5-

tetramethylpyrrolidine (CMH). CMH (200µM) was prepared in Krebs-Hepes Buffer (KHB)
with deferoxamine (DF) and diethyldithiocarbamic acid sodium salt (DETC). After
washing with KHB +DF/DETC, cells were incubated in CMH for 30 minutes at 37°C.
Cells were scraped and resuspended before measuring the EPR signal in 100 µL of cell
mixture. The EPR signal was measured using a Bruker E-Scan Table Top EPR
spectrometer. The live and total cells were counted in 10 µL of cells using a TC20
Automated Cell Counter. The EPR signal was adjusted to the amount of signal per cell.

2.9

Collagen Contraction Assay
Human mammary fibroblasts were suspended (500,000 cells/mL) in a rat tail

collagen I solution (2.2 mg/mL; BD Biosciences, San Jose, CA, USA) as described [412].
MEM (Invitrogen, Carlsbad, CA, USA) supplemented with 1.8 mg/mL NaHCO3 (SigmaAldrich, St. Louis, MO, USA) and 2.3 mg/mL L-glutamine (Invitrogen) was used as a
diluent and pH was adjusted with 0.22 M NaOH. For each replicate, 500 µL cell-collagen
mixture was dispensed into a single well of a 24-well plate and incubated at 37°C for 1
hour to facilitate collagen polymerization. Next, the collagen gels were detached from the
well using a pipet tip. Culture media (500 µL) was then added and plates were incubated
at 37°C in a humidified, 5% CO2–containing atmosphere. Images of the collagen matrix
were taken at the end of contraction time point, and surface area was measured with
ImageJ software (NIH).
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2.10

Invasion Assay
The in vitro invasive properties of the breast cancer cells were performed using

the BD Bio-Coat Matrigel invasion assay system (BD Biosciences) as previously
described [141]. Briefly, 2 X 105 cancer cells in serum free media were seeded into the
Matrigel inserts consisting with 8-um filter pores. After 16 h of incubation, the upper
surface of the transwell chambers was removed with a cotton swab and cells that have
invaded through the Matrigel were lysed with the Luc-Screen Extended-Glow Luciferase
Reporter Gene Assay System kit (Thermo Fisher Scientific, # T1033) and analyzed for
luciferase activity using the Tecan Infinite M200 Pro plate reader. In some experiments,
invaded cells were counted after being fixed and stained using a crystal violet solution
(2% crystal violet, 50% methanol, 10% acetic acid).

2.11

T Cell Activation Assay
Autologous T cells were procured as PBLs from the UNMC Elutriation Core after

isolation from monocytes. T cells were labeled with 7.5 µM CFSE (BD Biosciences
#565082) for 15 minutes at 37˚C. After washing, T cells were plated in empty wells or on
top of treated macrophages after washing off treatment. Activation of T cells was
achieved with anti-CD3 co-stimulation (OKT3, Biolegend #317302) at 0.1 ug/mL in RPMI
with 10% FBS and Pen/Strep. The non-adherent T cells were washed out of the well
using DPBS and re-suspended in FACS buffer before measuring CFSE using a LSRII
flow cytometer.

2.12

MDA-MB231 Growth Assay
Conditioned media from treated and untreated macrophages was collected, spun

down, and filtered. This media was stored at -80˚C until use. MDA-MB231.luc (MDA-
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MB231 cells stably expressing luciferase) were plated in complete RPMI media in a 96
well white walled plate at a concentration of 2,000 cells per well. Conditioned media was
added to the wells to make it a final concentration of 50% conditioned media. Luciferase
activity was measured on day 1, 3 and 4, to assess cell growth over time in the various
conditions. Luc-Screen Extended-Glow Luciferase Reporter Gene Assay system
(ThermoFisher #T1035) was used according to the manufacturer’s guidelines. Buffer 1
(50 µL) and buffer 2 (50 µL) were added directly to cells in 100 µL of culture media. Cells
were mixed briefly and incubated for 10 minutes before measuring luciferase on a
TECAN Infinite M200 Pro plate reader.

2.13

In Vivo Tumor Study
Eight-week-old female athymic nude mice were obtained from Harlan

Laboratories Inc. (Indianapolis, IN, USA). The nude mice protocol was reviewed and
approved by the Animal Care and Use Committee of the University of Iowa. Breast
cancer cells (MDA-MB231.luc or Ec.20 at 1 X 106) were injected alone or co-injected
with 3 x 105 mammary fibroblasts (RMF or RMF-HGF) into both sides of the 4th
mammary fad pads, in the presence of 50% Matrigel. Tumor growth was monitored
weekly by bioluminescence imaging as previously described [142].

2.14

Patient Sample Preparation
Excess DNA samples collected through the Breast Cancer Collaborative Registry

(BCCR) (IRB# 253-13 EP, PI: Dr. Kenneth Cowan) were used for pyrosequencing
analysis. BCCR is a web-based biomedical data and biospecimen repository developed
by the Fred & Pamela Buffett Cancer Center. The BCCR provides a critical platform for

97

the Northern Great Plains Personalized Breast Cancer Program (NGPPBCP) funded by
The Leona M. and Harry B. Helmsley Charitable Trust. Seventy one locations across
the U.S. including seven cancer centers in the Northern Great Plains that are actively
enrolling patients on the BCCR. Formalin fixed tissue blocks collected from the cancer
centers were sent to the FPBCC for centralized review. Specimens that are deemed
adequate for whole exome DNA sequence studies were then sent to the tissue facility at
the FPBCC for sectioning. Trained tissue technologist then performed macro-dissection
on each specimen to concentrate the number of tumor cells and reduce the
contamination of adjacent normal breast tissue. DNA isolation from the FFPE tumor
specimens was performed by the Fred & Pamela Buffett Cancer Centers's Molecular
Biology/High-Throughput Screening facility. DNA was extracted and purified using
QIAamp DNA FFPE Tissue (QIAGEN) kits, quantified by Nanodrop 2000, followed by
double-stranded DNA assessment using Qubit (3.0) dsDNA HS Assay kit (Invitrogen).
Following the extraction of DNA from each patient’s breast cancer, the quality and
quantity of DNA in each sample is determined. RNAs were extracted by using the
QIAGEN RNeasy FFPE kit. The gene array expression profiling was performed by
Agendia Inc. USA.

2.15

SOD3 Pyrosequencing
Only the DNA samples with available gene expression profiling data were used

for the correlation analysis between the expression levels of SOD3 and its promoter
methylation pattern (N = 75 tumor samples and 14 normal tissues). Approximately 500
ng of breast tumor genomic DNA were treated with sodium bisulfite using the EZ DNA
Methylation-Direct kit (Zymo Research, Orange, CA). This process deaminates
unmethylated cytosine residues to uracil leaving methylated cytosine residues
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unchanged. A 323 base pair region of the SOD3 promoter was captured from each
sample using PCR and custom designed primers: sense strand 5’TGTTGTGTGTTGAAGGTTATTGGTTATA-3’, anti-sense strand 5’CAACTCCTCCAAAAAAACTTTCTCTCCT-3’, and pyrosequencing primer 5’TGTTGAAGGTTATTGGTTATAA-3’. Methylation percentage of each CpG (-19 to -108
relative to transcription start site) was determined using the PCR product generated
using Roche Diagnostic Corporation (Indianapolis, IN) High Fidelity FastStart Taq DNA
Polymerase kit and a Qiagen (Valencia, CA) Pyromark Q96 pyrosequencer according to
manufacturer’s recommendations. Along with the samples a positive (high methylation
level) control, Roche Diagnostic Corporation (Indianapolis, IN) human lymphocyte
genomic DNA was methylated using M. SssI (CpG) methylase kit (New England Biolabs,
Ipswich, MA) and untreated Roche human lymphocyte genomic DNA served as a
negative (low methylation level) control were sequenced to access proper sequencing
performance. The area of the SOD3 promoter examined includes the Sp1/Sp3
transcription factor binding site as previously described [413].

2.16

TCGA Database Analysis
Copy number and expression of SOD3 within the Cancer Genome Atlas (TCGA)

breast carcinoma samples were queried using the cBioPortal for Cancer Genomics
multidimensional cancer genomics data sets search engine (http://www.cbioportal.org/).

2.17

Copy Number Variation Analysis
Copy number and expression of SOD3 within the Cancer Genome Atlas (TCGA)

breast carcinoma samples were queried using the cBioPortal for Cancer Genomics
multidimensional cancer genomics data sets search engine (http://www.cbioportal.org/).
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2.18

Statistical Analysis
All statistical analyses were done using three or more biological replicates unless

otherwise stated. Statistical analyses were performed using GraphPad Prism 5 software.
For some experiments, a single-factor ANOVA followed by post-hoc Tukey test was
used to determine statistical differences between means. Statistical analyses were
assessed using a two-tailed Student’s t test. Statistical significance was achieved when
P < 0.05. Unpaired t test or Mann-Whitney test was applied when comparing two groups.
When comparing three or more groups, one-way ANOVA and post-hoc test were used.
Spearman test was used for correlation analyses.
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CHAPTER 3:

Extracellular Superoxide Dismutase Inhibits Hepatocyte Growth
Factor-mediated Breast Cancer-Fibroblast Interactions

Data in this chapter have been published in the following manuscript:
Golden B. Ormsbee*, Griess B.*, Mir S., Fitzgerald M., Kuperwasser C., Domann F.,
Teoh-Fitzgerald M. Extracellular superoxide dismutase inhibits hepatocyte growth factormediated breast cancer-fibroblast interactions. Oncotarget. 2017; 8: 107390-107408.
*Contributed equally
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3.1

Introduction
We have previously shown that expression levels of the extracellular form of

SOD, (EcSOD or SOD3) is significantly down-regulated in a majority of breast
carcinomas and its expression levels inversely correlated with clinical stage [142].
Overexpression of this antioxidant in breast cancer cells inhibited in vitro proliferation,
clonogenic survival, invasion, tumor growth and metastasis [141, 142]. EcSOD is the
only extracellular enzyme that scavenges superoxide (O2-) which is the essential first
step in eliminating the downstream production of more potent ROS (e.g. H2O2, OH, and
ONOO-). Considering its unique cell-surface localization and the fact that the substrate
for EcSOD, O2-, crosses membranes poorly, loss of EcSOD is anticipated to promote an
oxidative extracellular environment that will likely alter autocrine and/or paracrine signal
transductions initiated at cell surface receptors.
Receptor tyrosine kinases (RTKs) such as the epidermal growth factor receptor
(EGFR) have been shown to be ROS-sensitive or utilize ROS-dependent mechanisms
for activation [414]. ROS can activate signal transduction pathways by oxidizing and
therefore inhibiting the cysteine regions of the active sites of protein tyrosine
phosphatases (PTPs), which promotes activation of tyrosine kinases. Recently,
oxidative stress has also been suggested to be involved in activating c-Met signaling
[415]. Therefore, loss of EcSOD expression and the resulting increase in extracellular
O2•- is expected to promote HGF/c-Met signaling. Upon activation, c-Met undergoes
phosphorylation that evokes a variety of oncogenic responses leading to increased
proliferation, scattering and motility, invasion, survival, angiogenesis, and metastasis
[416]. In breast cancer, c-Met is overexpressed in 20-30% of cases, and is a strong,
independent predictor of decreased survival [417]. Moreover, several types of signal
cooperation and cross-talk between c-Met and EGFR pathways have been
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demonstrated in recent years [418]. This has driven the development of inhibitors that
target c-Met as an anti-cancer strategy [419].
In addition to overexpression, c-Met activation can be promoted through
mutations, or autocrine signaling in malignant cells. Mutations in c-Met that confer its
constitutive activation independent of its ligand (hepatocyte growth factor, HGF) has
been observed and autocrine upregulation of HGF has been reported in lung cancer
[420]. However, breast cancer cells rarely express the c-Met ligand, but often acquire
HGF from stroma fibroblasts or the cancer-associated fibroblasts (CAFs) via a paracrine
interaction [421]. CAFs are now recognized to be one of the key players in the tumor
microenvironment that not only supports cancer cells but also interacts with the other
stroma cells such as macrophages and endothelial cells, in a community fashion, to
promote cancer cell proliferation, survival, malignant progression, angiogenesis, and
metastasis [422]. These fibroblasts differ from the normal quiescent fibroblasts in their
activated phenotypes and their pro-tumorigenic secretory profile. Pro-inflammatory [423]
and pro-oxidative [424] phenotype have also recently been associated with CAFs.
Understanding factors that contribute to the paracrine HGF/c-Met signaling during
cancer-fibroblast interactions will therefore have a positive clinical impact for c-Met
overexpressing cancers.
The objective of this study is to determine the effect of EcSOD and oxidative
stress on HGF/c-Met-signaling in breast cancer. We found that overexpression of
EcSOD inhibited HGF-mediated c-Met phosphorylation and resulted in an inhibition of
three-dimensional (3D) Matrigel growth of MDA-MB231. This antioxidant enzyme also
inhibited HGF-mediated cancer-fibroblast interactions in our co-culture model. In a
prolonged co-culture study where breast cancer cells were seeded for multiple passages
with mammary fibroblasts, followed by re-isolation of individual cell types,
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overexpression of EcSOD significantly suppressed the invasiveness of breast cancer
cells that were pre-exposed to HGF-secreting fibroblasts, when compared to the
parental MDA-MB231 cells. Concurrently, the isolated HGF secreting fibroblasts, which
were co-cultured with EcSOD–overexpressing MDA-MB231 cells showed attenuated
phenotype in their ability to promote naïve breast cancer cell invasion.
Furthermore, we have shown that upregulation of NADPH oxidase 4 (Nox4)
contributes to the activated phenotype of HGF expressing fibroblasts, via promoting
oxidative stress. Scavenging ROS with an SOD mimetic, MnTE-2-PyP significantly
suppressed the HGF-stimulated 3D growth and invasion of MDA-MB231 cells. In
addition, targeting the ROS-generating Nox4 enzyme inhibited the ability of activated
fibroblasts to contract collagen matrix. Our in vivo study further showed that scavenging
ROS with EcSOD in MDA-MB231 significantly inhibited HGF-mediated tumor growth in
mice. Overall, our study indicates a contributing role of an oxidative tumor
microenvironment in promoting an activated-phenotype of fibroblasts in addition to
supporting HGF/c-Met signaling during cancer-fibroblast interactions.

3.2 Results

3.2.1

EcSOD Inhibits c-Met Phosphorylation
To determine if scavenging cell surface-generated ROS with EcSOD will affect

the phosphorylation status of RTKs, we utilized PathScan® RTK Signaling Antibody
Array Kit (Cell Signaling). As shown in Figure 3.1A, amongst the 28 RTKs screened, the
most significant change is observed for c-Met phosphorylation (Pan-Tyr), where
overexpression of EcSOD (Ec.20 cell line) drastically inhibited activation of this RTK
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relative to its vector control MDA-MB231 cell line. Quantification of the pixel intensities is
shown on the right bar graph (A), revealing a more than 85% decrease in c-Met
phosphorylation in Ec.20 cells versus MDA-MB231. The array shown in Figure 3.1A also
shows a down-regulation of c-Abl phosphorylation (pan-Tyr), a non-receptor tyrosine
kinase which has recently been shown to be activated downstream of c-Met [425-427].
To further confirm that overexpression of EcSOD affects c-Met activation in MDAMB231, we performed western blot analysis. Figure 3.1B shows that when cells were
stimulated with a recombinant human HGF (rHGF), c-Met phosphorylation (at
Y1234/1235) was significantly suppressed in Ec.20 cell line when compared to that of
MDA-MB231 cells. Moreover, transient overexpression of this extracellular antioxidant
using an adenovirus vector (AdEcSOD) at M.O.I. of 50 also resulted in an inhibition of cMet activation relative to the control vector (AdEmpty) infected sample. To determine
whether the superoxide scavenging activity of EcSOD is required for this inhibition, we
overexpressed an inactive form of EcSOD where two critical residues were mutated as
previously described [428]. The inactive EcSOD expression was generated to be
expressed only under doxycycline induction and the cell line was named iMutEcSOD.
When MutEcSOD cells were treated with doxycycline, we observed no alterations in cMet signaling as shown on the right panel in Figure 3.1B. These data suggest that
HGF/c-Met signaling is sensitive to ROS modulation. To further show that the inhibitory
effect of wild type EcSOD on c-Met is not limited to MDA-MB231 cell line, we repeated
the assay with another basal like breast cancer cell line, MDA-MB468 and demonstrated
similar down-regulation of this signaling pathway (Figure 3.1C).
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FIGURE 3.1. Overexpression of EcSOD inhibited c-Met phosphorylation and HGFstimulated Matrigel growth of MDA-MB231 cells
(A) Cell lysates of the parental MDA-MB231 or an EcSOD overexpressing stable cell line
(Ec.20) were screened for activation of a panel of receptor tyrosine kinases using the
PathScan® RTK Signaling Antibody Array. A fluorescence image of the array chip
revealing phosphorylation of c-Met and c-Abl in MDA-MB231 cells vs. EcSODoverexpressing Ec.20 cells. Pixel intensities of the array signal is shown on the bar
graph. (B) Left–western blot analysis confirming that either transient overexpression of
EcSOD using adenovirus vectors (AdEcSOD) or stable overexpression in Ec.20 clones
showed significant decreases in c-Met activation (phosphorylation at Y1234/1235). Cells
were serum starved overnight followed by rHGF stimulation (50 ng/mL) for 15 min prior
to cell lysate preparation. Right–Overexpression of inactive mutant EcSOD (N180A,
R186A) did not affect c-Met activation in MDA-MB231 cells. Doxycycline (100 ng/mL)
was used to induce the expression of the mutant EcSOD in iMutEcSOD cells. Cells were
serum starved overnight followed by HGF stimulation (50 ng/mL) for 15 and 60 min prior
to cell lysate preparation. Signal intensity of phosphorylated c-Met over total c-Met was
analyzed by densitometry as shown. (C) Phosphorylation of c-Met (Y1234/1235) was
also inhibited by EcSOD in MDA-MB468 cells. Cells were infected with AdEcSOD or
AdEmpty for 24 hours prior to stimulation with 50 ng/mL of rHGF. Cell lysate was then
harvested for western blot analysis after 15 min of stimulation. Representative blots from
3 independent experiments are shown. Signal intensity of phosphorylated c-Met over
total c-Met and phosphorylated p44/42 over total p44/42 was analyzed by densitometry
as shown. (D) Extracellular protein array analysis comparing the secreted factors in
Ec.20 cultured media to that of the vector control MDA-MB231 cells. (E) EcSOD
inhibited HGF-stimulated invasive morphology and growth in 3D co-culture. Top–
Mammary fibroblasts (RMF or RMF-HGF) were embedded in Matrigel and breast cancer
cells (MDA-MB231 or Ec.20) were seeded on top of the matrix as illustrated in the top
panel. Bright field images showing the 3D growth of MDA-MB231 or Ec.20 cells when
co-cultured with RMF-HGF for 4 days. Representative images of N = 3 separate
experiments. Bottom–Cellular growth of breast cancer cells was quantified after 4 days
of co-culture with a luciferase activity assay. RLU = Relative Light Units. Representative
data from N = 3 separate experiments. Error bars = SD of 6 separate samples. (F)
Catalytically inactive EcSOD did not affect the 3D morphology and growth of iMutEcSOD
cells. Top–3D growth of iMutEcSOD in co-culture with RMF or RMF-HGF. 100 ng/mL of
dox was used to induce the mutant EcSOD expression. Bottom–After 5 days of culture,
cells were isolated from the matrix and counted for growth analysis. Error bars = SD of 4
separate samples. (G) Wild-type EcSOD but not the inactive mutant (N180A, R186A)
inhibited breast cancer cells invasion, under the stimulation of RMF-HGF. Top–
Representative Matrigel invasion of MDA-MB468 cells when EcSOD was overexpressed
with AdEcSOD versus AdEmpty. Conditioned media (CM) harvested from fibroblasts
(RMF and RMF-HGF) were used as chemoattractant. Invaded cells were analyzed after
20 hours of seeding. Data are mean ± SD of 3 separate samples. Bottom–
Representative invasion of iMutEcSOD when the expression of an inactive mutant
EcSOD was induced with 100 ng/mL of dox, in the presence of CM harvested from RMF
and RMF-HGF. Data are mean ± SD of 3 separate samples.

106

107

3.2.2

EcSOD Upregulates Extracellular Thrombospondin Levels
To further determine whether EcSOD mediates suppression of c-Met signaling

via an alteration of secreted factors, we performed an extracellular protein array
analysis. As shown in Figure 3.1D, levels of thrombospondin-1 and 2 (TSP-1 and TSP2) were significantly increased in conditioned media of Ec.20 compared to that of the
vector control cells. Both TSP-1 and TSP-2 are anti-angiogenic and anti-metastatic
factors that show inverse correlation with malignant progression in breast cancer [429,
430]. TSP-1 possesses a strong affinity for HGF [431] which mobilizes HGF away from
the extracellular matrix and cell surface proteoglycans hence preventing its receptor
binding [432]. Our results suggest that EcSOD inhibits c-Met activation partly through
sequestering of its ligand via anti-angiogenic TSPs.

3.2.3

EcSOD Inhibits HGF-mediated Breast Cancer Invasive Morphology and Growth

in 3D Culture
Since tumor stroma cells such as activated fibroblasts are the predominant
source of HGF, we determined if EcSOD will affect the cancer cell-fibroblast interactions
in the context of HGF stimulation. Here, we co-cultured MDA-MB231 cells with
mammary fibroblasts that were generated to overexpress HGF (RMF-HGF) [406]. The
parental fibroblasts, RMF are non-malignant fibroblasts isolated from reduction
mammoplasty as described [406]. The 3D co-culture system (Figure 3.1E) shows that
RMF-HGF greatly stimulated the growth and stellate formation of MDA-MB231 relative to
the cells co-cultured with RMF. This stimulatory effect of RMF-HGF was inhibited in the
presence of EcSOD, where Ec.20 cells showed stunted 3D growth with minimal stellate
formation when co-cultured with RMF-HGF. Growth of MDA-MB231 and Ec.20 cells
under the RMF-HGF stimulation was quantified using a luciferase activity assay and
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presented on a bar graph in Figure 3.1E. The inactive mutant form of EcSOD on the
other hand, did not affect the 3D stellate formation nor the growth of MDA-MB231, in the
presence of HGF, as shown in Figure 3.1F. Moreover, overexpression of the wild type
EcSOD with an adenovirus vector (AdEcSOD) suppressed the HGF-stimulated Matrigel
invasion of MDA-MB468 cells (Figure 3.1 G-top panel), whereas the mutant EcSOD has
no influence on the invasiveness of breast cancer cells, when conditioned media
harvested from RMF-HGF fibroblasts were used as a chemoattractant (Figure 3.1Gbottom panel).

3.2.4

Prolonged Co-culture with EcSOD Overexpressing Breast Cancer Cells

Attenuated Pro-invasive Phenotype of RMF-HGF
To determine the effects of scavenging extracellular ROS with EcSOD on the
reciprocal interactions between cancer cells and activated fibroblasts, we performed
serial passages of MDA-MB231 cells with mammary fibroblasts using a transwell coculture chamber as illustrated in Figure 3.2A. After four passages, fibroblast-co-cultured
MDA-MB231 and Ec.20 cells were isolated and tested for their invasiveness through
Matrigel. Figure 3.2B shows that as expected, MDA-MB231 cells are more invasive after
prolonged co-cultivation with RMF-HGF (CC.RMF-HGF) when compared to cocultivation with RMF (CC.RMF). In contrast, invasiveness of Ec.20 cells was not affected
by the pro-longed interactions with RMF-HGF (CC.RMF-HGF), suggesting that EcSOD
inhibits HGF-mediated invasion of cancer cells.
In parallel, RMF and RMF-HGF were also isolated from the co-cultures and
tested for their ability to promote breast cancer cell invasion. As shown in Figure 3.2A,
fibroblasts were seeded into the bottom wells of invasion chambers where naïve MDAMB231 cells were seeded on the Matrigel layer on the top inserts. The bar graph in
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FIGURE 3.2. Prolonged co-culture with Ec.20 breast cancer cells inhibits pro-invasive
phenotype of RMF-HGF
(A) Breast cancer cells were in-directly co-cultured with RMF or RMF-HGF for 4
passages using transwell chambers. Breast cancer cells were subsequently isolated and
evaluated for their invasiveness through Matrigel as shown in (B). Fibroblasts were also
isolated and examined for their ability to promote invasion of naïve MDA-MB231 cells
(C). Error bars = SD of 3 separate samples, representative data from N = 3 separate
experiments.
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Figure 3.2C shows that RMF-HGF that were pre-educated by MDA-MB231 in this coculture system (CC.MDA-MB231) became more aggressive in their ability to promote
breast cancer cell invasion when compared to the fibroblasts that have not been cocultured with the cancer cells. This shows a reciprocal pro-oncogenic stimulation
between the fibroblasts and the breast cancer cells. However, RMF-HGF that were cocultured with Ec.20 cells (CC.Ec.20) exhibited suppressed ability of this process. These
data imply that ROS are involved in regulating the reciprocal cancer cell-fibroblast
interactions in the context of HGF/c-Met activation.

3.2.5

HGF Expressing Fibroblasts Exhibit Higher Levels of ROS and an Upregulation

of NADPH Oxidase 4.
Since RMF-HGF shows an attenuated phenotype after the prolonged co-culture
with Ec.20 cells (Figure 3.2C), we next determined if this oncogenic cytokine promotes
oxidative stress in the activated fibroblasts. Figure 3.3A shows an increase in DHE
oxidation in RMF-HGF when compared to RMF, indicating a higher level of O2•generation in the HGF expressing fibroblasts. As expected, DHE oxidation decreased
when RMF-HGF were treated with an SOD mimetic, MnTE. Despite performing the DHE
oxidation assay using a more superoxide-specific setting at 405 nm excitation (instead of
the non-specific 488 nm excitation) and 570 nm emission, as described [433], we have
further determined the O2•- levels in the fibroblasts with electron paramagnetic resonance
(EPR) spectroscopy. As shown Figure 3.3B, RMF-HGF indeed possess ~ 53% increase
in superoxide-specific EPR amplitude per cell as compared to RMF. We also utilized
another oxidative stress indicator, CellROX® reagent, which is sensitive to ROS
modifications. An increase in CellROX oxidation further shows that HGF overexpression
promoted generation of ROS in mammary fibroblasts and this increase in ROS was
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FIGURE 3.3. RMF-HGF fibroblasts generate higher levels of ROS in comparison to RMF
(A) Intracellular O2•− level was quantified with DHE by FACS analysis in fibroblasts. Cells
were treated with 15 uM of MnTE for 16 h prior to DHE labeling. Data are mean ± SD of
3 separate samples, representative data from N = 3 independent studies. (B)
Representative electron paramagnetic resonance (EPR) spectroscopy analysis of
O2•− using a superoxide-specific probe, 1-hydroxy-3-methoxycarbonyl-2,2,5,5tetramethylpyrrolidine (CMH). Data are mean ± SD of 3 separate samples. (C) ROS
level was determined using CellRox reagent. Fibroblasts were treated with NAC (5 mM)
for 16 h prior to labeling cells with CellRox reagent. Representative data from N = 3
independent studies. Data are mean ± SD of 3 separate samples. (D–F) RMF-HGF
show significantly increased levels of both the total GSH and the oxidized form, GSSG,
when compared to RMF, resulting in a reduction in the GSH:GSSG ratio. Data are mean
± SD of 3 independent experiments. (G) Real time-PCR analysis shows an upregulation
of Nox4 and CYBA in RMF-HGF vs. RMF fibroblasts. Data are mean ± SD of 3
independent experiments. (H) Representative superoxide-specific EPR analysis of RMFHGF. Fibroblasts were exposed to CM harvested from Ec.20 versus vector control MDAMB231 cells (V.1) for 48 hours. Data are mean ± SD of 4 separate samples. (I)
Extracellular H2O2 levels as determined by Amplex Red assay. RMF and RMF-HGF
were co-cultured (CC) with V.1 or Ec.20 cells for 48 prior. RMF-HGF were also treated
with 10 μM of diphenyleneiodonium (DPI), a pan Nox and flavoprotein inhibitor, as a
control. Data are mean ± SD of 3 separate samples.
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reduced when cells were treated with an H2O2 scavenger, NAC (Figure 3.3C). In
addition, cellular glutathione (GSH) levels were also analyzed as an overall indicator of
cellular redox status. GSH is the most abundant antioxidant in aerobic cells and a
decrease in the ratio of reduced to oxidized form (GSH:GSSG) indicates an increase in
cellular oxidative stress, as often detected in cancer cells. We found that not only is GSH
generation increased in RMF-HGF (Figure 3.3D), these fibroblasts also possess a close
to 3-fold higher levels of oxidized GSSG (Figure 3.3E), resulting in a significantly
reduced GSH:GSSG ratio (Figure 3.3F), when compared to that of RMF. Taken
together, all of these indicate an increase oxidative stress in RMF-HGF versus RMF, due
in parts to accumulation of O2•- and other ROS.
To gain insight into the mechanisms that promoted oxidative stress in RMF-HGF
versus its parental fibroblast strain, RMF we profiled mRNA expression of a small panel
of antioxidant related genes in these fibroblasts using TaqMan® Array Human
Antioxidant Mechanisms kit. We found that CYBA (also known as p22phox) is highly
upregulated in RMF-HGF when compared to the RMF. CYBA is an essential component
of the membrane-associated enzyme NADPH-oxidases (Noxs), more specifically Nox14. An increase in expression of CYBA suggests that activation of Noxs is one of the
contributing factors in promoting oxidative stress in RMF-HGF. We have indeed
confirmed that there is a 20-fold increase in Nox4 mRNA expression in RMF-HGF
versus RMF (Figure 3.3G), while no significant difference was observed in the mRNA
expression levels of Nox1-3 (data not shown). This suggests that Nox4 is the
predominant source of ROS in HGF-overexpressing fibroblasts.
To show the effect of cancer-fibroblast co-culture on cellular redox status of the
fibroblasts, we determined the O2- levels in RMF-HGF when cultured in the presence of
conditioned media harvested from Ec.20 breast cancer cells. Figure 3.3H shows that
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there was a significant reduction in superoxide-specific EPR amplitude in these
fibroblasts in the presence of EcSOD-containing media. Since H2O2 can cross
membrane, we also measured the extracellular levels of this peroxide as an indirect
indicator of the cellular H2O2 levels. Figure 3.3I shows that the extracellular H2O2 levels
of RMF-HGF were also significantly reduced, when co-cultured with Ec.20 breast cancer
cells. These suggest that exogenous sources of EcSOD can regulate cellular redox
status of RMF-HGF.

3.2.6

Nox4 Promotes Collagen Contraction Activity of Fibroblasts
To determine the effects of Nox4-generated ROS on the activity of fibroblasts, we

performed collagen contraction assays where Nox4 was overexpressed in RMF using an
adenovirus vector (AdNox4). This 3D collagen gel contraction is a standard assay
utilized for functionally quantifying a contractile phenotype of activated fibroblasts. Figure
3.4A shows that the control adenovirus vector (AdEmpty) infected RMF showed similar
contraction rate compared to the mock infected control sample. However, in the
presence of Nox4, a reduction in the collagen disc area was observed, indicating an
increase in collagen contraction activity of AdNox4 infected RMF. Figure 3.4B shows
that when compared to RMF, HGF-overexpressing fibroblasts showed a significant
increase in collagen contraction, indicating a more activated and aggressive phenotype
of the RMF-HGF. In the presence of a Nox inhibitor DPI, RMF-HGF showed an
attenuated ability to contract collagen. This suggests that ROS-generating Nox enzymes
contribute to fibroblast activation. Since DPI targets the activity of all Noxs, we
specifically inhibited Nox4 expression in RMF-HGF using a siRNA and observed that
down-regulation of Nox4 also significantly impaired the ability of RMF-HGF to contract
collagen (Figure 3.4C). Protein expression levels of Nox4 in these fibroblasts was
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FIGURE 3.4. Nox4 promotes collagen gel contraction ability of fibroblasts
(A) RMF was induced to overexpress Nox4 with adenovirus vector (AdNox4 vs AdEmpty
as a control). Collagen contraction activity of fibroblasts was then analyzed after 16 h of
seeding the cells, where area of contracted collagen discs were quantified by Image J.
The effect of Nox4 on contraction activity of RMF-HGF was determined by (B) inhibiting
the ROS-generating activity of Nox4 with DPI and by (C) suppressing expression of
Nox4 using a siRNA (siNox4 vs siNC#1 as a control). White bar marks 1cm in length.
Representative images from N = 3 independent collagen contraction experiments. Error
bar = SD of 3 separate samples. (D) Western blot analysis showing the expression
levels of Nox4 in fibroblasts. Representative images from 3 independent experiments.
(E) Nox4 knockdown in RMF-HGF down-regulates mRNA expression of myofibroblast
markers. Real time PCR analysis of siRNA transfected RMF-HGF. Error bar = SD of 3
separate experiments.
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verified using western blot analysis as shown in Figure 3.4D. In addition to collagen gel
contraction, we also evaluated the mRNA expression levels of some myofibroblast
markers in Nox4-knocked down fibroblasts. Figure 3.4E shows that transfection with
siNox4 down-regulated expression of stroma derived factor 1 (SDF1), smooth muscle
actin (SMA), and platelet derived growth factor receptor alpha (PDGFR) in RMF-HGF
when compared to the control siNC#1 transfected cells. Together, this study indicates
that Nox4 upregulation in RMF-HGF promotes an activated phenotype of the fibroblasts.

3.2.7

Scavenging ROS with an SOD Mimetic Inhibited HGF-mediated Growth and

Invasion of Breast Cancer Cells
To further provide evidence that ROS contributes to HGF-mediated oncogenic
stimulation, we treated breast cancer cells with an SOD mimetic, MnTE-2-PyP (MnTE).
This compound has been demonstrated to effectively scavenge ROS [434]. We first
stimulated 3D growth of MDA-MB231 with rHGF and observed that MnTE treatment
inhibited the induction of breast cancer cell growth and stellate formation by HGF (Figure
3.5A). Next, we co-cultured breast cancer cells with RMF-HGF. In this co-culture, MnTE
also greatly reduced the 3D colony sizes and invasive stellate formation of MDA-MB231
as seen in Figure 3.5B. Moreover, this inhibitory effect of MnTE is observed when
cancer cells were stimulated with conditioned media harvested from RMF-HGF (Figure
3.5C). Cellular growth in conditioned media (shown in Figure 3.5C) was quantified using
a luciferase activity assay and presented in Figure 3.5D. The antioxidant, MnTE inhibited
HGF-mediated growth of breast cancer cells by 76% (P = 0.017). In addition to the 3D
growth behavior, we also determined the effects of scavenging ROS with MnTE on HGFmediated invasion of breast cancer cells. Figure 3.5E shows that while conditioned
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FIGURE 3.5. Scavenging ROS with an SOD mimetic inhibited HGF-mediated 3D growth
and Matrigel invasion of MDA-MB231
Growth of MDA-MB231 cells was stimulated with either rHGF (50 ng/mL, A) or in coculture with RMF-HGF (B), or with conditioned media (CM) harvested from fibroblasts
(C). Cells were treated with an ROS scavenger, MnTE-2-PyP (MnTE, 15 uM) for 4 days.
Representative bright field images of N = 3. Quantitation of the proliferation of MDAMB231 in (C) is shown in (D). After 4 days of culture with conditioned media from RMF
or RMF-HGF, MDA-MB231 cells were lysed and luciferase activity was measured. (E)
MDA-MB231 cells were seeded into Matrigel® invasion chamber and their ability to
invade into conditioned media harvested from RMF or RMF-HGF in the present and
absence of MnTE (15 uM) was analyzed. N = 3 independent studies. Data are mean ±
SD of 3 separate samples. RLU = Relative light units.
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media from RMF-HGF promoted invasion of MDA-MB231, this stimulation was
significantly reduced in the presence of MnTE. These studies reveal that HGF-mediated
cancer cell-fibroblast interactions involve ROS and that administration of antioxidants
can suppress the oncogenic HGF/c-Met signaling.

3.2.8

EcSOD Inhibited HGF-mediated Tumor Growth
To determine the regulation of HGF-stimulated tumorigenesis by ROS, we

utilized an orthotopic mammary tumor model. RMF-HGF was co-injected with the cancer
cells as the source of c-Met ligand as well as in providing a model for studying the
tumor-fibroblast interactions. The top panel of Figure 3.6A shows the presence of the
breast cancer cells following the mammary fat pad injection. After 6 weeks post injection,
RMF-HGF greatly stimulated the primary tumor growth of MDA-MB231, as expected
(bottom panel). In contrast, EcSOD overexpressing cells (Ec.20) were irresponsive to
the growth stimulation by RMF-HGF. Quantitation of the primary tumor growth is
presented in Figure 3.6B as determined by photon flux over time.

3.2.9

EcSOD is Significantly Under-expressed in Breast Carcinomas
To further evaluate the expression levels of EcSOD in breast carcinomas, we

analyzed deposited Oncomine datasets. Differential expression analysis of breast
carcinomas versus normal tissues showed that EcSOD (or SOD3) is significantly downregulated in different types of breast carcinomas in two main datasets, TCGA and Curtis
Breast (Figure 3.7A). Specifically, in invasive breast carcinomas, SOD3 is ranked in the
top 1% and 6% most significantly under-expressed genes as shown in the box plots in
Figure 3.7B. The fold change of this gene is -5.475 in the TCGA and -2.654 in the Curtis
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FIGURE 3.6. EcSOD suppresses HGF-stimulated tumor growth
(A) Bioluminescence imaging showing tumor growth of luciferase expressing breast
cancer cell lines in athymic nude mice. At Day 0, 106 MDA-MB231 or Ec.20 cells were
co-injected with 3 × 105 fibroblasts (RMF or RMF-HGF) into both sides of the
4th mammary fad pads. Mice were imaged over time to monitor tumor growth as shown
in representative images in (A) and the quantitation of the primary tumor growth is
shown in (B). N = 6 per group. *P < 0.01 Ec.20 + RMF-HGF vs. MB231 + RMF-HGF.
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FIGURE 3.7. Oncomine SOD3 (EcSOD) gene analysis in breast cancer
(A) Comparison of SOD3 expression across 14 breast cancer analyses. The heatmap
represent the relative expression in patients with the indicated breast carcinomas
compared with normal tissue. Blue indicates underexpression. The reported median rank
and P value consider all indicated studies simultaneously. (B) Box plots derived from
gene expression data comparing invasive ductal carcinomas to normal tissues from
TCGA and Curtis studies. The number of samples in each group is indicated in brackets.
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datasets.

3.2.10 Low EcSOD Expression Confers Poor Survival in Breast Cancer Patients
An integrative microarray data analysis using the Kaplan Meier Plotter [152]
shows that low EcSOD expression is associated with significantly reduced relapse free
survival in all breast cancer subtypes, including the basal-like (ER−, PR−, Her2−, CK
5/6+, and/or EGFR+) breast cancers (Table 3.1). Survival analysis was performed where
restriction was set to exclude systemically untreated patients. The numbers of samples
in each group are indicated in parentheses, and the hazard ratios (HR) and log rank p
values are shown.

3.3

Discussion
A breast cancer genome-wide association study (GWAS) of the NCI Cancer

Genetic Markers of Susceptibility project identified c-Met signaling as the second highest
ranked pathway that may contribute to breast cancer susceptibility [435]. Since breast
cancer cells primarily rely on their stroma fibroblasts for the c-Met ligand, understanding
the contributing factors that fuel this reciprocal communication between cancer cells and
their stroma partners will therefore, help in identifying novel targets for c-Met driven
cancer. In this study, we identified c-Met as one of the RTKs regulated by an
extracellular antioxidant enzyme, EcSOD in basal-like breast cancer cells via modulating
the cellular redox status. Expression of this enzyme has been shown to be suppressed
in a variety of cancers, including breast cancer [142, 165, 413]. Conversely, upregulation
of EcSOD has been reported to inhibit both in vitro and in vivo growth as well as the
oncogenic phenotype of breast cancer, prostate cancer, pancreas cancer, melanomas,
and lung cancer [141, 158, 161, 162, 171, 172, 413], suggesting tumor
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TABLE 3.1. Relapse free survival rate of breast cancer patients based on low versus
high expression levels of EcSOD
Gene expression data and survival information are downloaded from GEO (Affymetrix
HGU133A and HGU133+2 microarrays), EGA and TCGA (http://kmplot.com). Months
shown are upper quartile RFS rate except for * which indicates median survival
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All Subtypes
Luminal A
Luminal B
Her2+ve
Basal-like

Low expression cohort
(No. of patients)
61* months (469)
42 months (223)
43.9 months (149)
16 months (33)
11.31 months (105)

High expression cohort
(No. of patients)
173.2* months (1412)
97 months (638)
171.4 months (447)
22.6 months (92)
30.42 months (194)

Hazard Ratios
(HR)
0.46
0.48
0.42
0.57
0.46

P values
1.00E-16
2.90E-08
4.00E-11
5.30E-02
1.70E-05

129

suppressive effects of this antioxidant.
The oncogenic RTK, c-Met is one of the cell surface receptors known to be
activated by ROS. Stimulation of lung cancer cells with exogenous ROS (i.e. H2O2)
enhanced tyrosine phosphorylation of c-Met and activated its downstream signaling
cascades in lung cancer cells [415]. In these same cells, an increase in ROS
production was also observed when c-Met was activated by HGF treatment [415]. In
addition, ROS-induced invasive activity of hepatoma cells has been demonstrated to be
mediated through an autocrine/paracrine loop of HGF, where ROS directly augment
mRNA expression of HGF [436]. Our study provides further evidence that a pro-oxidative
environment is involved in activating and sustaining the oncogenic HGF/c-Met signaling
and that re-expressing EcSOD in breast cancer cells inhibits HGF-stimulated
oncogenesis. Further supporting an association of c-Met signaling with loss of EcSOD
expression, a gene expression profiling study identified EcSOD as one of the genes that
was down-regulated in both c-Met driven mouse liver tumors and human hepatocyte
carcinomas, and that this change has a significant predictive power on overall and
disease-free survival [437].
Although the second messenger role of ROS in cellular signaling is well
recognized, it is not clear how EcSOD specifically regulates c-Met signaling amongst the
other kinases screened in this study. Interestingly, phosphorylation of other RTKs such
as EGFR, ERBB2, and FLT-3 have recently been shown to be promoted when EcSOD
is overexpressed in thyroid cancer cells [169]. Despite increased phosphorylation of
these RTKs, EcSOD overexpressing cells showed a reduced level of growth and
migration signal transductions, through down-regulation of small GTPase regulatory
genes [169]. The same study also showed a reduction of HGFR (or c-Met)
phosphorylation in EcSOD enriched cells. The discrepancies between our RTK findings
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with the exception of c-Met phosphorylation could be due to specificity issues related to
the cell type examined and possibly also influenced by the dose-dependent effect of this
ROS scavenger, as suggested by the authors.
In addition to c-Met, phosphorylation of c-Abl is also targeted by EcSOD in breast
cancer cells (Figure 3.1A). This oncogene has been demonstrated to promote an
aggressive phenotype of breast cancer cells [438]. Genetic and pharmacological knockdown of c-Abl impairs c-Met-triggered solid tumor formation in vivo and this kinase is
required for c-Met-dependent cell scattering, tubulogenesis, migration, and invasion,
through induction of Rho signaling [425]. In the same study, this kinase has also been
demonstrated to promote the phosphorylation of c-Met at tyrosine residues required for
engaging downstream signaling pathways, suggesting that down-regulation of c-Abl by
EcSOD will block this feed-forward c-Ablc-Met signaling and likely contribute to the
overall suppression of c-Met signaling in breast cancer cells.
One mechanism by which EcSOD could inhibit c-Met signaling is by reducing
bioavailability of its ligand HGF, via TSPs, as shown by our extracellular protein array
analysis. Thrombospondin 1, TSP-1 is a well-known anti-angiogenic protein that elicits a
variety of cellular processes, including a recently discovered role in maintaining
dormancy of disseminated tumor cells [439]. The TSP-1 interactome is still not fully
defined but HGF has been identified to be one of its ligands [440]. We have shown here
for the first time that EcSOD expressing cells secrete higher levels of TSP-1 and TSP-2
(Figure 3.1 D). Not only is the function of HGF affected by TSP-1, the expression of this
anti-angiogenic factor has also been shown to be down-regulated by HGF-c-Met
interactions in breast cancer cells [441], indicating a negative regulatory circuit of TSP1
and HGF. Further supporting a regulatory effect of EcSOD on TSP-1, a microarray
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expression analysis has identified TSP-1 as one of the growth suppressors upregulated
by this antioxidant in thyroid cancer cells [169].
It is now well recognized that the progression from normal to benign, malignant,
and metastatic, as well as therapeutic resistance is driven not just by what is happening
inside the cancer cell but by reciprocal communication between the cancer cells and
their stroma microenvironment. Our heterotypic co-culture studies indicate an ROSmediated reciprocal interaction between cancer cells and fibroblasts (Figure 3.2). After a
prolonged co-cultivation with CAF-like RMF-HGF, breast cancer cells showed a
heightened aggressiveness in invasive properties and they also pre-educated RMF-HGF
to increase their ability to promote breast cancer invasion. This symbiotic relationship is
compromised when breast cancer cell overexpress EcSOD. The presence of EcSOD in
breast cancer cells not only inhibited this RMF-HGF-stimulated invasion, but on top of
that prevented the reprograming of RMF-HGF in their tumor-promoting phenotype. This
suggests that an oxidative microenvironment is a contributing factor in regulating HGF-cMet-mediated tumor stroma co-evolution. This is particularly important considering the
fact that 86% of the aggressive basal-like tumors are positively correlated with the HGF
signature [442]. Furthermore, among basal-like patients that are positive for the HGF
signature, patients had worse overall survival [442]. These results emphasize the
importance of HGF signaling in aggressive breast cancer, particularly the basal-like
breast cancer. While some c-Met signaling can arise from an autocrine manner, the
predominant activation mode of c-Met in breast cancer is through a paracrine tumorstroma interactions. Immunohistochemitry analysis shows that the HGF/c-Met paracrine
pattern is seen in 59.1% of tumors; and that this paracrine signaling is associated with a
worse outcome when c-Met staining is more intense at the tumor front [443].
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Cancer associated fibroblasts (CAFs) actively participate in the outcome of
breast cancer by providing extracellular matrix components and secreting signaling
factors that enhance cancer cell growth, survival, oncogenic progression, and
metastasis. However, the intrinsic factor(s) contributing to the “activated” fibroblast
phenotype of CAFs remains to be elucidated. A recent study showed that oxidative
stress is necessary for triggering fibroblast activation in the pathological condition of
fibrosis. NADPH oxidases (Noxs) are the predominant enzymes that produce O2- on the
plasma (and organelle) membrane and their activation has been linked to the etiology of
cancer. Importantly, Nox4 is the only Nox that is expressed as an active enzyme. Thus,
elevated Nox4 will lead to an increase in ROS generation. Nox4 has been suggested to
play an important role in inducing fibroblast activation during fibrosis [444] in cardiac and
pulmonary fibroblasts and in TGFβ-induced myofibroblast activation [445], but the role of
Nox4 in CAFs is not known. Here we have shown that the HGF-induced activated
phenotype of mammary fibroblasts involves Nox4-generated ROS (Figure 3.3 and 3.4).
This explains the suppressive effects of EcSOD during co-cultivation of breast cancer
cells with RMF-HGF as well as in our in vivo tumor model. Modulating the redox tumor
microenvironment will therefore, not only inhibit the oncogenic c-Met pathway in cancer
cells, but also target the activated phenotype of CAFs, thus suppressing their tumorstroma interactions.
Despite the name implying that EcSOD is an extracellular antioxidant, the O2scavenging effect of this enzyme is not limited to cell surface and secreted compartment
but more widely distributed to endocytic vehicles and nucleus. By harboring a heparin
binding domain at its c-terminus, EcSOD interacts with cell surface heparin sulfate
proteoglycan [446] once it is secreted. This interaction has been shown to be critical for
the re-entry of this enzyme through a clathrine-mediated endocytosis [73] and its nuclear
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tranlocation [75]. This feature renders EcSOD more readily available to cells or tissues
that do not express this enzyme and internalization of exogenous EcSOD has been
reported in mouse preadipocytes and endothelial cells [73, 447]. Here, the secreted
EcSOD from Ec.20 cancer cells is also likely to be taken up by the co-cultured RMFHGF, resulting in a decrease in O2- levels of the fibroblasts (Figure 3.3H), thereby
attenuating the tumor-promoting effects of RMF-HGF, as seen in Figure 3.2.
Although Nox4 has been historically considered as a superoxide generating
enzyme, an increasing number of studies have reported that the major product of Nox4
is H2O2, although other studies have detected O2- generation [120, 448-450]. It is
plausible that some of the discrepancies may have resulted from non-specificity issues
of the ROS detection reagents or that the O2- produced (in membrane compartments)
remains cryptic and inaccessible to assay reagents prior to its dismutation to form H2O2.
Since the oxygen-reducing heme group at the catalytic site of Nox4 is an obligate oneelectron donor, a direct formation of H2O2 without a O2- intermediate is mechanistically
implausible, implying that Nox4 is both a O2- and H2O2 producers. This is supported by a
recent study using cell-free isolated Nox4, where the authors found that approximately
80% of the product from the isolated Nox4 was detected as H2O2, while ~20% was
detected as O2- [448].
Since EcSOD catalyzes the dismutation of O2- to H2O2, some may argue that
EcSOD would exacerbate the H2O2 levels in Nox4-overexpressing RMF-HGF, and if so
overexpression of EcSOD would not have inhibited but promoted c-Met signaling, which
is known to be activated by H2O2 [415]. Whether overexpression of SOD can increase
the production of H2O2 has been a hotly debated issue. Although some studies have
attributed the consequences of SOD overexpression to this counter intuitive effect in
increasing H2O2 levels, the views that SOD should elevate H2O2 formation merely
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because it catalyzes an H2O2-producing reaction has been disputed. Liochev and
Fridovich [451, 452] reasoned that an excess of SOD should decrease the steady-state
levels of O2- without increasing the endogenous formation of H2O2, at least in vivo. So it
is doubtful that the inhibitory tumor-stroma effects seen with EcSOD overexpression in
our current study, is due to an overproduction of H2O2. Moreover, the copper ion located
in the catalytic domain of EcSOD are sensitive to H2O2 attack and by acting in a “suicidal
mode”, EcSOD can have peroxidase-like properties [121]. Our data showing a decrease
in both cellular O2- levels and the extracellular H2O2 levels in the co-cultures (Figure
3.3H and 3.3I) support the view that overexpression of this extracellular O2- scavenger
does not contribute to H2O2 accumulation.
Although H2O2 has long been the main focus as the ROS-mediated signaling
molecule, partly due to it being a more stable and longer lived species than O2- , O2has recently been viewed as an important mediator of cellular effects. Superoxide affects
both serine/threonine protein phosphatases (PPs) and protein tyrosine phosphatases
(PTPs), by oxidizing the metal ion center of the former class of phosphatases and via
nucleophilic attack of the cysteine residue in the later class [52, 53]. The rate of
superoxide signaling has been estimated to be about 10-100 times higher than that of
H2O2 signaling [54, 55]. In addition to being kinetically more efficient, O2- is chemically
more specific than H2O2 in this process as the catalytic site of PTP-1B is surrounded by
positively charged residues [28]. This provides an efficient fine-tuning ability of O2- in
regulating signal transduction. Therefore, loss of EcSOD expression in cancer cells and
the resulting increase of O2- in the tumor will likely promote and sustain oncogenic
signal transduction such as the c-Met pathway.
In comparison to the other two intracellular SODs, EcSOD is the new comer in
terms of its tumor suppressive role in cancer and the mechanisms involved are less well
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understood. The degree of differential expression of this antioxidant in cancer versus
normal cells/tissues however, is more pronounced and prevalent than the other SODs in
breast cancer. Oncomine gene expression signature analysis identifies EcSOD as one
of the top 1% to 6% under-expressed genes in invasive ductal breast carcinomas versus
normal tissues from both the TCGA and Curtis datasets (Figure 3.7). Down-regulation of
EcSOD expression in cancer cells has been associated with epigenetic silencing,
upregulation of oncomir microRNA-21, Ras oncogene-mediated gene silencing, chronic
estrogen-induced gene suppression, single nucleotide polymorphisms, DNA copy
number variation, and loss of heterozygosity as reviewed recently [453]. All of these
observations imply that deregulation of EcSOD expression, distribution, or function
provides a selective advantage in cancer cells. Furthermore, association of low EcSOD
expression levels with poor relapse-free survival as shown in Table 3.1 underscores the
importance of EcSOD as a potential tumor suppressor gene, inhibiting the progression of
malignant phenotype in human breast cancer. However, the mechanisms of how EcSOD
loss could promote oncogenesis is not fully understood.
Taken together, our study shows that ROS contributes to HGF-stimulated c-Met
activation and that overexpressing the extracellular antioxidant enzyme, EcSOD
suppresses this oncogenic cancer-fibroblast interaction. Modulating the redox tumor
microenvironment not only inhibits the oncogenic c-Met pathway in cancer cells but also
targets the redox-mediated activated phenotype of CAFs. ROS as merely a damaging
bystander species that induce cytotoxic effects does not provide a complete picture of
their biological effects. Rather, they should be considered as critical players in finetuning cellular signaling events in a temporal and purposeful manner in cancer. Future
studies to unravel the specific modifications of signaling molecules/factors by O2- and
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H2O2 and how EcSOD regulates oncogenic signal transduction pathways will help to
identify specific redox-mediators as potential cancer targets.

137

CHAPTER 4:

Scavenging Reactive Oxygen Species Selectively Inhibits M2
Macrophage Polarization and their Pro-tumorigenic Function
in part via Stat3 Suppression

Data in this chapter have been published in the following manuscript:
Griess B., Mir S., Datta K., Teoh-Fitzgerald M. Scavenging reactive oxygen species
selectively inhibits M2 macrophage polarization and their pro-tumorigenic function, in
part via Stat3 suppression. Free Radical Biology & Medicine. 2019 (under revision)
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4.1

Introduction
Macrophages are known to exhibit high plasticity which allows for dramatically

different functions based on signals received from the microenvironment. In general,
macrophages can polarize toward two extremes, the proinflammatory M1 and the
immunosuppressive M2. The classically activated M1 macrophages are characterized by
enhanced bacteria killing via an oxidative burst of reactive oxygen species (ROS),
increased antigen presentation and phagocytosis, high IL-12 production, and promotion
of a TH1 response. Conversely, M2 macrophage are characterized by increased
efferocytosis, high IL-10 secretion, high levels of scavenger receptors, such as CD163
and CD206, promotion of a TH2 response, and immunosuppression. This is, however, an
oversimplification of the complexity of macrophage polarization as recent studies
indicate a much broader range of polarization states, such M2b, M2c, Mox, and M4,
depending on the stimulating factor(s) within the milieu, as detailed in the these reviews
[335, 336].
Macrophages are the most abundant immune cell in the tumor stroma and can
account for up to 50% of tumor mass in breast cancer [454]. These tumor-associated
macrophages (TAMs) are known to promote cancer cell growth, metastasis, and cancer
cell evasion of the immune system [455]. Then unsurprisingly, TAMs are correlated with
decreased survival in many types of solid cancers, such as breast, lung, and pancreatic,
among others [348, 456-465]. While TAM are a heterogeneous population, they are
mostly skewed toward a predominantly M2 phenotype [466]. The M2 surface marker,
CD163, is correlated with poor patient survival, metastasis, and grade in breast cancer
[349, 351, 467, 468]. Macrophage depletion in mouse models decreases tumor growth
and metastasis [469-471]. Therefore, a further understanding of the M2 macrophages
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polarization and function is required to develop therapies to target their detrimental
effects seen in many different solid cancers.
During activation, M1 macrophages produce ROS via Nox2 to activate NF-κB,
thereby stimulating phagocytosis and the inflammasome [472]. However, few studies
have investigated the role of ROS in M2 polarization and function. Some studies suggest
that M2 macrophages have key differences in ROS production and metabolism
compared to M1 macrophages [472]. Promoting a pro-oxidative condition by lowering
glutathione (GSH) levels has been shown to increase IL-10 and decreased IL-12
production in macrophages, indicative of a more M2 polarization state [367]. Conversely,
increasing glutathione levels promoted M1 polarization as shown by an increase in IL-12
production and a decrease in IL-10 levels [367]. Therefore, the redox status of
macrophages could be a contributing factor of macrophage polarization and function.
Furthermore, butylated hydroxyanisole (BHA), a commonly used food preservative that
prevents fatty acid oxidation, inhibits M-CSF mediated M2 polarization [368]. However,
BHA also has off-target effects, such as disruption of the electron transport chain, which
could also disrupt macrophage polarization [369]. Despite all the recent advancements
in understanding macrophage biology, the direct role of ROS during TAM or M2
polarization and function remains unclear.
MnTE-2-PyP5+ (MnTE), also known as AEOL10113 and BMX-010, is a member
of the manganese porphyrin (MnP) ring family of redox-active drugs. MnTE has been
safely administered in preclinical models with very little negative side effects [278]. It is
currently used in clinical trials for atopic dermatitis and plaque psoriasis. Additionally, an
analog of MnTE, MnTnBuOE-2-PyP5+, is also being tested as a radioprotectant in
patients with multiple brain metastases, anal cancer, high grade glioma, and advanced
head and neck cancer. MnPs were initially designed to mimic the activity of superoxide

140

dismutases (SODs). However, the small molecule MnPs lack the large protein bulk of
SODs, which provide selectivity toward O2•− via steric hindrance. Thus, MnPs have a
more promiscuous active site that can readily react with other reactive species, such as
peroxynitrite and hydrogen peroxide [277]. Furthermore, recent evidence indicates that
MnPs can act as a pro-oxidant in certain cancer cell lines and in tumor tissue. This effect
is especially potent when MnPs are combined with high levels of intravenous ascorbate
and/or radiation [279, 281, 282]. Interestingly, there is some circumstantial evidence that
MnTE may affect macrophages in breast cancer. MnTE treatment in the 4T1 mouse
model of stage IV breast cancer reduced macrophage infiltration, along with reduced
levels of angiogenesis and metastasis, which are both processes induced by M2
macrophages [290]. This study provided rationale for determining the effect of MnTE on
macrophage polarization and function directly.
Tumors are known to have a highly oxidative microenvironment compared to
adjacent normal tissue, in part due to an increased ROS production from cancer cells
[473]. The role of this highly oxidative tumor microenvironment on the interactions
between cancer cells and the surrounding stromal cells is not clear. Particularly, the
influence of this oxidative tumor microenvironment on TAM function is not known. Due to
the high plasticity of macrophages and the key role they play in the immune response to
cancer, we sought to determine the role of ROS on macrophage polarization and
function. The objectives here were to characterize the redox profile in pro-tumorigenic
M2 macrophages versus anti-tumorigenic M1 macrophages and to determine
differences in their sensitivity to MnTE, with the goal of selectively targeting the M2
macrophages. We found that M2 macrophages showed an increase expression levels of
some key antioxidant enzymes and lower levels of some pro-oxidants, when compared
to the M1 macrophages, suggesting an increase ability to tolerate an oxidative
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environment. Interestingly, despite the lower levels of ROS levels in M2 macrophages,
these cells seem to require an optimum range of ROS to maintain their proper function
and are more sensitive to ROS scavengers. Polarization of the M2 but not the M1
macrophages was attenuated by the redox-active drug, MnTE and the pan-Nox inhibitor,
diphenyleneiodonium (DPI) [474]. These data suggest that the M1 macrophages can
tolerate a wider range of ROS levels whereas the M2 macrophages are more vulnerable
to alterations in cellular redox status. We have further shown that MnTE inhibited IL4stimulated polarization of M2 macrophages by decreasing Stat3 activation.
Consequently, MnTE treated macrophages showed reduced ability to promote breast
cancer cell growth and T cell suppression. This study highlights a critical role of ROS in
M2 macrophage function and implies that targeting the redox susceptibility of these
macrophages could be a promising consideration for a more effective anti-cancer
strategy.

4.2

Results

4.2.1

MnTE Reduces Expression Levels of M2 Markers
To determine the role of ROS during macrophage polarization, primary human

macrophages were treated with MnTE during differentiation and polarization to M1 or
M2. The changes to cellular morphology were the first indications this antioxidant
affected macrophage polarization. When stimulated with M-CSF and IL-4, activated M2
macrophages showed an elongated morphology as demonstrated in Figure 4.1A, while
M1 macrophages have a more rounded spherical cell shape. MnTE treatment inhibited
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FIGURE 4.1. MnTE inhibits M2 polarization
Primary human macrophages were generated from isolated monocytes which were
differentiated to macrophages and polarized to M1 or M2 types. The macrophages were
analyzed 24 hours after polarization. (A) Representative phase contrast pictures of M1
and M2 macrophages treated with varying concentrations of MnTE. Expression of (B)
M1 and (C) M2 mRNA markers in macrophages treated with or without 15 μM MnTE
from 3 and 4 different donors, respectively. (D) A representative histogram of CD206
surface staining in M1 and M2 macrophages. (E-F) Box plots depicting flow cytometry
analysis of M2 surface marker levels, (E) CD163 and (F) CD206, in M2 macrophages
from 6 different donors treated with varying concentrations of MnTE. Relative values
were calculated by comparing the change of MnTE treated samples to its untreated
donor-specific control. Error bars are the standard deviation. Student t-test was used to
calculate p-value with statistical significance being < 0.05. Symbols indicate significance
between the treatment groups and M2 control (* < 0.05, $ < 0.005, # < 0.0005).
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the elongated phenotype of M2 macrophages in a dose-dependent manner (Figure
4.1A). The morphology of the MnTE treated M2 macrophages resembled that of the
rounded phenotype in M1 macrophages. Contrary to the M2 macrophages, MnTE
treatment did not affect the overall morphology of the M1 macrophages (Figure 4.1A).
We then analyzed M1- vs. M2- specific marker expression in these macrophages and
found that MnTE indeed decreased the mRNA expression of M2 markers, IL-10 and
CD163 (Figure 4.1B). MnTE treated M1 macrophages had increased levels of the M1
marker, TNFα, as well as a trend toward an increase in IL12b, another M1 marker
(Figure 4.1C). To further confirm the effect of MnTE on M2 polarization, we analyzed the
surface levels of the M2 markers, CD163 and CD206. Flow cytometry analysis showed
that both markers were significantly decreased in a dose-dependent manner with MnTE
treatment (Figure 4.1D-F).
4.2.2

MnTE Inhibits M2 Macrophage Function In Vitro
We next determined the effect of MnTE on macrophage function. It is known that

M1 macrophages inhibit the growth of cancer cells, while M2 macrophages promote
cancer cell growth [475, 476]. Therefore, we isolated conditioned media (CM) from M1
and M2 macrophages with or without MnTE pre-treatment and examined its ability to
affect cancer cell growth. As expected, MDA-MB231 breast cancer cells showed a
decreased proliferation in the presence of CM isolated from the M1 macrophages, when
compared to the CM from the M2 macrophages and unpolarized M0 macrophages
(Figure 4.2A). While MnTE did not affect the ability of M1 macrophages to inhibit MDAMB231 cancer cell growth, as shown in Figure 4.2B, CM from M2 macrophages pretreated with MnTE significantly reduced cancer cell growth (Figure 4.2C). Since MnTE is
still in the CM of treated macrophages, we assessed the effect of MnTE treatment alone
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FIGURE 4.2. MnTE treatment inhibits M2-mediated cancer cell growth
MDA-MB231 breast cancer cells were grown in 50% conditioned media from M1 or M2
macrophages, with or without MnTE pre-treatment. (A-C) Line graphs depicting the
relative growth of MDA-MB231 cancer cells in macrophage conditioned media from 4
different donors. (A) This line graph compares growth of MDA-MB231 in the control
conditioned media (of unstimulated M0 macrophages) to M1 and M2 macrophages. (BC). Line graphs depicting the effect of 5 μM MnTE pre-treatment on (B) M1 and (C) M2
macrophage conditioned media versus control conditioned media. (D) The relative
cancer cell growth after 4 days in unconditioned media with the addition of varying MnTE
doses. Error bars are the standard deviation. Student t-test was used to calculate pvalue with statistical significance being < 0.05. P-values between MnTE pretreated
conditioned media and their respective controls are indicated by lines between the
different groups.

146

147

on cancer cell growth over 4 days. Over this short time period, MnTE alone had no direct
effect on the growth of breast cancer cells (Figure 4.2D). These data suggests that the
growth inhibition of MnTE-treated M2 macrophages was due to changes to the
macrophages not the effect of the drug alone. Thus, MnTE inhibits the M2 pro-tumor
phenotype in vitro.

4.2.3

MnTE Inhibits M2-mediated T Cell Suppression
Next, we examined whether MnTE pre-treatment will affect the T cell suppressive

function of the M2 macrophages. To do so, we utilized autologous T cells labeled with
the fluorescent dye, CFSE, to track proliferation as a marker of T cell activation. The T
cells were first stimulated with anti-CD3 to promote their activation. Then, macrophages
were co-cultured with T cells where they provide the secondary signal that can promote
or suppress T cell activation. M2 macrophages are known to suppress T cell activation in
this method [477]. In figure 4.3A, a representative histogram indicates the activated T
cell population as a leftward shift away from the unstimulated monocultured T cells. The
histogram also shows that stimulated T cells co-cultured with M1 macrophages have
more activated T cells than those co-cultured with M2 macrophages, as indicated by the
higher peaks within the activated T cell bracket. The bar graph in figure 3B shows the
results of four replicates from a representative donor. This experiment was repeated with
similar results in two additional donors. As expected, anti-CD3 alone in the monoculture
condition (mono) did not readily activate the T cells, while M1 macrophages activated T
cells much better than their M2 counterparts. Furthermore, MnTE treatment, while
having no effect on M1-stimulated T cell activation, dramatically reverted the T cell
suppressive effect of the M2 macrophages (Figure 4.3B-C). MnTE pre-treated M2
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FIGURE 4.3. MnTE inhibits M2-mediated T cell suppression
A T cell activation assay was performed to assess the ability of macrophages to modify
T cell activation. Human peripheral blood lymphocytes (PBLs) were stained with CFSE
to track their activation. PBLs were directly co-cultured with autologous control of
pretreated macrophages and stimulated with anti-CD3. Flow cytometry was used to
track the dilution of CFSE as a proxy for T cell activation. (A) A representative histogram
of T cells comparing unstimulated mono-culture T cells with anti-CD3 stimulated T cells
co-cultured with either M1 or M2 macrophages. The bracket delineates the activated T
cells measured in the bar graph. (B) A bar graph depicting the average percent T cell
activated after direct co-culture with the control or pre-treated M1 and M2 macrophages.
Four technical replicates from a representative donor are shown here. Similar results
were obtained in 3 different donors. (C) A representative histogram highlighting the
ability of pre-treated M2 macrophages to promote T cell activation. (D-F) Flow cytometry
analysis of surface markers known to affect T cell activation in treated M1 and M2
macrophages. The following co-activators of (D) CD80, (E) CD86 were analyzed.
Relative expression levels of the coinhibitory molecule, PD-L2, in 2 different donors (F).
Error bars are the standard deviation. Student t-test was used to calculate p-value with
statistical significance being < 0.05. Symbols indicate significance between the groups
indicated via the line (* < 0.05, $ < 0.005, # < 0.0005).
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macrophages are now able to induce T cell proliferation to the same extent as the M1
macrophages.
To determine the mechanism behind this dramatic change, we analyzed some
key co-activators and co-inhibitory molecules expressed by macrophages that are
known to promote/inhibit T cell activation. Amongst these are the co-activators CD80
and CD86 [478], which we found to be significantly lower in M2 macrophages compared
to M1 macrophages (Figure 4.3D-E). MnTE treatment had no effect on CD80 or CD86
levels in M1 or M2 macrophages suggesting neither CD80 nor CD86 plays a role in the
dramatic change of treated M2 macrophages promoting T cell activation. We next
evaluated PD-L2, a co-inhibitory molecule expressed on M2 macrophages that is known
to play a key role in M2-mediated inhibition of T cell proliferation [479]. MnTE treatment
significantly decreased surface levels of PD-L2 in a dose-dependent manner (Figure
4.3F). This suggests that MnTE treatment inhibits M2-mediated immunosuppression in
part through reduction in PD-L2 surface levels.

4.2.4

M2 Macrophages Have Differential Redox Status Compared to M1 Macrophages
Our data suggests that M2 macrophages are more sensitive to ROS

manipulation than M1. Therefore, we hypothesized that inherent differences in the redox
status of M1 and M2 macrophages could explain the differential effect of ROS
manipulation. To determine if there were any potential redox differences in these
macrophages, we analyzed the ROS levels of fully polarized M1 and M2 macrophages.
M2 macrophages showed significantly lower levels of ROS as assessed by DCFH
staining (Figure 4.4A). Additionally, DHE labeling of the superoxide-enriched
fluorescence (Ex. 405nm) and the non-specific ROS fluorescence (Ex. 488nm) were
both trending lower in M2 macrophages compared to M1 (Figure 4.4B). To further
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FIGURE 4.4. M2 macrophages have differential redox status compared to M1
Primary human macrophages were analyzed after 24 hours of polarization. The ROS
levels of primary human macrophages from 7 different human donors were measured by
(A) DCFH. (B) DHE measured ROS levels in primary human macrophages from 4
different donors. DHE excitation at 405nm and 488nm was used to measure superoxidespecific levels and general ROS levels respectively. (C, D) The levels of oxidized GSSG
and total GSH were measured using GSH/GSSG-glo assay in 5 different donors. (E)
The levels of extracellular H2O2 were measured using AmplexRed via plate reader from
4 different donors. (F, G) The levels of mitochondrial ROS production and mitochondrial
number in macrophages from 4 different donors were assessed using MitoSox and
MitoTrackerGreen respectively. Each line indicating changes between M1 and M2 for
each specific donor. (A, B, F, G) Fluorescence was assessed using flow cytometry.
Relative values were calculated by comparing the change of the M2 sample to its donor
specific M1 sample making each change donor specific to account for the heterogeneity
of different human donors. Error bars are the standard deviation between all donors M1
or M2 samples. Student t-test was used to calculate p-value with statistical significance
being < 0.05.
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assess the overall redox status of the cells, we analyzed the levels of cellular glutathione
(GSH). In general, cells that exhibit a higher level of ROS will show a higher level of
oxidized GSH (GSSG). However, Figure 4.4C shows no significant difference in GSSG
levels between the M1 and M2 macrophages while the total levels of GSH are
significantly increased in M1 versus M2 macrophages (Figure 4.4D). This suggests that
M1 macrophages maintain a higher intracellular level of GSH to combat the increased
ROS seen in these classically activated macrophages, whereas the M2 macrophages
are less reliant on the GSH pathway. Next, we sought to determine if the cellular ROS
differences were driven by certain cellular compartments, such as an extracellular
oxidative burst or an internal spike in mitochondrial ROS production. Figure 4E shows
that M2 macrophages had significantly reduced extracellular hydrogen peroxide
production compared to M1 macrophages. While, mitochondrial ROS levels were
unchanged between M1 and M2 macrophages (Figure 4.4F), despite a slight decrease
in mitochondrial content in M2 macrophages (Figure 4.4E).

4.2.5

M2 Macrophages Have Reduced ROS Producing Enzymes
We next determined the sources of increased ROS levels in the M2

macrophages. Due to the large disparity in extracellular hydrogen peroxide levels, we
analyzed the membrane bound ROS producing enzymes, NADPH oxidases (Nox). We
found that mRNA expression of Nox2, Nox5, and CYBA (p22phox) was significantly
lower in M2 macrophage compared to M1 (Figure 4.5A). Interestingly, Duox1 and its
activator DuoxA1 both were dramatically increased in M2 whereas essentially no
expression of these genes was detected in M1 macrophages (Figure 4.6A). Despite the
dramatic increase in Duox1, Nox2 is still the most expressed Nox family member in both
M1 and M2 macrophages (Ct values for real time-PCR analysis were 19 for Nox2 and 26
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FIGURE 4.5. M2 macrophages have lower ROS producers than M1
(A) mRNA was isolated from M1 and M2 macrophages 24 hours after addition of
polarizing cytokines. The mRNA expression of Nox family members and co-factors was
measured using rt-qPCR. The differences between M1 and M2 were calculated using
the ΔΔ Ct method with 18S as the loading control. Analysis of gene expression was
performed using N = 3-5 donors. (B) The protein expression of Nox2, p47phox, and βactin in M1 and M2 macrophages was analyzed using Western blot analysis from 5
different donors. (C) Densitometry analysis of Nox2 and p47phox compared to the
loading control, β-actin, is indicated in line graphs comparing the change of the change
of M2 sample to its donor specific M1 sample to account for the heterogeneity of
different human donors. The bar graphs indicate the average gene expression with error
bars indicating the standard deviation. Student t-test was used to calculate p-value with
statistical significance being < 0.05.
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FIGURE 4.6. Nox family members are differentially expressed in M1 and M2
macrophages
(A-B) mRNA was isolated from M1 and M2 macrophages 24 hours after addition of
polarizing cytokines. The mRNA expression of Nox family members was measured
using rt-qPCR. (A) The differences between M1 and M2 were calculated using the ΔΔ Ct
method with 18S as the loading control. Analysis of gene expression was performed
using 4 different donors for DuoxA1 and 5 different donors Duox1. (B) Table indicates
the raw Ct value for Nox family members in M1 and M2 macrophages averaged across
different donors with the standard deviation included.

157

158

for Duox1 in M2 macrophages). Additionally, both M1 and M2 macrophages expressed
comparably low levels of Nox1 and Nox4 (Figure 4.6B). Western blot analysis showed a
slight trend of Nox2 expression in M2 macrophages versus donor matched M1
macrophages (Figure 4.5C). The cytosolic subunit of Nox2 required for its activation and
ROS production, p47phox, is also dramatically reduced in M2 macrophages (Figure
4.5C), suggesting that Nox2 activity is greatly reduced in these macrophages. These
data may explain the dramatic differences in extracellular hydrogen peroxide production
seen in figure 4E.

4.2.6

M2 Macrophages Have Differential Expression of ROS Scavenging Enzymes
In a further effort to determine the cause of the lower ROS levels in M2

macrophages, we examined several key antioxidant enzymes. Gene expression of both
the superoxide scavenger, copper-zinc superoxide dismutase (Cu/ZnSOD), and
hydrogen peroxide scavenging enzymes, glutathione peroxidase 1 (Gpx1), Gpx4, and
catalase, was found to be increased in M2 macrophages (Figure 4.7A). The only
antioxidant gene found to be increased in M1 macrophages was MnSOD (Figure 4.7A).
However, contrary to the mRNA expression, there was no change in MnSOD protein
levels and a slight increase in activity between M1 and M2 macrophages (Figure 4.7BD). We found a trend toward increase in Cu/ZnSOD protein expression and activity in
M2 macrophages. Additionally, M2 macrophages had higher levels of the hydrogen
peroxide scavenging proteins, Gpx1 and GPX activity, with a trend toward increased
Gpx4 protein levels (Figure 4.7B-D).
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FIGURE 4.7. M2 macrophage have higher antioxidant enzyme expression and activity
compared to M1
(A) Antioxidant gene expression was measured using rt-qPCR to determine differences
between M1 and M2 macrophages. Analysis of gene expression was performed using N
= 3-4 donors. (B) Western blot analysis of antioxidant genes indicating the differential
protein levels between M1 and M2 macrophages from 4 different donors. (C)
Densitometry analysis of Gpx1, Gpx4, MnSOD, and Cu/ZnSOD compared to the loading
control, RhoGDI. The line graphs indicate the relative difference between M1 and M2
samples of each individual donor. (D) In-gel activity assays for Gpx and SOD proteins
using M1 and M2 whole cell lysate. (E) Line graph indicating relative difference between
M1 and M2 for each specific donor. Relative values were calculated by comparing the
change of the change of M2 sample to its donor specific M1 sample making each
change donor specific to account for the heterogeneity of different human donors. Error
bars are the standard deviation of the M2 samples relative to donor-specific M1 sample.
Student t-test was used to calculate p-value with statistical significance being < 0.05.
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4.2.7

ROS Promotes IL-4 Stimulated M2 Polarization
Next, we sought to determine the mechanism by which MnTE inhibits M2

polarization and function. Since MnTE is a redox-active drug, it can act as a pro-oxidant
activating additional signaling pathways or an antioxidant reducing M2 signaling
cascades. To determine how MnTE is acting in macrophages, both intracellular and
extracellular ROS levels were measured in treated and control macrophages.
Interestingly, intracellular ROS levels were unchanged in MnTE treated M1
macrophages compared to control (Figure 4.8A). However, MnTE significantly reduced
ROS levels by almost 40% in M2 macrophages compared to control. Extracellular
hydrogen peroxide levels were also reduced by 40% in MnTE-treated M2 macrophages
compared to PBS control with no changes in M1 macrophages (Figure 4.8B). Thus,
MnTE is functioning as an antioxidant during M2 polarization. To further test the role of
ROS during M2 polarization, Nox-derived ROS production was inhibited using DPI. DPI
reduced M2 markers similar to MnTE (Figure 4.8C). Additionally, directly adding
exogenous hydrogen peroxide as a bolus injection during M2 polarization increased M2
markers (Figure 4.8D). However, the negative effects of high levels of hydrogen
peroxide are seen as M2 markers begin to drop around 20 μM.
Additionally, EcSOD inhibited the ability of conditioned media from MDA-MB231
to increase M2 markers suggesting EcSOD inhibits M2 polarization (Figure 4.9A).
Furthermore, TEMPO, another ROS scavenging drug, reduces M2 markers and
increases M1 markers (Figure 4.9B-C). However, caution must be applied to not over
interpret the data using conditioned media with EcSOD and TEMPO, as these data were
only performed in one donor. Interestingly, addition of NAC, a commonly used
antioxidant increased M2 polarization (Figure 4.9D). However, analysis of ROS levels
indicated that NAC had no significant effect on ROS levels in either M1 or M2
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FIGURE 4.8. ROS is a required secondary messenger during IL-4 stimulated M2
polarization
(A) Flow cytometry analysis of ROS levels using DCFH in M1 and M2 macrophages
from 4 different donors treated with or without 15 μM MnTE. (B) Line graph depicting the
relative change in extracellular H2O2 levels in control versus 15 μM MnTE treated M1
and M2 macrophages from 4 different donors. (C, D) Measurement of M2 mRNA
markers 24 hours after addition of IL-4. Macrophages were treated with either (C) DMSO
or 10 μM DPI for 1 hour before addition of IL-4 or (D) varying concentrations of
exogenous H2O2 immediately after addition of IL-4. (E, F) Macrophages were treated
with MnTE at different times throughout the differentiation and polarization protocol. (E)
Diagram indicating the M2 polarization protocol with arrows indicating when MnTE was
added in the different samples. (F) Relative M2 mRNA marker expression of
macrophages compared to untreated control measured 48 hours after addition of IL-4.
Error bars are the standard deviation. Student t-test was used to calculate p-value with
statistical significance being < 0.05. Symbols indicate significance between the treatment
groups and M2 control (* < 0.05, $ < 0.005, # < 0.0005).
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FIGURE 4.9. The effect of additional antioxidants on macrophage polarization
(A) Macrophages were polarized in 50% conditioned media from MDA-MB231 or
EcSOD overexpressing cell line, Ec.20. M1 and M2 markers were analyzed after
polarization. (B-C) Macrophages were treated with TEMPO throughout differentiation
and polarization. M1 (B) and M2 (C) markers were analyzed after polarization. (D)
Macrophages were treated with 5 mM NAC throughout differentiation and polarization.
M2 markers were analyzed after polarization. (E) ROS levels were measured after
polarization via DCFH. Macrophages were treated with NAC throughout differentiation
and polarization.
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macrophages suggesting its effects are ROS-independent (Figure 4.9E). These data
provide further evidence that reducing ROS levels inhibits M2 polarization.
Next, MnTE was added during different times throughout M2 polarization to test if
MnTE was inhibiting IL-4 signaling during M2 polarization or activating other signaling
pathways such as NF-κB and Nrf2 on its own that would shift macrophage polarization
toward a more M1-like state. As indicated in Figure 4.8E, MnTE was added throughout
differentiation and polarization, just prior to polarization, half-way through polarization,
and just before RNA isolation. M2 mRNA markers were measured 48 hours after IL-4
addition. Figure 4.8F indicates pre-treatment is required for MnTE inhibition of M2
markers. Additionally, MnTE may affect M-CSF signaling since the effect of MnTE added
just before polarization was not quite as strong as the effect of MnTE treatment
throughout differentiation and polarization. However, MnTE treatment after IL-4
polarization had virtually no effect on M2 markers. Thus, MnTE modulates short-term IL4 signaling. It is unlikely that MnTE is modifying macrophage polarization by activating
other transcription factors via increased ROS production. These data indicate that ROS
is required during M2 polarization, likely as a ROS burst during the initial signaling
events, and that MnTE is inhibiting M2 polarization and acting as an antioxidant in this
specific context.

4.2.8

ROS is Required for IL4-induced Stat3 Activation.
We next examined key signaling pathways during M2 polarization to determine

the MnTE-mediated mechanism of inhibition. Stat6 is a major transcription factor during
M2 polarization and is activated via canonical type I IL-4 signaling [480]. Additionally,
Stat6 has been shown be regulated by H2O2 during IL-4 signaling [481-483]. Although
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FIGURE 4.10. Stat6 activation is affected by MnTE in a small subset of donors
(A-C) Western blot analysis of p-Stat6, total Stat6, and loading control GAPDH in
macrophages from three different donors treated with varying concentrations of MnTE.
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FIGURE 4.11. MnTE inhibits Stat3 activation
(A-C) Western blot analysis of p-Stat3, total Stat3, and loading control GAPDH in
macrophages from different donors treated with MnTE or DPI. Macrophages were serum
starved overnight before IL-4 addition. Macrophages were stimulated with IL-4 for
varying time points indicated above each lane. The densitometry indicating the relative
p-Stat3/total Stat3 ratio is include below the total Stat3 blot. (A) Macrophages were
treated with PBS or MnTE (5 μM or 15 μM) throughout differentiation and IL-4
stimulation. (B) Macrophages were treated with PBS or MnTE (15 μM) 1 hour before
addition of IL-4. (C) Macrophages were treated with DMSO or DPI (10 μM) for 1 hour
before stimulation with IL-4.
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we found that MnTE inhibited IL4-mediated Stat6 activation in some cases, this effect is
inconsistent amongst the various donor samples suggesting that another pathway was
involved in this phenomena (Figure 4.10A-C). Therefore, we next turned our attention
toward the less studied type II IL-4 signaling, which activates Stat3 via dimerization of
the IL-4Rα with the IL-13Rα1 receptor [484, 485]. Additionally, ROS is known to activate
Stat3 [486, 487]. Stimulation of macrophages with IL-4 clearly increased Stat3
phosphorylation at Y705, indicating activation (Figure 4.11A-B). MnTE treatment
resulted in a reduction of phospho-Stat3 levels in four human donors and in a dose
dependent manner compared to the PBS controls (Figure 4.11A-B). Furthermore, DPI
was used to determine if inhibiting Nox-derived ROS would also inhibit Stat3 activation,
as it reduced M2 markers. Similar to MnTE, DPI treatment reduced phospho-Stat3 levels
compared to DMSO control (Figure 4.11C). Furthermore, the M2 markers genes, IL-10,
CD163, and PD-L2, are known target genes of Stat3 [488-490]. These M2 markers are
all suppressed by drug treatment as indicated earlier in this study. All these studies
clearly showed that either scavenging ROS with MnTE or inhibiting Nox activities with
DPI, reduce phospho-Stat3 levels and inhibit Stat3 activation.
4.3

Discussion
It is well known that cancer cells have higher intracellular ROS levels than their

normal counterparts. It is also becoming clear that the tumor microenvironment (TME) is
highly oxidized compared to their normal tissue counterparts. However, the role of the
oxidative TME on cellular functions within the tumor remains relatively understudied. It
has been shown that the oxidative TME contributes to immunosuppression in cancer,
where increased extracellular ROS inhibited CD8+ T cell activation while inducing Treg
activation [380, 381, 491-493]. Our data show that M2 or TAM-like macrophages have
increased redox buffer, suggesting their high tolerance within the oxidative TME.
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Additionally, this study indicates ROS is a necessary secondary messenger for proper
M2 polarization and function. Furthermore, addition of exogenous hydrogen peroxide
promotes M2 polarization. Thus, it is reasonable to speculate that the oxidative TME
may actively promote an immunosuppressive environment via polarizing TAM to a M2like phenotype, while also inhibiting T cell activation and increasing Tregs.
Due to the plasticity of macrophages, there are a plethora of studies examining
the differences in M1 and M2 states via large scale transcriptomics. Some key
differences in the expression levels of ROS producing and scavenging enzymes was
identified by Beyer et al in M1 vs. M2 macrophages [494]. Their results show that M2
macrophages have increased expression of genes in the peroxiredoxin family,
specifically PRDX1, PRDX3, and PRDX6, which may further contribute to the lower
levels of ROS in M2 macrophages. Some of the largest changes in ROS-related genes
were seen in the glutathione-S-transferase (GST) family, specifically lower GSTO1 and
higher GSTP1, mGST2, and GSTT1, in M2 macrophages, which may lead to different
glutathionylation patterns as a potential regulator of macrophage polarization and
function. Our data agree with their RNA-seq data that Nox2 is the highest expressed
Nox family member with the others being very lowly expressed or undetectable. Their
observations also support our findings of differential expression of Nox2, Duox1,
DuoxA1, MnSOD, catalase, Gpx1, and Cu/ZnSOD in M1 and M2 macrophages. Our
study also takes these data a step further by analyzing the protein and activity levels of
these genes, as well as analyze the effect of these changes on the redox status of M1
and M2 macrophages.
Our data implicate ROS as a required secondary messenger during IL-4
signaling for optimal Stat3 activation and M2 polarization. Futhermore, our data shows
optimal M2 polarization, in part, requires Stat3 activation. The ability of ROS to promote
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Stat3 activation by ROS has also been shown in other cell types [486, 495-499].
Additionally, hydrogen peroxide has been demonstrated to activate Jak2 and Tyk2,
which are upstream activators of Stat3 [495, 499, 500]. Our studies imply that this ROS
is likely generated from Nox2, as it is the most abundant ROS producing enzyme in
these macrophages. Further supporting this, the pan-Nox inhibitor, DPI suppressed
Stat3 activation and reduced M2 marker expression. However, DPI is a flavoprotein
inhibitor that can inhibit enzymes other that Noxs, such as nitric oxide synthases,
xanthine oxidases, and enzymes involved in the pentose phosphate pathway and TCA
cycle [501]. Therefore, we cannot rule out the possibility that DPI may also inhibit M2
polarization through modulation of metabolic pathways [502]. Due to the use of primary
human macrophages, the ability to genetic silence Nox members to test this hypothesis
was limited. However, a study using mouse macrophages derived from the Nox1/2
double knockout mice noticed a similar M2 polarization deficiency [503]. Although, it was
unclear whether this deficiency occurred during macrophage differentiation or during M2
polarization, this study supports our speculation that Nox-generated ROS contributes to
M2 macrophage polarization and their pro-tumorigenic phenotype.
ROS typically act as a secondary messenger during signaling through reversible
oxidation and inactivation of protein tyrosine phosphatases (PTPs), which are the off
switches of many signaling pathways. Therefore, we hypothesize that Nox2-derived
ROS oxidizes and inactivates PTPs that are negatively regulating the IL-4 signaling
pathway. Among the long list of PTPs that have been shown to negatively regulate Stat3
are SHP-1, SHP-2, PTP1B, and TCPTP, all of which can be inhibited via ROS-mediated
reversible oxidation [504-507]. Furthermore, this mechanism may also be applicable to
additional pathways that activate Stat3. These include IL-6, IL-10, and IL-22, which
polarize macrophages to similar states as the IL-4 stimulated M2 used in this study [508-
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510]. Additionally, non-macrophage cells in the TME, such as myeloid-derived
suppressor cells, are known to require Stat3 activation and ROS production for their
immunosuppressive phenotype [380, 511]. Thus, MnTE may have a wider ability to
inhibit Stat3-mediated immunosuppression in macrophages and MDSCs than what our
study examined.
Additional research indicates that MnTE also acts on other immune cells besides
macrophages. In CD4+ T cells, it skews their polarization by promoting TH1 response
and inhibiting TH2 in vivo [292, 293]. Interestingly, Stat3 is required for optimal TH2
polarization and function [512]. Due to closely related process of macrophage and CD4+
T cell polarization, we speculate that MnTE inhibits M2 polarization and TH2 polarization
via similar mechanisms [336]. Furthermore, MnTE increases both CD4+ and CD8+ T cells
in the spleen, as well as B cells and NK cells, suggesting it is activating several different
types of immune cells that may provide additional anti-tumor effects [294]. It also
increased production of IL-2, an immunostimulatory cytokine released primarily via TH1
CD4+ T cells. Additionally, tumor mouse models treated with MnTE or its analog,
MnTnBuOE-2-PyP5+ affect monocyte infiltration and have increased M1 macrophages
[291]. Our study adds evidence that MnTE also stimulates the immune system through
inhibiting M2 polarization.
Several strategies have been proposed to target TAM for antitumor therapy.
These include blocking macrophage recruitment to the tumor, decreasing total
macrophage number via targeting therapies, and reprogramming of TAMs from the protumorigenic M2 to proinflammatory M1 macrophages [513]. Reprogramming TAM has
shown efficacy as a single therapy in inhibiting tumor growth and metastasis, thereby
promoting survival in mouse models [363, 514]. While MnTE does not entirely reverse
the M2 markers, this study clearly shows that it inhibits some of the critical negative
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effects of M2 macrophages. Additionally, the immunosuppressive function of TAM is a
known mechanism of resistance to immune checkpoint blockade inhibitors [515].
Therefore, use of MnTE, to reprogram immunosuppressive TAM in combination with
inhibitors for immune checkpoint blockade to stimulate T cell activation, presents a
potentially promising and exciting combination approach to overcome this known
resistance mechanism to immunotherapy.
In conclusion, this study further confirms key differences between M1 and M2
macrophages in their production and scavenging of superoxide and hydrogen peroxide
hinted at in previous studies. Additionally, we show that clinically relevant redox-active
drugs could be used as a promising approach to selectively target M2 macrophages to
inhibit their pro-tumorigenic and immunosuppressive functions. This study also supports
the concept of the oxidative TME in actively and purposefully promoting M2 polarization
in TAM. Future studies are required to determine the direct role of the oxidative TME on
cell-cell interactions within the tumor. Additionally, more studies are needed to determine
the efficacy of MnTE to inhibit M2 polarization in tumor models in vivo, as well as in
combination with T cell activating immunotherapy to synergistically reduce tumor growth.
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CHAPTER 5:

Association of SOD3 Promoter DNA with Its Expression Levels
in Breast Carcinomas

Data in this chapter have been published in the following manuscript:
Griess B., Klinkebiel D., Kueh A., Desler M., Cowan K., Fitzgerald M., Teoh-Fitzgerald
M. Association of SOD3 Promoter DNA methylation with its expression levels in Breast
Carcinomas. Clinical Epigenetics. 2019 (submitted)
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5.1

Introduction
Breast cancer is the most prevalent cancer in women and it is the second leading

cause of cancer -related death. It is estimated that one out of eight women will be
diagnosed with breast cancer throughout the lifetime. On the molecular level, breast
cancer is a complex and heterogeneous disease. Therapeutic strategies are mainly
guided by tumor burden and molecular subtypes. The four main breast cancer subtypes
are categorized based on the presence of receptor(s), which include: Luminal A
(estrogen receptor, ER+ and/or progesterone receptor, PR+, Her2-, and low ki67 index),
Luminal B (ER/PR+, Her2+, and high ki67 index), Her2-enriched (ER/PR-, Her2+, and
high ki67 index), and triple-negative (TNBC) (ER-, PR-, Her2-, and high ki67 index).The
standard management of breast cancer is a multidisciplinary approach that involves local
regional resection of tumor, systemic therapies (anti-hormonal, anti-Her2, or
chemotherapies), and radiation therapies. Poly (ADP- ribose) polymerase, PARP
inhibitors are also used for BRCA mutation carriers.
Our previous study indicated that down-regulation of extracellular superoxide
dismutase (EcSOD, a.k.a. SOD3) is frequently detected in breast carcinomas and reexpression of SOD3 in TNBC cell lines significantly suppressed tumor growth and
metastasis in vivo [142]. SOD3 is the only secreted member of the superoxide
dismutase (SOD) family, which are the primary antioxidant enzymes involved in
regulating reactive oxygen species (ROS) [516]. These SODs utilize metal cofactors for
catalyzing one-electron oxidation followed by one-electron reduction of two O2•- anions
to form hydrogen peroxide, H2O2, which is further reduced into water molecules by
catalase and glutathione peroxidases [112, 117]. While the three mammalian SODs
catalyze the same dismutation reaction at the same rate, the individual isoform is
expected to provide specific and non-redundant biological function, due to their
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distinctive cellular localizations and membrane impermeability of their substrate, O2•-. In
contrast to the other SODs, which are ubiquitously expressed, SOD3 is expressed in a
tissue and cell type-specific manner [62]. The presence of SOD3 is also detectable in
milk, plasma, synovium, and lymph [61, 70]. Most importantly, loss of SOD3 expression
is associated with decreased breast cancer patient survival, suggesting a potential tumor
suppressive function [161, 517].
Hypermethylation of CpG islands within the promoter region of a gene is
recognized as an important epigenetic mechanism of transcriptional silencing of tumor
suppressor genes during cancer development [518]. The fact that SOD3 expression is
tightly controlled in a cell type and tissue-specific manner [443], and with a promoter
that shows a CpG structure similar to other genes silenced by aberrant cytosine
methylation [519] indicates a potential association of epigenetic regulation via DNA
methylation with SOD3 gene expression in breast cancer. The SOD3 promoter (-550 bp
upstream to 100 bp downstream) has 18 CpG sites, which have been shown to be
hypermethylated in breast and lung cancer tissues when compared to the normal control
tissues [142, 413]. Due to the limited number of tissues analyzed in our previous study,
the association of SOD3 promoter methylation could not be determined in a subtypespecific manner for breast cancer. This study, therefore seeks to enrich those results via
pyrosequencing analysis of the SOD3 promoter using a subset of the cohort from the
Breast Cancer Collaborative Registry, which is run by the Northern Great Plains
Personalized Breast Cancer Program (NGPPBCP). The NGPPBCP was designed to
use whole exome DNA sequencing to find genetic drivers in breast cancer with the goal
of developing new targeted therapies. Our study indicates that SOD3 expression is
significantly down-regulated in breast tumors compared to normal breast tissues.
Moreover, there is an inverse correlation between the expression levels and the %
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methylation in breast cancer patient samples. Pam 50-based subtype analysis further
revealed that SOD3 is most significantly down-regulated via DNA methylation in Luminal
B breast cancers.

5.2

Results

5.2.1

SOD3 Expression is Downregulated in Breast Tumors
Agendia gene array analysis performed on clinical specimens collected from the

BCCR showed that there was a significant decrease in SOD3 expression in breast
tumors when compared to the normal tissues (Median = 10.991 vs. 12.215 or 2.33 fold
reduction), as shown in Figure 5.1A. In the tumor subset where molecular subtypes were
identified, we observed that the lowest SOD3 expression was seen in the Luminal B
subtype (Figure 5.1B). A similar trend was observed when we analyzed Oncomine®
datasets, which is a publicly available microarray-based database, where significantly
lower expression levels of SOD3 were observed in the tumor tissues compared to the
normal ones (Figure 5.1C). Two datasets, the Curtis Breast (Figure 5.1D) and Gluck
Breast (Figure 5.1E) further showed the lowest SOD3 expression in Luminal B breast
cancers (red arrow).

5.2.2

SOD3 Expression Levels are Inversely Correlated with Its Promoter CpG

Methylation
Next, we analyzed six CpG sites within the SOD3 promoter as depicted in Figure
5.2A. These sites were selected as they occur within known transcription factor binding
sites or adjacent to them [142, 413]. In comparison to the normal breast tissues, breast
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Figure 5.1. SOD3 expression is downregulated in breast cancer
(A-B) Agendia gene array analysis of SOD3 expression in the BCCR cohort. (A)
Comparison of SOD3 expression in normal breast tissue versus cancer breast tissue.
(B) SOD3 expression level in the different breast cancer subtypes. (C) Analysis of the
SOD3 expression in the publicly available microarray data in the Oncomine dataset
comparing normal breast tissue versus breast tumor. (D-E) Analysis of SOD3 expression
levels in different subtypes of breast cancer compared to normal tissue in the (D) Curtis
Breast dataset and the (E) Gluck Breast dataset.
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Figure 5.2. Methylation Status of the SOD3 Promoter
(A) A diagram depicting the pyrosequencing region of the SOD3 gene. The binding sites
of known transcription factors are highlighted in sequence. The CpG sites are indicated
by the blank lines and the number of bases away from the transcription start site for
SOD3. (B) The average methylation across all 6 CpG sites tested by pyrosequencing
comparing normal to tumor tissue. (C) The average methylation of all CpG sites within
the SOD3 promoter comparing the different breast cancer subtypes to the normal breast
tissue control. (D) The average methylation of each individual CpG examined in the
SOD3 promoter comparing the tumor tissue to normal breast tissue. (E) A heatmap
indicating the methylation status of each CpG site for all the samples tested. The tissue
type is indicated on the left edge of the heatmap.
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tumors showed significantly higher levels of CpG methylation in the SOD3 promoter
region (Average of the 6 CpG sites = 53.6% in tumors vs. 25.2% in normal), as
presented in Figure 5.2B. A high % methylation is predicted to be associated with a
suppression of SOD3 gene expression. Our results here support SOD3 expression
being lower in breast tumors relative to normal tissue as shown in Figure 5.1A. Figure
5.2C shows the methylation pattern of SOD3 gene across the clinical subtypes. Figure
5.2D shows the methylation pattern at each of the queried CpG sites, which indicates
most tumors having significantly increased methylation across all of the 6 CpG sites
while the normal tissue showed predominantly hypomethylation of CpGs in this SOD3
promoter region (p < 0.05). The highest methylation levels were seen at position -78 bp
in both the normal and tumor tissues. Methylation at this site is known to interfere with
SP1/SP3 binding, thereby leading to a suppression of SOD3 gene expression. The
methylation pattern at the queried CpG sigtes for each sample is also shown in the
heatmap in figure 5.2E.

5.2.3 Luminal B Subtype Shows the Highest Correlation of SOD3 Methylation with Its
Expression
We then determined the correlation between the % methylation and SOD3
expression (from the Agendia array) with Spearman’s correlation coefficient analysis (R
values). As shown in Figure 5.3A, there was a moderate inverse correlation in all the
tumor samples analyzed regardless of the molecular subtype (R = -0.383). A strong
correlation was observed in the Luminal B subtype (R = -0.540), which is followed by the
Luminal A subtype (R = -0.417) while a weak correlation was observed in the triplenegative/basal-like subtype (R = -0.3652), as shown in figure 5.3 A-D (left panels).
Correlation analysis was not determined in the Her2+ subtype since the number of
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Figure 5.3. Correlation of SOD3 Expression with Promoter Methylation
(A-I) Spearman’s correlation between the % methylation of the SOD3 promoter and
expression levels of SOD3 was used to determine the strength and direction of their
association. Each graph indicates in the upper left corner which data set was used either
the (A-D) BCCR cohort or the (E-I) TCGA database. The subtype of breast cancer is
also indicated on the top of graph.
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samples available was too low to generate a statistically meaningful result. These
pyrosequencing analyses suggest that promoter DNA methylation of SOD3 is likely a
major contributor to the reduced expression levels of this antioxidant in Luminal B breast
cancers but less influential on the triple-negative/basal-like subtype.

5.2.4 TCGA Database Analysis Showed Similar SOD3 Promoter Methylation Patterns
These data trends in our cohort are also seen in the breast carcinoma samples
from the TGCA database. The right panels on Figure 5.3E-I show the triplenegative/basal-like subtype having the lowest correlation (R = -0.192) while the Luminal
B having the highest correlations (R = -0.561) with the gene expression levels. Good to
moderate correlations were also seen in the Luminal A subtype (R = -0.507) and Her2+
subtype from the TCGA database (R = -0.388), respectively. The TCGA methylome
analysis (Illumina 450K array analysis) only covers two overlapping CpG sites as our
pyrosequencing region (-97 and -78 from the TSS shown in Figure 5.2A). The TCGA
methylome sites are marked chr4:24795366_cg03577139 and
chr4:24795385_cg11372436. These data suggest that pyrosequencing analysis of the
chosen SOD3 promoter area with 323 nucleotides region used in this study is a potential
predictive region and a more cost effective approach in determining the association of
this epigenetic mechanism with its gene expression in breast carcinomas. The
methylation study also suggests that there are likely other factors leading to downregulation of SOD3 expression in the triple-negative/basal-like subtype.
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5.2.5 Specific CpG Methylation Status in Breast Cancer Subtypes
When correlation between methylation patterns of each CpG site and the mRNA
expression of SOD3 was further analyzed in individual breast cancer subtypes, we
observed that Luminal B subtype shows the highest correlation coefficient at the -78
position while the -19 CpG location shows the highest correlations in the Luminal A and
TN/basal-like subtypes (Table 5.1). These observations suggest that the association of
site-specific methylation with the SOD3 mRNA expression is subtype dependent.

5.2.6 SOD3 gene deletion is detected in the most aggressive subtypes of breast cancers
Another known mechanism of SOD3 silencing in cancer is genetic deletion.
Therefore, we analyzed SOD3 copy number variation (CNV) in the TCGA database.
Table 5.2 shows that shallow deletion is more prevalent than a gain/amplification of the
SOD3 gene copy number in breast tumors. Amongst the subtypes, SOD3 is deleted
most often in basal (51.3%) and Her2-enriched (44.2%) cancers, suggesting gene
deletion to play a more prominent role in regulating gene expression in these aggressive
diseases.
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Table 5.1. Correlation between Specific SOD3 CpG Methylation Sites and mRNA
Expression in Clinical Subtypes

-0.5222
1.4E-11
-0.4515
2.1E-11
-0.5816
6.9E-12
-0.5609
4.7E-13
-0.5732
2.9E-11

-0.3828
4.5E-06
-0.3194
5.1E-06
-0.2948
5.9E-07
-0.2673
6.8E-07
-0.3850
3.0E-06

1.0E-16

-0.4674

2.0E-17

-0.4214

3.6E-16

-0.4302

9.4E-16

-0.4148

7.3E-15

-0.4533

5.9E-17

-0.4008

-0.5075
1.7E-12

-0.2195

Lum A

Lum B

2.1E-06

TN/Basal

3.2E-33

-0.4184

1.4E-36

-0.3871

4.4E-34

-0.3870

1.1E-32

-0.3637

6.6E-32

-0.4062

5.8E-35

-0.3693

All subtypes

p-value

Correlation

p-value

Correlation

p-value

Correlation

p-value

Correlation

p-value

Correlation

p-value

Correlation

-19

-35

-78

-97

-99

-108

CpG sites
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Table 5.2. Subtype-specific Copy Number Variation of SOD3
The SOD3 copy number variation data in the TCGA database broken down by breast
cancer subtype. The bottom row indicates the % of samples with either deep or shallow
deletion.
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Lum A

Lum B

Her2

Basal-like

Normallike

Deep Deletion

0

0

2

0

0

Shallow Deletion

25

24

21

40

1

Diploid

175

79

29

38

7

Gain

6

7

1

1

0

Amplification

0

0

0

1

0

% Deleted

12.5%

23.3%

44.2%

51.3%

12.5%
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5.3

Discussion

The discovery that tumor suppressor genes are often epigenetically silenced
during cancer development [518] has served as a foundation for the use of small
molecule epigenetic modifiers in novel cancer therapy strategies. DNA promoter
methylation is significantly associated with the development of various human tumors.
SOD3 lacks a standard CpG island but contains a cluster of 18 CpG sites surrounding
the transcriptional start site (-550 bp upstream to 100 bp downstream) with known
transcription factor binding sites, such as Sp1/Sp3. SOD3 CpG sites have been reported
to be hypermethylated in tumor tissue from gallbladder, liver, prostate, lung, and a small
subset of breast cancer samples [142, 153, 192-194]. SOD3 is also hypermethylated
and downregulated in other diseases, such as coronary artery disease [195].
Highlighting the functional role of epigenetic silencing of EcSOD, treatment with 5-aza-2'deoxycytidine (5-aza-dC), an inhibitor of DNA methylation increased EcSOD expression
in both normal and cancer cells [142, 153, 159, 196-198]. This methyltransferase
inhibitor increased DNA accessibility via nucleosome remodeling thereby increasing
RNA polymerase II and Sp3 binding to the SOD3 promoter [198].
In this study, we focused on the differential methylation of CpG sites, which are
located in the TSS -19 to -108 region of the SOD3 gene. We found that methylation of
the six CpG sites in this region is highly associated with an inverse correlation with the
mRNA expression levels of SOD3 in breast tissues. While the normal breast tissues
showed low levels of methylation in the SOD3 promoter, higher levels of methylation
were found in breast tumors of all molecular subtypes. Interestingly, the highest extent of
this negative correlation was detected in the Luminal B subtype and the lowest
correlation was seen in the TN/basal-like subtype. Moreover, we showed that SOD3
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expression is most significantly down-regulated in the Luminal B subtype of breast
cancer.
Luminal subtypes are the most commonly diagnosed breast cancers (60-70%). In
comparison to the Luminal A subtype, the Luminal B cancers are associated with higher
grade (26% grade III in luminal B compared to 8% in luminal A), micropapillary histology,
and high frequency of nodal metastasis (54 vs. 43%) [520]. Patients with the Luminal B
subtype also has a higher proportion of local recurrence and bone metastasis than in
patients in the non-luminal groups [521]. The landscape of breast cancer methylomes
have been shown to be different between biologically distinct subtypes. Stefansson et al
[522] showed that DNA methylation patterns linked to the Luminal B subtype are
characterized by CpG island promoter methylation events while a large fraction of basallike tumors are mainly characterized by hypomethylation events occurring within the
gene body.
In addition to DNA methylation, Alterations of SOD3 expression, tissue
distribution, and/or function can also occur via single nucleotide polymorphisms (SNPs).
The SOD3 SNPs that have been associated with cancer risk and progression include
rs1799895, rs2536512, rs2284659, and rs699473, and their effects are reviewed in
Griess et al [453]. However, no SNPs are identified to be associated with SOD3
expression in our breast patient cohort, as analyzed by the whole exome DNA sequence
analysis. Several reports indicate the SOD3 gene, located on chromosome 4p15.34p15.1, is a hotspot for loss of heterozygocity in cancer. The deletion of chromosome
4p15.1-15.3 has been observed in many types of solid cancers, such as cervical, breast,
head and neck, liver, colorectal, lung, and bladder [149, 153, 240-248]. These loses
range from 30% in bladder cancer up to 60% in lung cancer [245, 248]. Our copy
number variation analyses indeed revealed a higher association of SOD3 gene deletion
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in the basal-like subtype compared to the other subtypes. This data also matches
previous data indicating that deletion of chromosome 4p is most common in basal-like
breast cancers [523].
In conclusion, this study expands upon the data examining the role of promoter
DNA methylation in regulating SOD3 gene expression. These data provide clear
evidence of the negative correlation of promoter methylation and down-regulation of
SOD3 expression in our cohort of breast cancer specimens. This study also highlights
that despite reduction of SOD3 in all breast cancer subtypes, there are key differences in
the silencing mechanism for each subtype. Promoter hypermetylation of SOD3 are more
prevalent in the Luminal B cancers while SOD3 gene silencing is affected mostly via
CNV in TN/basal-like cancers. Analysis of breast cancer data by Kaplan-Meier Plotter
(http://kmplot.com) showed that low SOD3 expression is significantly associated with
poor outcome (relapse free survival, RFS) in breast cancer patients [453]. This suggests
that loss of this extracellular redox regulator promotes a conducive microenvironment
that favors cancer progression. The vast array of genetic and/or epigenetic mechanisms
reported in mediating dysregulation of SOD3 expression, function, and cellular
distribution [453] further supports that loss of this extracellular antioxidant provides a
selective advantage to cancer development.
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6

Summary and Future Directions

6.1

Summary of Research
Breast cancer is a highly heterogeneous disease with many different molecular

subtypes. The most aggressive subtype is the basal-like subtype, which largely overlaps
with the triple negative breast cancer (TNBC) subtype. TNBC is a fast growing and
metastatic subtype, which unlike the other subtypes lacks any targeted therapies.
Therefore, determining novel mechanisms that lead to its aggressive phenotype provide
therapeutic approaches to reduce its invasive nature in breast cancer patients. One of
the novel areas of research into TNBC is its ability to modify the area within the tumor,
also known as the tumor microenvironment (TME). The TME is highly complex with
many different activated cell types resulting in a complicated network of signaling driven
by the altered signaling in the cancers cells. The major cell types within the TME are
fibroblasts, macrophages, endothelial cells, and T cells. All of which can be activated by
cancer cells or each other. Additionally, the ECM undergoes dramatic changes
throughout cancer progression, which further contributes to complexity of the signaling
network. It has become clear that the TME plays a large role in determining the
aggressiveness of breast cancer. Many studies have correlated activation of fibroblasts
with negative patient outcomes. Macrophages are also associated with poor survival and
metastasis in breast cancer depending on the type of macrophage polarization. Thus,
there is a need to determine how these cells are activated by cancer cells to help
promote its own aggressive phenotype. Inhibiting these activation steps provides a novel
therapeutic approach to treating aggressive breast cancers, such as TNBC, which
currently lacks any suitable drug targets.

201

Extracellular superoxide dismutase (EcSOD) is a member of the SOD family,
which are antioxidant enzymes that catalyze the dismutation reaction of superoxide into
hydrogen peroxide. It is the most recently discovered and least researched member of
its family. It has two unique domains that separate it from the closely related Cu/ZnSOD,
which are its heparin binding domain and its signal sequence. The signal sequence
results in its secretion into the extracellular space allowing it to control levels of reactive
oxygen species (ROS) between cells. The heparin binding domain allows EcSOD to bind
to proteoglycans on the cell surface or within the extracellular matrix (ECM). This ability
to bind to the cell surface allows EcSOD to be endocytosed into the interior of cells, as
well. It is expressed in a tissue- and cell-specific manner. However, in solid cancers,
expression of EcSOD is lost. The loss of EcSOD correlates with poor patient outcome in
many cancers, such as breast, lung, and pancreatic. Additionally, re-expression of
EcSOD inhibits cancer cell growth and invasion in vitro, as well as inhibits tumor growth
and metastasis. However, the exact mechanism behind this tumor suppressive
phenotype remains unknown. Due to its unique localization, I hypothesized that loss of
EcSOD promotes an oxidized TME (oxTME), which promotes activation of stromal cells,
such as fibroblasts and macrophages, leading to an aggressive breast cancer
phenotype.
Previous studies clearly showed the loss of EcSOD in breast cancer is pervasive
and occurs through many different mechanisms. However, due to low sample size, the
main cause of EcSOD downregulation in breast cancer remained unclear. Therefore, we
sought to determine the mechanism by which EcSOD is downregulated in breast cancer.
Previous studies indicated DNA methylation at its promoter can result in epigenetic
silencing of EcSOD. Additionally, aberrant DNA methylation is a well-known marker of
cancer. Therefore, we hypothesized that EcSOD silencing correlated with increased
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DNA methylation at its promoter. We utilized patient samples from the Breast Cancer
Collaborative Registry run by the Northern Great Plains Personalized Breast Cancer
Program (NGPPBCP). Pyrosequencing analysis of the EcSOD promoter indicated
increased DNA methylation in breast cancer patients. The DNA methylation was
significantly correlated with decreased mRNA expression of EcSOD in those same
patients. This correlation was strongest in the Luminal B breast cancers, which are most
likely to have a local recurrence and metastasize to the bone. Despite similar levels of
EcSOD expression, basal-like breast cancers had the weakest correlation. Due to the
higher genetic instability within basal-like breast cancer, we analyzed the gene copy
number in the TGCA database and determined the EcSOD gene is deleted frequently
and most often in this subtype of breast cancer.
Previous studies in our lab have shown tumor suppressive effects of EcSOD in
breast cancer cells. To determine the mechanism of these effects, a receptor tyrosine
kinase (RTK) signaling array and extracellular protein array were used to determine if
EcSOD overexpression inhibited specific pathways in the TNBC cell line, MDA-MB231.
The c-Met receptor and its downstream kinase c-Abl were significantly inhibited by
EcSOD. Additionally, thrombospondin 1 (TSP-1), a secreted factor that sequesters the cMet ligand, hepatocyte growth factor (HGF), and prevents its signaling, was significantly
increased in EcSOD expressing cells (Ec.20). In breast cancer, HGF/c-Met signaling
occurs in a paracrine fashion with fibroblasts secreting HGF, which then activates c-Met
on breast cancer cells. Therefore, we utilized normal mammary fibroblast (RMF) and
HGF-overexpressing fibroblasts (RMF-HGF) in co-culture with breast cancer cells.
EcSOD expression in MDA-MB231 significantly inhibited HGF-mediated cancer cell
invasion induced by RMF-HGF to levels similar to control fibroblasts, RMF. Furthermore,
3D growth of MDA-MB231 was stimulated by RMF-HGF compared to RMF control.
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However, EcSOD expression inhibited the RMF-HGF-mediated growth stimulation.
Additionally, we found that long-term co-culture of MDA-MB231 and RMF-HGF
increased the ability of fibroblasts to promote cancer cell invasion. Interestingly,
expression of EcSOD inhibited this enhanced aggressive phenotype in the fibroblasts
indicating that ROS plays a role in activation of fibroblasts. Further analysis of the RMFHGF fibroblasts indicated that they have higher ROS production through increased
expression of the ROS generating enzyme, Nox4. Nox4 knockdown or inhibition with
DPI reduced fibroblast activation as evidence by their reduced ability to contract and
remodel collagen. MnTE-2-PyP (MnTE), a redox active drug, also decreased collagen
contraction indicating ROS is required during fibroblast activation. MnTE also replicated
the results of the EcSOD inhibition of HGF/c-Met signaling in MDA-MB231 reducing their
growth and invasion. We have further shown that scavenging ROS with EcSOD
significantly inhibited RMF-HGF-stimulated orthotopic tumor growth of MDA-MB231.
This study suggests the loss of EcSOD in breast cancer plays a pivotal role in promoting
the HGF/c-Met-mediated cancer-fibroblast interactions. Additionally, this study highlights
the role of ROS in activating fibroblasts during breast cancer progression.
To further study the role of the oxTME during activation of stromal cells, we
tested how ROS effects macrophage polarization. Macrophages have high plasticity and
are very sensitive to their surrounding environment. Macrophages polarize toward two
extremes under normal conditions; the anti-tumor and pro-inflammatory M1 type and the
pro-tumor and immunosuppressive M2 type. However, in cancer, macrophages are
activated by cancer cells and called tumor associated macrophages (TAM), which
enhance the aggressiveness of breast cancer via promoting growth, metastasis, and
immunosuppression. TAM are closely related to the M2 type of macrophages. The goal
of this study was to examine primary human monocyte-derived M1 and M2
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macrophages for key redox differences and determine sensitivities of these
macrophages to redox-active drugs. MnTE, which previously inhibited fibroblast
activation, reduced levels of M2 markers. Additionally, the function of M2 macrophages
was inhibited by MnTE. Treatment reduced M2 macrophage mediated-cancer cell
growth. Furthermore, MnTE reduced the immunosuppressive nature of M2
macrophages, as determined by co-culture of treated macrophages and T cells during a
T cell activation assay. The T cell suppressing molecule, PD-L2, was reduced by MnTE
in a dose dependent manner. Additionally, this study also determined that there are key
differences in ROS generation and scavenging between M1 and M2 macrophages. Our
results indicate that M2 macrophages have lower levels of reactive oxygen species
(ROS) and lower production of extracellular hydrogen peroxide compared to the M1
macrophages. These differences are due in part to reduced expression levels of prooxidants, Nox2, Nox5, and the non-enzymatic members of the Nox complex, p22phox
and p47phox, as well as higher levels of antioxidant enzymes, Cu/ZnSOD, Gpx1, Gpx4,
and catalase. However, analysis of ROS levels indicated that MnTE treatment reduced
ROS levels in M2 but not M1 macrophages. Inhibition of Nox-derived ROS with DPI and
addition of the ROS scavenger, TEMPO, also reduced M2 markers. Additionally,
conditioned media from EcSOD expressing cancer cells, MDA-MB231 Ec.20, inhibited
the cancer cell-mediated increase in M2 markers. Conversely, increasing ROS via direct
addition of hydrogen peroxide increased M2 markers. Therefore, despite the lower ROS
levels, M2 macrophage require ROS for proper polarization and pro-tumor functions.
Mechanistically, MnTE decreased Stat3 activation during IL4-induced M2 polarization,
as evidenced by reduced phosphorylation of Stat3 and reduced expression of
downstream genes. Overall, this study reveals key redox differences between M1 and
M2 primary human macrophages and that redox-active drugs can be used to inhibit the
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pro-tumor and immunosuppressive phenotype of TAM-like M2 macrophages. This study
also provides rationale for combining MnTE-2-PyP5+ with immunotherapies.
In conclusion, this dissertation sought to determine the role of ROS in activating
stromal cells within the TME in breast cancer. We focused on fibroblasts and
macrophages, since they are the most abundant stromal cells within the TME. These
studies indicate that loss of EcSOD promotes an oxTME, which serves to activate
fibroblasts and promote pro-tumor macrophage polarization. We also identified the use
of MnTE, a drug in clinical trials, as a potential therapeutic approach to reprogram the
hostile TME seen in aggressive breast cancers.

6.2

Future Directions

6.2.1

EcSOD and Its Inhibitory Role in Breast Cancer
The role of EcSOD silencing during tumorigenesis remains unclear. In normal

breast epithelial cells, EcSOD is lost when polarity is lost and with long-term stimulation
with estradiol. These suggest that loss of EcSOD occurs early in tumorigenesis.
Therefore, we hypothesize that EcSOD expression would prevent or delay development
of breast cancer. To test this hypothesis, I propose the use of the spontaneous breast
cancer mouse model, MMTV-PyMT, which expresses the polyoma virus middle T
antigen (PyMT) under the mouse mammary tumor virus promoter/enhancer (MMTV).
This model will be crossed with SOD3 knockout mice to examine if EcSOD plays a role
in delaying tumor development [138]. Additionally, ROS alone activates CAFs and
promotes immunosuppression. Therefore, this model can also be used to determine the
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effect of EcSOD regulating the TME by analysis of CAF activation and immune cell
infiltration.
Furthermore, the mechanism by which EcSOD inhibits HGF-c-Met signaling
remains unanswered. There are two main hypotheses for how EcSOD functions in this
regard: increased protein tyrosine phosphatase (PTP) activity and increased TSP1/2
secretion. The first is by reducing ROS levels to prevent ROS-mediated inhibition of
PTPs. PTPs, such as PTP1B, TCPTP, SHP-1, and SHP-2, de-phosphorylate and inhibit
c-Met signaling downstream [524-526]. Therefore, we hypothesize that EcSOD
expression reduces PTP oxidation enhancing its activity, thereby decreasing c-Met
signaling. Analysis of c-Met activation during inhibition or silencing of these PTPs will
provide the initial impetus to narrow down the choices of PTPs. The second hypothesis
is through increased sequestration of HGF by thrombospondin 1/2 (TSP1/2). TSP1 has
a strong affinity for HGF sequestering it away and preventing binding to c-Met [431,
432]. TSP1/2 are anti-angiogenic and anti-metastatic factors that show inverse
correlation with malignant progression in breast cancer [429, 430]. Therefore, we
hypothesize that silencing of TSP1/2 via inducible short hairpin RNA (shRNA) in breast
cancer cells overexpressing EcSOD would determine the contribution of TSP1/2 to cMet inhibition phenotype of EcSOD overexpressing breast cancer cells. This could be
tested by both direct addition of HGF, co-culture of cancer cells with RMF-HGF, or coinjection of cancer cells with RMF-HGF or RMF.
Another aspect of EcSOD function that remains unstudied is its ability to
preserve nitric oxide and reduce peroxynitrite levels. By removal of superoxide, nitric
oxide cannot react with it to form peroxynitrite. Both, peroxynitrite and nitric oxide are
increased in breast cancer [527]. Several studies have implicated nitric oxide as a driver
of cancer progression, angiogenesis, and reduced survival [528-530]. However, many
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studies fail to draw the distinction between effects of nitric oxide and peroxynitrite, as it is
also associated with metastasis, angiogenesis, and poor survival [373, 531, 532].
Additionally, peroxynitrite is more reactive than nitric oxide causing nitration of proteins
leading to NF-κB activation, as well as reduced CXCL12 and CCL2 signaling resulting in
impaired leukocyte chemotaxis and tumor infiltration [533-535]. Therefore, loss of
EcSOD is believed to promote the increase of peroxynitrite levels and the potential loss
of nitric oxide, due to its ability to scavenge superoxide. In particular, extracellular
peroxynitrite causes nitration of ECM proteins leading to release of growth factors, such
as VEGF, and enhanced fibroblast migration [536-539]. The extracellular peroxynitrite
also promotes immunosuppression by nitration of T-cell receptor (TCR)-CD8 complex,
inhibition of T cell activation, and reduced infiltration due to inactive nitrated chemokines
[380, 540]. Due to its ability to regulate extracellular superoxide, loss of EcSOD in breast
cancer may play a pivotal role in controlling peroxynitrite levels, which remains
understudied. Therefore, I propose the analysis of nitrotyrosine and EcSOD in tumors to
determine if EcSOD loss increases nitrotyrosine levels, a marker of peroxynitrite.
Analyzing nitration levels on fibronection, CCL2, and CXCL12, may also provide a
mechanism for the reduced metastasis in EcSOD expressing cells. Another potential
mechanism for the EcSOD-mediated inhibition of metastasis is the preservation of nitric
oxide in the pulmonary endothelial cells. Nitric oxide is a vasoprotector that prevents
endothelial cell activation and limits adhesion to the vessel wall [541]. A new study
implicates reduced nitric oxide in the early stages of breast cancer lung metastasis
through reduced endothelial activation and permeability [542]. Additionally, vascular
permeability is increased in basal-like breast cancers where it promotes metastasis and
reduces efficient drug delivery [543-545].
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Finally, since aggressive breast cancer cells have increased NOS2 expression, a
producer of nitric oxide, and increased ROS levels, due in part to loss of EcSOD, they
are likely to have higher peroxynitrite levels. Peroxynitrite, like all reactive species, can
induce stress and lead to apoptosis at high levels. Therefore, loss of EcSOD may
indicate cancer cells that are more sensitive to cell death induced by peroxynitrite donors
through Akt inactivation and MLK activation [546]. Doxorubicin is a potent anti-tumor
agent that induces cell death in a peroxynitrite-dependent manner [547]. Therefore,
EcSOD expression may be a valuable marker to predict response rates in BC patients.

6.2.2

ROS and Its Role in M2 Macrophage Polarization
While my work provides strong evidence that ROS is directly affecting M2

macrophage polarization, there is also a reasonable amount of evidence that GSH also
effects macrophage polarization. Previous studies have found that increasing GSH
levels increased M1 polarization, while increasing oxidized GSH (GSSG) levels
increased M2 polarization [367]. Interestingly, my own data suggests that addition of
NAC, a GSH precursor, increases both M1 and M2 polarization. However, NAC is also
used as an antioxidant that scavenges hydrogen peroxide, which contradicts the data
that shows hydrogen peroxide increases M2 polarization. This may be explained by the
off target effects of NAC, such as antagonism of proteasome inhibitors and reduction of
disulfide bonds [548, 549]. Additionally, ROS levels were not measured after NAC
addition to determine if it was functioning as an antioxidant, as some studies have found
NAC to have no effect on ROS levels [550]. These results require further study into the
effect of NAC and GSH in macrophage polarization.
Alterations in glutathione-S-transferases (GST), as seen in Beyer et al., between
M1 and M2 macrophages may provide a potential mechanism behind the similar effects
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of NAC and hydrogen peroxide on macrophage polarization, despite their likely disparate
effects on ROS levels. GSTs are a family of proteins that regulate glutathionylation
which can effect protein activity and act as a signaling event [551]. A recent study has
found glutathionylation levels in macrophages change depending on the environmental
cues [552]. Additionally, during LPS stimulation in macrophages, GSTO1 activity is
required for production of ROS and pro-inflammatory cytokines, while GSTP1 activity
reduced LPS-mediated iNOS and COX-2 expression [553, 554]. Since NAC also
increases GST activity, the different effects of GSTs on macrophage polarization may
provide an ROS-independent mechanism by which NAC effects polarization [550].
My work represents a novel function of MnTE to inhibit M2 polarization in primary
human macrophages. However, this system, while very informative, is quite artificial and
limited to in vitro applications. Since macrophages rely on many signals from multiple
cells to control their polarization, it is important to test the ability of MnTE to inhibit M2
polarization in vivo. There are several mouse models used to study M2 polarization. The
in vivo wound healing assay would provide a fast and robust method to examine the
ability of MnTE to inhibit the function of M2 macrophages, as they are vital for proper
and effective wound closure [503, 555]. The more relevant model to study the role of
MnTE treatment on TAM in BC would be the use of MMTV-PyMT, 4T1, and E0771
mouse models. Due to the ability of cancer cells to induce specific changes and not a
generalized macrophage response, it will be important to use multiple mouse models to
properly assess the effect of MnTE on TAM polarization and function [556]. While MnTE
can effect macrophages, it can also inhibit TH2 response in CD4+ T cells and reduce
hypoxia and angiogenesis in the 4T1 model [290, 292]. Furthermore, TH2 cells produce
IL-4 that promote M2 polarization in MMTV-PyMT mouse models. Therefore, we also
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propose the use of the T cell deficient mice, such as BALB/c scid and B6 Rag1, to
untangle the effect of TH2 response and macrophage polarization [557].
While MnTE effectively inhibits macrophage polarization in vitro, it has a mild
effect on tumor growth when used as a single agent [290]. Therefore, to help BC
patients in the clinic, it is necessary to combine MnTE with other treatments. The
research into combined treatments with MnTE has largely focused on radiation, as it
acts a radioprotectant and a radiosensitizer [291, 558, 559]. Recent research has also
shown efficacy in combination with chemotherapy and ascorbate [283, 560, 561].
However, to date, MnTE or any of its analogs have not been used in combination with
immunotherapies. PD-L1 is a transmembrane protein that interacts with PD-1 on T cells
causing their immunosuppression and is upregulated in TNBC [562]. Therefore, I
hypothesize that combination of PD-L1 targeting therapies, which activate T cells, with
MnTE would provide a synergistic effect in treating aggressive and metastatic BC.
Besides macrophage-mediated T cell suppression, immunotherapy also
struggles to overcome “cold” tumors, which lack immune cell infiltration [563].
Chemotherapy-induced cancer cell death enhances immune cell recruitment turning the
tumor “hot” [564]. This is best illustrated by a phase III clinical trial combining paclitaxel
with atezolizumab, a PD-L1 targeting antibody, which has significantly increased
progression-free survival in metastatic TNBC patients [8]. Interestingly, MnTE reduces
chemotherapy-induced peripheral neuropathy, which is a dose-limiting side effect,
without inhibiting the efficacy of paclitaxel [565, 566]. Therefore, in addition to inhibiting
an immunosuppressive TME and increasing the efficacy of immunotherapies, a
combination of all three modalities may provide an even more beneficial outcome while
reducing the negative effects of chemotherapy. Similarly, radiation is also used to turn
tumors “hot” and is being combined with immunotherapies. As highlighted earlier, the
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use of MnTE in radiotherapy to reduce negative side effects and increase efficacy is well
studied. Therefore, there is also strong rationale for combination of MnTE,
immunotherapy, and radiotherapy in aggressive BC.
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